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ABSTRACT
Nanotechnology, the science and application of objects smaller that 100 nanometres, is evolving rapidly in many fields. 
Besides the countless beneficial applications, including in health and medicine, concerns exist on adverse health 
consequences of unintended human exposure to nanomaterials. 
In the 2010 Parma Declaration on Environment and Health, ministers of health and of environment of the 53 Member States 
of  the WHO Regional Office for Europe listed the health implications of nanotechnology and nanoparticles among the key 
environment and health challenges.
The WHO Regional Office for Europe undertook a critical assessment of the current state of knowledge and the key 
evidence on the possible health implications of nanomaterials, with a view to identify options for risk assessment and policy 
formulation, and convened an expert meeting to address the issue.
Current evidence is not conclusive.  As complexity and uncertainty are large, risk assessment is challenging, and formulation 
of evidence-based policies and regulations elusive.
Innovative models and frameworks for risk assessment and risk governance are being developed and applied to organize 
the available evidence on biological and health effects of nanomaterials in ways to inform policy. 
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1. Introduction
Nanomaterials and products based on nanotechnological applications are being commercialized and 
used at an increasing pace. In the Parma Declaration on Environment and Health,1 the health implications 
of nanotechnology and nanoparticles are listed among the key environment and health challenges that 
ministers are committed to act on. Along with a call for increased research on the use of nanoparticles in 
products and nanomaterials, the ministers pledged to develop and use improved health risk and benefit 
assessment methods. Research into the environmental, health and safety aspects of nanomaterials is 
extensive and growing rapidly. The World Health Organization (WHO) Regional Office for Europe has been 
reviewing recent and current research, with a view to clarifying the connections between nanotechnology 
and health. Findings from this exercise suggest that a rigorous risk assessment is not feasible and that 
a pragmatic model of “risk governance” seems desirable. In order to explore how the Regional Office 
can contribute to progressing risk governance of nanotechnologies, a two-day workshop was held in 
December 2012. Participants with a wide range of expertise were invited to present their work, with 
the purpose of providing input to WHO. A background document on nanotechnology and health (not 
representing a comprehensive or systematic overview of the issue) was used as the basis for this meeting 
and is included in this report. Abstracts of the presentations made by participants are included in the 
annex. The workshop’s discussion focused on four key areas (i) exposure assessment of nanomaterials, 
(ii) nanotoxicology, (iii) risk assessment, and (iv) regulation and risk governance.
1.1. Global nanomaterial uses and trends
Nanomaterials are making their way into all aspects of our lives; these materials are being increasingly 
used in pharmaceutical and medical applications, cosmetics and personal products, energy storage 
and efficiency, water treatment and air filtration, environmental remediation, chemical and biological 
sensors, military defence and explosives (Chaudhry, 2012), and in countless consumer products 
and materials. For instance, in the area of food, nanomaterials can be used to provide new tastes 
and flavours; functional foods; hygienic food processing and packaging; intelligent, lightweight and 
strong packaging; extended shelf-life; and reduced agrochemicals, colours, flavours and preservatives 
(Chaudhry, 2012). The reasons for using nanomaterials differ, according to application. For example, 
some applications can benefit from the increase in surface area per unit mass, which gives greater 
functionality. Other applications can profit from gaining better control of material properties, improved 
dispersion and stable formulations, or a reduced use of chemical ingredients. Again, others exploit 
the enhanced uptake of nutrients and supplements or increased chemical and biochemical activity 
(Chaudhry, 2012). According to Chaudhry (2012), nanometals and nanopolymers have been developed 
to a “mature stage”, in the sense that they have a high manufacturing output. Nanotubes, nanofibres 
and fullerenes continue to increase in output. At the moment, advanced functional materials are at an 
“immature” stage with low manufacturing output, or at an early stage, i.e. recently put on the market 
or being final tested (for example, for targeted drug delivery systems). This is expected to change 
dramatically in the future (see red line in Figure 1).
1 The Parma Declaration on Environment and Health was signed at the Fifth Ministerial Conference on Environment and 
Health, Parma, Italy, 10–12 March 2010 (http://www.euro.who.int/__data/assets/pdf_file/0011/78608/E93618.pdf).
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Figure 1. Manufacturing output by nanomaterial class 
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Note: “Immature” materials are those that are still at the research and development stage, 
whereas “mature” materials are already being produced and commercialized. 
Source: Chaudhry (2012). Reproduced by permission.
2. Exposure assessment
2.1. Assessing direct and secondary exposures 
There are multiple possible primary and secondary exposure pathways stemming from current and potential 
nanotechnology applications, leading to occupational and consumer exposure. This exposure can occur 
via inhalation, ingestion or skin absorption depending on the nanomaterial and the specific application 
(for treated patients, injection is also relevant) (Hansen, 2012; Poland, 2012). Therefore, there is an urgent 
need to assess the level of population exposure to nanomaterials, over time and for different population 
subgroups. Normally, exposure assessment would involve an estimation of the concentrations by mass 
to which workers, consumers and other environmental receptors are exposed, through all different 
pathways. Extensive data is required to complete a full exposure assessment including information about 
manufacturing conditions, level of production, industrial applications and uses, consumer products and 
behaviour, and environmental fate and distribution (Hansen, 2012). Unfortunately, such detailed information 
is lacking for virtually every type of nanomaterial or group of nanomaterials, and technical difficulties hamper 
accurate measurement of nanomaterials in the workplace as well as in the environment. Despite significant 
progress in recent years, the biological and environmental pathways taken by nanomaterials remain largely 
unexplored (Hankin, 2012; Hansen, 2012; Howard, 2012; Poland, 2012). Substantial efforts have been 
made to estimate, predict or assess occupational, consumer and environmental exposures; the applicability 
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of current exposure assessment methods and guidelines for chemicals has also been reviewed in the light 
of what we know about nanomaterials. These efforts have been hampered by both the lack of information, in 
general, and poor access to information needed to complete exposure assessment. It is clear that there are 
a number of challenges related to assessing exposure and these need to be overcome if we are to progress 
towards a better assessment of possible health and environmental risks. 
2.2. Determination of exposure metrics 
When it comes to nanomaterials and nanoparticles, it has been repeatedly observed that mass 
concentration might not be the most significant metric for exposure assessment in relation to health 
effects. Determination of the most appropriate metric for reporting exposure is restricted not only by 
limited knowledge of possible mechanisms of action, but also by a number of technical difficulties, such 
as the lack of consistent sampling and analytical methods to detect and quantify concentrations of 
nanoparticles by dose or by particle number, which can be used to characterize exposure in real time 
(Poland, 2012. An important caveat with regard to determining the optimal metric to report exposure is 
that it has to be consistent with classical toxicological dose metrics. For nanotoxicology, however, the 
usual recommendation is to report more than one dose metric.
2.3. Exposure in children and other vulnerable subgroups
There is an urgent need to consider and assess exposure to nanomaterials in children and other vulnerable 
subgroups. It is well known that children are disproportionately more sensitive than adults when it comes 
to hazardous chemicals2 and that children have a larger relative body surface area (WHO, 2008). In 
addition, it is important to note that some nanoproducts are intended for use by specific subgroups, such 
as children and the elderly, for example with baby bottles, pacifiers, and health-care products containing 
nanosilver for antimicrobial activity (Chaudhry, 2012).
2.4. Exposure assessment and toxicological data generation
Arguably, research to date has focused primarily on generating toxicological data and investigating 
toxicological mechanisms and modes of action, with less attention paid to exposure assessment. This may 
be due to the relatively early stage of engineered nanomaterials production and little opportunity to conduct 
extensive exposure studies. However, given the knowledge gaps, exposure assessment is vitally important 
and needed in order to orient and prioritize the collection of toxicological data for use in risk assessment. 
In order to design and conduct informative toxicological studies, knowledge is needed, for instance, on the 
most relevant routes of exposure for different subgroups, e.g. workers, consumers, children and the elderly. 
In addition, information is needed to determine what the realistic exposure ranges might be for different 
subgroups (Chaudhry, 2012). 
2 For instance, due to unique exposure pathways (transplacental, breastfeeding), high metabolic rate, high rates of cell 
division, poor ability to metabolize, immature excretory capacity and exploratory behaviours leading to exposures (hand-
to-mouth, object-to-mouth, non-nutritive ingestion).
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3. Nanotoxicology 
3.1. General toxicological methods 
Several studies on various forms of nanomaterials (C60, single- and multiwalled carbon nanotubes, among 
others) have observed that the toxicological response was related to “dose by mass”, i.e. the higher the dose 
that laboratory animals are exposed to, the more severe the adverse effect observed. From the available 
research, it is evident, however, that the toxicity of nanoparticles is not only mass-dependent but might also 
dependent on physical and chemical properties that are not routinely considered in toxicity studies (Howard, 
2012; Loft, 2012; Vogel, 2012). For instance, for low-solubility, low toxicity particles, one hypothesis is that the 
surface area of the nanoparticles is a better predictor of toxicity in terms of inflammation (Howard, 2012; Vogel, 
2012). Other studies found that particle number was the best dose metric; in others, toxicity was related to the 
number of functional groups on the surface of nanoparticles. 
What are the properties that determine or influence the inherent hazards of nanoparticles? This is still an open 
question, partly because of the general lack of characterization of those nanoparticles tested (Howard, 2012). 
Questions have furthermore been raised about the appropriateness of current health and safety test protocols, 
guidelines and animal models, used as a basis for assessing the risks to humans. Specifically, there are doubts 
about whether the most appropriate animal species and models are being used to identify long-term, low-dose 
effects (Howard, 2012; Kearns, 2012; Loft, 2012). So far, no scientific research has univocally demonstrated 
that new biological endpoints or toxicological effects are triggered by exposure to nanomaterials (CCA, 2008, 
Hankin et al., 2011). 
3.2. Possible adverse health effects 
Since the early 2000s, concerns have been raised about whether carbon nanotubes (CNTs) might be 
hazardous. These concerns were initially based on the physical similarities with asbestos fibres, and indeed 
since 2004 a series of experimental studies have indicated that some CNTs are able to cause asbestos-like 
effects (Poland et al., 2008). This was one of the factors, among others, that influenced the United States 
National Institute for Occupational Safety and Health (NIOSH) to issue a recommended exposure level 
(REL) of 1 microgram (μg) per cubic metre of elemental carbon as a respirable mass 8-hour time-weighted 
average (TWA) concentration (NIOSH, 2011). For titanium dioxide nanoparticles it has been shown that 
20–30 nanometre (nm) particles are considerably more toxic when it comes to respiratory health than their 
microparticle (>100 nm) counterpart (Vogel, 2012). For humans, it is known that nanoparticles deposit 
in the alveoli, where they are predominantly cleared via normal macrophage mediated mechanisms. A 
proportion of particles can translocate and this appears dependent on physicochemical properties; but 
whether chronic exposure leads to sufficient particle accumulation to trigger disease is unclear (Howard, 
2012; Poland, 2012). For titanium dioxide, NIOSH has proposed an occupational exposure limit (OEL) of 
0.3 mg/m3 for nano-titanium dioxide, compared to 2.4 mg/m3 for fine titanium dioxide particles (Vogel, 
2012). In general, healthy skin is a better barrier than the respiratory tract, but further research is needed 
to assess the effect of formulations and coatings, as well as effects on damaged skin, (such as burned 
or stretched skin). Transfer and systemic distribution of nanoparticles has been reported via the gut 
after oral exposure in several studies, with accumulations typically in the liver and other organs of the 
reticuloendothelial system. Further research is needed on the dosimetry, as well as long-term effects of 
such accumulations (Poland, 2012). 
Meeting report 5
3.3. Vulnerable subgroups
Although scarce, evidence from animal studies suggests that some nanoparticles might be toxic to vulnerable 
subgroups, such as fetuses. For instance, for 35 nm titanium dioxide nanoparticles Yamashita et al. (2011) 
have observed smaller uteri and smaller fetuses after pregnant mice had been injected intravenously, with 
nanoparticles being found in the placenta, fetal liver and fetal brain. Because humans are a long-lived 
species, the impact of early exposure to nanoparticles with possible, continued, long-term, chronic, low-dose 
exposure remains unknown. At present, acute toxicity seems not to be a problem for many nanoparticles. 
However, the effect of exposure during the development and imprinting of a number of systems, which 
may be susceptible to processes such as protein misfolding and immunological reactions, remains largely 
unknown. More generally, the nature and effects of proximal and distal exposure in organisms has yet 
to be robustly studied in toxicological research or understood in terms of the relevance on outcome and 
subgroups.  
4. Risk assessment
4.1. Assessing risks of nanomaterials one by one
Ideally, case-by-case risk assessment of nanomaterials should be performed in order to take the unique 
properties of specific nanomaterials into consideration (Kobe, 2012). Traditional chemical risk assessment 
is based on the notion that the chemical identity governs the risk of a chemical. However, for nanomaterials 
a number of other characteristics may be relevant for assessing human health risks, and it is known that a 
large number of nanoparticle characteristics may influence the overall hazard (Chaudhry, 2012; Hankin, 2012). 
On the one hand, this argues in favour of a case-by-case risk assessment approach because this is the only 
manner in which one can obtain a univocal determination of the risk of a given nanoparticle and its specific 
properties. Adopting a case-by-case risk assessment, changes in the specific properties (size, surface area, 
etc.) can lead to totally different risks, requiring separate estimation. 
On the other hand, the number of potential combinations of various material properties makes case-by-case 
risk assessment of nanomaterials so demanding as to be impracticable, unless the key specific properties 
driving the critical outcome of interest are well known. It has for instance been suggested that there are 
up to 50,000 potential combinations of single-walled carbon nanotubes (SWCNTs), depending on structural 
types, length, manufacturing and purification processes, and surface coatings. Each one of these SWCNTs 
has different chemical, physical and biological properties that may determine their overall hazard. Not all of 
these SWCNT varieties are expected to be of commercial relevance, but there are numerous other kinds of 
nanoparticles, such as fullerenes, quantum dots, metals and metal oxide nanoparticles, resulting in effectively 
countless types of nanomaterials, which may pose different types of risk. 
Thus, identifying patterns and similarities between various sets and families of nanomaterials, which can be 
addressed collectively by applying grouping and read-across with regards to their toxicological profile and 
possible health implications, would be extremely beneficial. It is also a practical necessity if risk governance 
of nanotechnology is to be pursued (Chaudhry, 2012). This requires reporting of case-by-case specific 
material properties and their implication for toxicological and environmental behaviour, to allow the recognition, 
description and evaluation of such families of nanomaterials and/or applications. 
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4.2. Options for evolution of risk assessment 
Given the challenges related to risk assessment, supplementary methods and tools to describe and manage 
the (potential) risk of nanomaterials need to be further explored, developed and applied. Examples of such 
methods are the Swiss Precautionary Matrix, NanoRiskCat and control/risk banding nano tools, outlined below.
Swiss Precautionary Matrix
As part of the 2008 Swiss Action Plan on “Synthetic Nanomaterials”, the Swiss Precautionary Matrix has been 
developed to assist in the creation of a strategy to control the risk of human engineered nanomaterials, within 
the framework of existing legislation. The matrix is based on a set of core principles. As a first principle, the 
developers decided that the scope of the matrix should encompass producers and consumers, as well as the 
environment. Second, input needs were kept low and only include a few particle properties, little information 
about the quantities of materials and some information on products and processes. Finally, the output of the 
matrix is based on worst case estimates of nano-specific risk potential. To address the question “How big 
is the need to assess nano-specific risks?” via the matrix, a score is derived based on; (i) information about 
whether the material is indeed a nanomaterial; (ii) the intrinsic properties of the nanomaterial (e.g. reactivity, 
stability); and (iii) potential human exposure and potential emissions to the environment. If the score is 0–20, the 
precautionary need is classified as “A”, i.e. the need for action is rated as low, whereas if the score is > 20, the 
precautionary need is classified as “B”, i.e. specific action is needed and existing measures should be reviewed 
(Riediker, 2012). The matrix has a dual purpose as it is intended to be used by industry as an early warning 
system during product development as well as a tool to fulfil the obligation of self-supervision according to the 
chemicals and environmental law (Riediker, 2012).
NanoRiskCat
Similarly, Hansen (2012) presented a concept called NanoRiskCat (NanoRiskCat) that has been developed 
at DTU Environment in order to provide support to companies and regulators in regard to assessing and 
communicating what they know about the hazard and exposure potential of a nanomaterial used in consumer 
products. The final outcome of NanoRiskCat is communicated as a short title describing the intended use, and 
five coloured dots. The first three dots refer to potential exposure of (i) professional end-users, (ii) consumers, 
and (iii) the environment. The last two dots refer to the hazard potential for (i) humans and (ii) the environment. 
Each dot can be assigned one of four different colours, i.e. red, yellow, green and grey indicating high, 
medium, low, and unknown risk, respectively. The potential human health and environmental hazard of a 
given nanomaterial in a given nanoproduct is evaluated by considering a number of different criteria, such as 
whether the nanomaterial is classified as a high aspect ratio nanoparticle, whether the bulk form of the material 
has been classified as hazardous and whether it is persistent or bioaccumulative in progressive sequence. 
Depending on whether a particular criterion is or is not fulfilled, a colour code is eventually assigned. 
Control/risk banding nano tools
NanoRiskCat is applicable to consumer products but does not consider occupational uses of nanomaterials; 
Brouwer (2012) presented a number of control/risk banding nano tools with a focus on occupational use 
of nanomaterials and nano-enabled products and articles. Most control banding tools are mainly based on 
qualitative risk assessment (risk is a function of hazard/severity and exposure/probability) and are not necessarily 
quantitative, due to scientific uncertainty. Control/risk banding provides a simplified approach to systematically 
collect, process and evaluate information on hazard (severity) and exposure (probability) by grouping into 
stratified risk (or control) bands. Risk bands are linked to the level of control e.g. CL1 (ventilation), CL2a/b 
(LEV/fume hood), CL3 (containment) and CL4a/b (full containment/review by specialist). There are currently 
several web-based control banding tools available for risk management purposes, which differ in regard to 
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the parameters addressed and how hazard and exposure bands are assigned. Furthermore, most of the tools 
address first generation nanomaterials, relying partially on information on the “parent” (bulk) material, and there 
is a serious need for calibration and performance checking, fine tuning of hazard banding and extension of the 
“validity” domain for exposure.
4.3. Life-cycle perspective of nanoproducts
So far most scientific and regulatory attention has been paid to assessing the risks of individual nanomaterials, 
considered in high purity and uniform formulations. Only recently has attention been given to the nature and 
toxicity of nanomaterials as they occur in various commercial products; to the overall resources used to 
manufacture, process and incorporate nanomaterials into products; to abrasion and aging of nanoproducts; 
and to waste containing nanomaterials. Assessing the overall risk of a nanoproduct is challenging as it requires 
knowledge of its general characteristics, how it is produced, where and how the nanomaterial is used and 
at which concentration, and how it is disposed of. Also, it is important to gather extensive information about 
the product itself, its changes during the life-cycle and the varying properties of nanomaterials due to different 
environmental surroundings and media. All this information is needed to paint a full picture of the health and 
environmental risks associated with the production and use of nanomaterials and nanoproducts during their 
life-cycle. 
4.4. Detection, tracking and monitoring 
Detection and tracking of nanomaterials pose significant challenges when it comes to possible human 
exposure situations (e.g. through inhalation, ingestion, skin absorption, etc.), as does understanding of the role 
of physicochemical characteristics such as surface modifications, vehicles and particle transformations during 
body penetration and distribution (Poland, 2012). This challenge also applies to investigating nanomaterials in 
different environmental media (i.e. air, water and soil) as well as throughout their life-cycles (i.e. manufacturing, 
processing, use and disposal). Current instruments and methods are too time-consuming and not robust 
enough to permit routine analysis of large numbers of environmental samples, even for a limited range of 
manufactured nanomaterials. As noted by the Royal Commission on Environmental Pollution in their 2008 
report, Novel materials in the environment: The case of nanotechnology, techniques will need to be extremely 
sensitive and able to distinguish different physicochemical forms of nanomaterials, usually against a background 
of natural nanoparticles with similar structure and chemistry (RCEP, 2008). Furthermore, effective monitoring of 
production, uses, exposures and overall health conditions among workers and the general population is key 
in order to develop early warning systems that enable identification of unexpected effects from the production 
and use of nanomaterials. An effective monitoring system would require the recording over time of factors 
such as: which manufacturers produced what, where, when and how much; how different occupations were 
involved and might be exposed; what protection equipment has been used; etc. 
5. Regulation and risk governance
5.1. Regulatory initiatives under way
Very few pieces of existing legislation in Europe have nano-specific provisions. Examples of legislation that do 
have such provisions are the European Union (EU) Biocidal Products Regulation and the Cosmetic Products 
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Regulation (Kobe, 2012). In principle, the European legislation on Registration, Evaluation, Authorization 
and Restriction of Chemicals (REACH) covers nanomaterials, as it is applicable to substances in any size or 
form and for all their identified uses, although it does not include explicit nano-specific provisions (Fabrega 
Climent, 2012; Kobe, 2012). In practice, however, inapplicable provisions (relating for example to specific 
tonnage triggers and phase-in status) render this regulation ineffective for nanomaterials, according to some 
stakeholders (Azoulay, 2012). Thus, there are issues and challenges that need to be addressed. For instance, 
so far only a few registration dossiers received by the European Chemicals Agency (ECHA) under REACH have 
contained nanomaterials-specific information. These dossiers were identified by the Nano Support Project 
carried out by the European Commission (EC) Joint Research Centre and ECHA. This project aimed to provide 
an analysis and assessment of the information provided in REACH registration dossiers, develop options for 
specific nanomaterial provisions in REACH and examine the human health, environmental and socioeconomic 
consequences of these options (Aschberger, 2012). 
Several activities have been initiated by, for example, ECHA, the EC, the Organisation for Economic Co-
operation and Development (OECD), academics and civil society organizations. ECHA, for instance, is 
currently concentrating on how the registered nanoforms of a given substance have been characterized, 
as characterization is seen as a prerequisite for proper risk assessment. Specifically, ECHA’s effort includes 
developing best practices by providing substantial feedback and advice to future registrants as well as requesting 
information that should have been provided (Fabrega Climent, 2012; Kobe, 2012). Various nanomaterials are 
currently being evaluated by different EU Member States, and consensus meetings and workshops are being 
held between ECHA, the EC, the EU Member States and representative registrants and stakeholders (Fabrega 
Climent, 2012; Kobe, 2012). 
With regard to national initiatives, France has initiated a compulsory declaration of nanomaterials that applies 
for manufacturers that produce, import, distribute or formulate nanomaterials in quantities of more than 100 g/
year. Belgium, Denmark, Germany and Italy, as well as the EC are exploring the option of having a harmonized 
database on the production and commercialization of nanomaterials. 
Industry relies on the technical guidance provided by ECHA for chemicals in general. A number of key nano-
specific guidance updates were implemented in 2012 through the outcomes and recommendations from 
two REACH implementation projects on nanomaterials. These include: sample preparation, reporting of key 
physicochemical properties, exposure measurements and modelling, appropriate use of metrics of hazard and 
exposure assessment, and applicability of nontesting approaches (Hankin, 2012). 
When it comes to chemical risk assessment, much of the technical guidance provide by ECHA to industry relies 
on the OECD’s approximately 150 test guidelines on physicochemical properties, human toxicity, ecotoxicity, 
etc. The general approach developed to date by the OECD and various OECD Member States for testing 
and assessment of chemicals is applicable to nanomaterials; however, particular test guidelines may have to 
be further adapted to their specificities (Kearns, 2012). To this effect, the OECD has initiated a sponsorship 
programme that aims at reviewing existing OECD test guidelines for adequacy in addressing the nanomaterials’ 
physicochemical properties, biotic systems, degradation and accumulation, and health effects (Kearns, 2012). 
5.2. Risk governance
Due to data gaps, scientific uncertainty and ambiguity, traditional risk analysis, where regulation and risk 
management measures are based foremost on an independent and complete scientific risk assessment, 
may tend to lead to “paralysis by analysis” (EEA, 2001, 2013). Too much time can be spent waiting for the 
completion of risk assessment procedures and too little focus is put on implementing measures to prevent or 
reduce possible risks. Thus, many review exercises concur about the need for approaches that build on risk 
assessment but are better designed to handle complexity. The Risk Governance Framework developed by 
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the International Risk Governance Council (IRGC), provides an example of such an approach for nanomaterial 
risk analysis, as it combines aspects of the traditional risk assessment framework with societal and ethical 
characteristics (Figure 2). This framework was considered particularly relevant for nanotechnology due to the 
uncertainties surrounding the potential health and environmental effects, and hence the need to involve a wide 
range of stakeholders when making decisions regarding nanotechnology’s use and implementation (Grobe, 
2012).
Figure 2. The IRGC Risk Governance Framework
Management Sphere: 
Decision on & Implementation of Actions
Assessment Sphere: 
Generation of Knowledge
To be defined before most 
nanoproducts are known
Multidimensional in 
nanotechnology
Communication
Specific to 4 nanoproduct 
generations
Risk Management
Implementation
• Option Realisation
• Monitoring & Control
• Feedback from Risk Mgmt. Practice
Decision Making
• Option Identification & Generation
• Option Assessment
• Option Evaluation & Selection
• Option Risk Reduction
Specific to natural, manufactured and bi-products NS
Tolerability & Acceptability Judgement
Risk Evaluation
• Judging the Tolerability 
& Acceptability
• Need for Risk Reduction 
Measures
Risk Characterisation
• Risk Profile
• Judgement of the 
Seriousness of Risk
Applied to specific NT areas
Risk Appraisal
Risk Assessment
• Hazard identification & Estimation
• Exposure & Vulnerability 
Assessment
• Risk Estimation
Concern Assessment
• Risk Perceptions
• Social Concerns
• Socio-Economic Impacts
Two frames for NT
Pre-Assessment
• Problem Framing
• Early Warning
• Screening
• Determination of Scientific 
Conventions
Knowledge development is 
critical for nanotechnology
Source: IRGC (2007). Reproduced by permission. 
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5.3. Risk communication
Communication is a key element of this framework as one cannot choose “not to communicate” (Grobe, 
2012). As noted by IRGC (2006) “lack of communication and understanding about the science, application 
and regulation of nanotechnology among all stakeholders may have negative effects on societal impressions 
and political/regulatory decision making”. Hence communication plays a central role as it is of major 
importance throughout the entire value chain and the product’s life cycle. Good communication serves a 
number of purposes. First of all, it should facilitate understanding among stakeholders, for example about 
the rationale behind the risk appraisal and risk management phases. Second, communication should 
help stakeholders make informed choices about risk when they are themselves involved in risk-related 
decision-making (IRGC, 2006). From a more holistic perspective, the heavy focus on communication 
between risk assessors and managers, between scientists and policy-makers, as well as civil society, is 
intended to “…foster tolerance for conflicting viewpoints and provides the basis for their resolution, and 
creates trust in the institutional means for assessing and managing risk and related concerns” (IRGC 
2006, 2008).
5.4. Multistakeholder dialogue
The current state of knowledge about nanomaterials is pervaded with uncertainty and ambiguity and 
this requires a continuous dialogue between various scientific disciplines, risk assessors, regulators, 
stakeholders and civil society about how best to exploit the benefits of nanomaterials and how to avoid the 
risks. Examination of the benefits and risks together is essential for a realistic discussion about what is at 
stake and the current and future role of nanotechnology (IRGC, 2008). Consumer studies have identified the 
need for more information about the functionality, benefits and safety of nanomaterials along the product life-
cycle. Efforts towards transparency and information sharing on the part of industry, regulators, consumers, 
interest groups and all relevant stakeholders, are essential; failure to promote and maintain a meaningful 
dialogue will result in problematic situations, similar, for example, to the debate around genetically modified 
organisms (GMOs) (Grobe, 2012).
5.5. Transboundary environmental, health and safety issues
More than 60 countries have government-led nanotechnology initiatives underway, but there is a 
need for more international coordination of these initiatives, along the lines, for example, of the EC 
Nanosafety Cluster. Also, more investment targeted towards achieving sustainable economic, social and 
environmental benefits for all is needed. It is important to remember that the environmental, health and 
safety issues that might be associated with the production and use of nanomaterials are transboundary 
in nature, e.g. with the physical transfer of nanomaterials, nanoproducts and nanowaste from one 
country to another via air, rivers and international trade. Rapid changes in manufacturing technologies 
and processes might also affect the need for and use of raw materials and natural resources, involving 
contrasting interests of developed and developing countries, as well as an uneven or inequitable risk–
benefit distribution among different countries and economic groups (IRGC, 2006). As noted by the IRGC 
(2006, 2008), current regulatory structures and processes are fragmented with respect to jurisdiction, 
type of regulation, and the lack of harmonization of risk assessment and management procedures, both 
nationally and internationally. The IRGC stated already in 2006 that “decision makers worldwide need to 
work towards a system of risk governance for nanotechnology that is global, coordinated, and involves 
the participation of all stakeholders, including civil society” (IRGC, 2006).
Meeting report 11
6. Conclusion
Research on nanotechnology and health has steadily increased over the past 10 years and has generated 
extensive knowledge. However, as described in the WHO background document in Annex 2, there is a general 
agreement that the overall data and evidence on the health effects of nanotechnology is far from conclusive. 
The toxicity and ecotoxicity of some nanomaterials has been described, with attention principally focused on 
in vitro toxicological assessment and exposure in the occupational setting. There are indications, for example, 
that CNTs and titanium dioxide might be a hazard in occupational settings, and that nanosilver might be 
an environmentally relevant contaminant. However, the public health implications are unclear. Although first 
generation nanomaterials are being used in a variety of applications and products, they do not seem to present 
an imminent public health issue. On the other hand, in light of the rapidly growing production of nanomaterials 
(and thus possible exposure), several research questions need to be addressed, especially about long-term 
impacts. 
Given the scientific uncertainty and still emerging evidence, and given the early indications of harm and possible 
adverse human health effects that have been hypothesised for some nanomaterials, a precautionary approach 
seems desirable. The possible extent of population-scale exposure, for example through consumer products, 
cosmetics, food additives, the speed of technological development and the projected proliferation of applications, 
has yet to be assessed. Accurate information about nanoparticle exposure and distribution in the human body, 
toxicological mechanisms and possible adverse health effects is needed, even though translating this information 
into an assessment of the risks for human health is challenging. Available methodology, current protocols and 
testing guidelines for chemical risk assessment, as applied in chemical safety, could be used as a basis for risk 
assessment of nanomaterials, but they need adaptation. Alternative or adapted models and frameworks are thus 
being developed and applied to organize the available evidence on biological and health effects of nanomaterials 
in ways to inform policy. Many of these approaches, developed by consortia of public and sometimes private 
agencies and expert groups, recognize the high degree of complexity and uncertainty; hence they are based on 
several steps (sequential or organized in flow charts), make provision for extended stakeholder consultation and, 
some, rather than focusing on one agent, involve comparisons of alternative ones. 
Since it is currently difficult to formulate conclusive and reliable assessments of the health risks of nanomaterials, 
due to knowledge gaps, it is important that adequate mechanisms are put in place, at various levels, to ensure 
transparent and fair negotiation between stakeholders. Further initiatives must be undertaken to use available 
evidence on health implications, to the extent possible, to inform the risk governance of nanotechnology. 
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NANO SUPPORT – Assessment of nanomaterials in REACH registration dossiers1
Dr Karin Aschberger, Scientific Officer, Nanobiosciences Unit, Joint Research Centre Ispra, European 
Commission
The Nano Support Project was conducted in close collaboration between the Joint Research Centre and ECHA 
for the EC Directorate-General for the Environment,. Its aim was to provide a comprehensive assessment of 
the availability and quality of data on the properties of nanomaterials in REACH registration dossiers due by 
December 2010. Based on the assessment, options to amend REACH to better address nanomaterials were 
developed. The final task comprised an assessment of the potential socioeconomic costs and benefits of 
these additional requirements (i.e. options).
From more than 26,000 submitted registration dossiers, covering 4,700 substances, 45 dossiers (referring to 
33 distinct substances) possibly addressing nanoforms or nanomaterials were identified. The selection was 
based on a combination of automated searches of the International Uniform Chemical Information Database 
(IUCLID), on knowledge of the substances selected for assessment in the OECD Working Party on Manufactured 
Nanomaterials (OECD-WPMN); and other criteria to identify substances considered to include a nanoform. It 
is possible that other dossiers could be considered to cover nanomaterials or nanoforms, however, they could 
not be identified as it was often not clear whether nanoforms were included within the scope of the registered 
substance. In addition, the information provided on the forms or granulometry of substances often did not 
allow for identification of particles in the nano-range. 
A first detailed analysis and assessment on substance identification, physicochemical properties and other 
relevant information in the 45 dossiers led to the exclusion of 20 dossiers (covering 15 substances) as they 
could not conclusively be considered to cover nanomaterials or nanoforms. A further assessment of the 
remaining 25 registration dossiers (covering 21 substances) led to the identification of three categories of 
registration dossiers: (i) the registrant recognized that nanomaterials or nanoforms were within the scope of the 
dossier (8 dossiers/5 substances), (ii) the substances were considered to exist only as nanomaterials without 
a bulk form (12/9), and (iii) the nanomaterials were identified on the basis of the presence of a “nanotail” in the 
provided particle size distribution (5/5). All 25 dossiers were subject to further detailed analysis and assessment 
of substance identity, physicochemical properties, human health, fate, ecotoxicity, classification and labelling 
and the chemical safety report. It should be noted that the assessment was not a compliance check nor any 
other formal REACH evaluation of the dossiers and substances analysed.
The examination of the substances’ identity and key physicochemical properties (e.g. granulometry, surface 
area) revealed that the information provided in the dossiers was, in general, insufficient to identify a nanomaterial 
or nanoform of a substance. The general observation for other endpoints, such as human health or environment, 
was that the test materials were usually not well characterized and different forms could not be distinguished.
Based on the result of this assessment, 21 options were developed for adapting REACH to better reflect 
the properties of nanomaterials. These options refer to five categories: (i) substance identification and 
physicochemical properties, (ii) general and specific options for human health hazards, (iii) environmental fate, 
(iv) environmental hazards and exposure assessment, and (v) risk characterization. 
An assessment of the consequences of these options for industry, consumers, human health and the 
environment during 2012–2022 was carried out by a contractor. As a first step for the definition of the baseline, 
it was decided that only nine of these options should be addressed for the impact assessment. The remaining 
12 options were, following intensive dialogue with ECHA staff, eventually considered part of the current 
requirements (i.e. the baseline) and therefore considered to represent compliance costs. 
1 The opinions in this presentation are those of the authors and not necessarily those of ECHA or the EC.
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The costs and benefits for human health were assessed quantitatively based on case studies and extrapolation 
to the whole market for nanomaterials. It was estimated that 500–2,000 substances (including different forms 
and surface modifications of the same substance) would be placed on the market, at more than 1 ton/year 
during 2012–2022. 
The costs of the option scenario (nine options) for industry, including testing and updating registration dossiers, 
were estimated to be €11–73 million, as a cumulative effort until 2022. If grouping and read-across approaches 
were not taken into account extensively, the costs would rise to €100–600 million. 
Human health benefits, e.g by improving the health of the general population were estimated to be €165 
million, on average (with a range of €83–248 million) for cumulative savings for 2012–2042. As health benefits 
are expected to accrue with significant delays after implementation of the options, a direct comparison with 
the costs is not possible. All estimations are associated with high uncertainty. Qualitative impacts of the 
implementation of the options include more transparency on the use and safety of nanomaterials, greater 
innovation and better possibilities for risk reduction measures.
The report finally concludes that, based on an implementation of the options, additional costs for companies 
can lead to a reduced uncertainty about potentially adverse effects. These may lead to considerable health and 
environmental benefits, if combined with appropriate risk reduction measures.
The results of this project had a direct impact on the EC evaluation of the need to review REACH for 
nanomaterials within the 2nd Communication of the regulatory aspect of nanomaterials in October 2012. In 
addition it will have an impact on the forthcoming envisaged modifications of the REACH Annexes, to better 
address the properties and risks of nanomaterials.
Control/risk banding nano tools
Derk H Brouwer, Netherlands Organisation for Applied Scientific Research (TNO)
Control banding was developed in the pharmaceutical industry as a pragmatic tool to manage the risk resulting 
from exposure to a wide variety of potentially hazardous substances in the absence of firm toxicological and 
exposure data (Zalk and Nelson, 2008). It is a risk assessment approach, in a context of uncertainty, using the 
generally accepted risk paradigm, where risk is a function of severity of impact (hazard) and the anticipated 
probability of that impact (exposure). Both hazard and exposure are graded into 2–5 different levels, usually 
referred to as “bands”. The two sets of bands are combined, most often in a matrix, resulting in control or 
risk bands. The production and use of (manufactured) nanomaterials and nanomaterial-enabled products and 
articles, however, may introduce new and unknown risks. In such a context of uncertainty, the control banding 
approach can be very helpful in implementing a risk management strategy according to a precautionary 
method. 
During the last five years, risk-management decision-support tools related to the use of nanomaterials have 
been developed and published; however, most of these are developed for occupational use of nanomaterials. 
In some cases, the application domain is extended to the use (application) of nano-enabled products. Risk 
categorization frameworks, such as the Precautionary Matrix (Höck et al., 2008), and NanoRiskCat (Hansen et 
al., 2011), include environmental exposure or impact, and consumer exposure.
The major tools used for the work environment are either control banding, where a proactive approach is used 
and control measures are not taken into account (indicating “potential” exposure); or risk banding, where a 
re(tro)active approach is used and control measures are taken into account (indicating “actual” exposure). 
Brouwer (2012) reviewed different “tools” for workplace risk management related to the production and 
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use of nanomaterials, among which was the Nano Control Banding Tool (Zalk et al., 2009); the Guidance 
(Cornelissen R et al., 2011); the French Agency for Food, Environmental and Occupational Health and Safety 
(ANSES) control banding tool (Riediker et al., 2012); Stoffenmanager Nano (Duuren-Stuurman et al., 2012); 
and NanoSafer (National Research Centre for the Working Environment, 2013). The first three tools are typical 
control banding tools, i.e. the output is a level of control, whereas Stoffenmanager Nano and NanoSafer are 
risk prioritization tools, i.e. the output indicates a relative risk. Both of these latter tools are web-based, where 
the underlying exposure model and the hazard categorization approach are not shown to the user. Figure A1 
provides an overview of control banding tools.
The methods used to assign a band differ between the various tools: the Nano Control Banding Tool uses a 
scoring system for both hazard and exposure banding; the Guidance, ANSES and Stoffenmanager Nano tools 
use a decision tree (binary system) to assign hazard band; and NanoSafer uses a mixed system to allocate 
a hazard band. Since specific hazard information on nanomaterials is often lacking, the hazard banding or 
categorization heavily relies on an evaluation of information on the “parent” (bulk) material.
The exposure banding aspect of Stoffenmanager Nano and NanoSafer is based on the conceptual model 
for inhalation exposure described by Schneider et al. (2011), which is a relatively simple near-field and far-
field source–receptor model. The conceptual model distinguishes four “source domains”, which refer to 
combinations of the process phase (or product chain stage) and the likelihood and form of aerosols emissions. 
For example, during the down-stream use a (nano)powder handling scenario is likely to generate agglomerated 
particles and only few unattached particles. In all tools, except NanoSafer, the hazard and the control bands 
are “independent” entities, i.e. the hazard and exposure bins are assigned based on their ranges. NanoSafer 
expresses the exposure banding as the ratio of the hazard-related pseudo-“occupational exposure limit” 
and the predicted exposure. The major characteristics of the tools are listed in Figure A1.1. Note that the 
Precautionary Matrix and NanoRiskCat are included for reason of comparison, and that the tool developed 
by the International Organization for Standardization (ISO) (declassification to be expected by March 2013) 
combines the ANSES tool and Stoffenmanager Nano. 
In general, most tools lack “calibration” or a check on performance, and the hazard banding needs fine tuning, 
particularly for the next generation of nanomaterials, where no “parent” materials are present.
In a workshop held in Amsterdam October 1, 2012 on control and risk banding tools, at which many prominent 
tool developers were present, the following priority areas for further development were identified: (i) providing 
guidance for the selection of the  tool that fits the intended use; (ii) providing training and guidance to users; 
(iii) embedding tools in a risk assessment framework (tiered approach); (iv) evaluation and validation using 
worked examples; (v) improving availability of information (material safety data sheet, suppliers, researchers); 
(vi) enhancing data on effectiveness of risk management measures and good practices; and (vii) creating 
a feedback loop to include new information in tools. The workshop concluded that all tools are valuable 
if used properly for their respective domains of application. Therefore, the first priority mentioned above is 
acknowledged to be a top priority that should result in a pre-selection of tools based on, for example, (i) 
the scope of the tool (proactive or retroactive); (ii) the stage of the product chain “covered” by the tool (e.g. 
nanomaterial versus nano-enabled articles); (iii) the domain (e.g. worker, consumer); (iv) the target user and/or 
scale (e.g. research or small and medium enterprises; (v) the needed (or available) knowledge level of the user 
(e.g. lay person or expert); or (vi) the required (or available) input data, or combinations of these parameters. 
This is intended to prevent inappropriate use of the tools and consequently ambiguous output, reducing the 
caveat of misinterpretation of tool performance. 
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Figure A1.1. Overview of the major characteristics of control banding tools
CB tool 
Short name
HAZARD BANDING EXPOSURE BANDING MATRIX
Allocation 
system
Source domains/ type of activities* Number 
of Bands/ 
Levels
binary score N Synthesis Powder 
handling
Application 
Ready 
to use 
products
Abrasion Emission 
potential
Exposure 
potential
N CB RL
Precautionary 
Matrix - +
1 (+) (+) (+) (+) + - 1 2 -
CB Nano Tool - + 4 + + - - + - 4 4 -
ANSES 
[ISO —(pro-active)] + 5 (+) + + + + - 4 5 -
Stoffenmanager 
Nano 
[ISO —(retro-active)]
+ - 5 + + + (+) - + 4 - 3
NanoSafer + + 4 - + - - - + 5 5
Guidance + - 3 + + + + + - 3 3 -
nanoRiskCat + - 3 + + 3 - -
1Not appropriate since the Precautionary matrix has no separate hazard and exposure bands
Parenthesis: implicitly addressed 
N: Number of bands
CB: Control Banding
RB: Risk Banding
RL Risk level
+ used/addressed by tool
- not used/addressed by tool
(+) only implicitly addressed by tool
Source: adapted from Brouwer (2012). Reproduced by permission of Oxford University Press.
References
Brouwer DH (2012). Control banding approaches for nanomaterials. Annals of Occupational Hygiene, 56:506–514 
(DOI: 10.1093/anhyg/MES039; http://annhyg.oxfordjournals.org/content/56/5/506.full.pdf, accessed 24 June 2013).
Cornelissen R et al. (2011). Guidance working safely with nanomaterials and nanoproducts. The guide for 
employers and employees. Amsterdam, Dutch Social Partners FNV, VNO-NCV and CNV.
Duuren-Stuurman B et al. (2012). Stoffenmanager Nano Version 1.0: A web-based tool for risk prioritization of 
airborne manufactured nano objects. Annals of Occupational Hygiene, 56:525–541.
Hansen FS, Braun A, Asptrup-Jensen K (2011). NanoRiskCat – A conceptual decision support tool for 
nanomaterials. Copenhagen, Danish Environmental Protection Agency.
Höck J et al. (2008). Precautionary Matrix for Synthetic Nanomaterials. Bern, Switzerland. Federal Office for 
Public Health and Federal Office for the Environment.
National Research Centre for the Working Environment (2013). Risk Evaluaton Tool and Good Practise for Safe 
Handling of Nanoparticles (NANOTOOL) [web site]. Copenhagen, National Research Centre for the Working 
Environment (http://www.arbejdsmiljoforskning.dk/en/projekter/arbejdsmiljoekatalog-om-haandtering-af-
nanopartikler-nanotool, accessed 18 July 2013).
Riediker M et al. (2012). Development of a control banding tool for nanomaterials. Journal of Nanomaterials 
(DOI: 10.1155/2012/879671; http://www.hindawi.com/journals/jnm/2012/879671/, accessed 24 June 2013).
Schneider T et al. (2011). Conceptual model for assessment of inhalation exposure to manufactured 
nanoparticles. Journal of Exposure Science and Environmental Epidemiology, 21(5):450–463.
Abstracts 21
Zalk DM and Nelson DI (2008). History and evolution of control banding: A review. Journal of Occupational and 
Environmental Hygiene, 5:330–346.
Zalk DM, Paik SY, Swuste P (2009). Evaluating the control banding nanotool: A qualitative risk assessment 
method for controlling nanoparticle exposures. Journal of Nanoparticle Research, 11:1685–1704.
European Chemicals Agency activities on nanomaterials
Julia Fabrega Climent, Directorate of Evaluation, European Chemicals Agency
Nanomaterials are described as particles with structures of at least one dimension within 1–100 nm. The 
manufacture of nano-size particles can result in novel physicochemical properties that may differ from those 
of their bulk counterpart. This can be exploited for innovative technological applications which offer substantial 
benefits to society. 
Given the rapid development of nanotechnology industries and the foreseen increase in production volumes 
of nanomaterials worldwide, it is expected that the number of products available in the European market 
will increase significantly in the coming years. Hence, it is important that comprehensive risk assessments 
are conducted for nanoforms, as the rapid increase in their manufacture and use raises inevitable questions 
regarding their potential effects on health and on the environment.
Although there are no explicit requirements for nanomaterials under the EC REACH or CLP2 regulations; the 
ECHA, the EU Member State competent authorities consider that nanomaterials meet the REACH definition 
for substances, and therefore REACH requirements apply. Many substances exist in different forms (solids, 
suspensions, powders, nanomaterials, etc.), and under REACH different forms can appear within a single 
registration of a substance. However, the registrant must ensure the safety of all included forms and provide 
adequate information to address the different forms in the registration dossier, including the chemical safety 
assessment and its conclusions, as well as different classifications, where appropriate (EC, 2012).
ECHA and EU Member State competent authorities agreed to develop a common approach to address the 
current information requirements in dossiers containing nanoforms, taking into account the scientific and 
legislative uncertainties in the framework provided by REACH. 
An assessment (performed on the ECHA database in 2011) on how nanomaterials have been addressed in 
REACH registrations showed that only seven substance registrations had selected “nanomaterial” as the form 
of the substance in voluntary fields. A further assessment identified additional substances with nanoforms. 
Many registrations for substances known to have nanomaterial forms do not mention clearly which forms 
are covered or how the information provided relates to the nanoform. Only limited information specifically 
addresses the safe use of the specific nanomaterials supposedly covered by the registration dossiers. These 
findings are partly explained by the absence of an adopted definition of the term “nanomaterials” at the time of 
the first registration deadline of December 2010, the lack of detailed guidance to registrants on registration for 
nanomaterials, and the general wording of the REACH annexes.
In 2012, ECHA began to examine dossiers registered under REACH containing nanoforms. When elements in 
a dossier indicate that the substance or forms of the substance may fall under the definition of a nanomaterial, 
ECHA has issued requests for information. The requests focussed on the characterization of nanomaterials, 
in particular on the size distribution and on surface treatment. The analysis of the information received from 
the registrants was still on-going at the editorial deadline. The registrants either did not react at all, answered 
2 Classification, Labelling and Packaging of chemicals.
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without providing the information requested, or did provide additional information on primary particle size and 
specific information on surface treatment. 
Currently, most nanomaterials are phase-in substances (substances listed on the European Chemical 
Substances Information System [EINECS] and preregistered Thus, the applicable registration deadline (2010, 
2013 or 2018) is triggered by the production volume (production volume per legal entity), as well as the 
hazardous classification of the substance. To date, only substances manufactured or imported to the EU 
at more than 1000 tonnes per year and substances classified as CMR1/2 (1 tonnes/year) or R50/53 (100 
tonnesyear) were registered. Lower tonnages will be registered at a later stage. Thus, this might be a relevant 
factor in the low number of dossiers received to date, given that the manufacture of most nanomaterials has 
not yet grown to high production volumes (> 1000 tonnes/year per legal entity). 
In October 2011, the EC adopted a recommendation on the definition of “nanomaterial”. The purpose of the 
definition was to enable determining when a material should be considered a particulate nanomaterial or a 
nano-constituent material, and should be covered by several EU regulations (EC, 2011). ECHA is implementing 
the definition as a benchmark in assessing substances within REACH and invites registrants to proactively 
characterize their substances in light of this definition. The characterization of nanoforms of a registered 
substance is a prerequisite to the proper determination of hazards and subsequently risks of the substance in 
its nanoform. ECHA’s current focus is seeking clarity on the physicochemical characteristics of nanomaterials. 
To this end, it will use the available REACH instruments to obtain available data (e.g. in accordance with 
Article 36) or request the generation of new data (Article 41). Such a gradual approach, combined with a 
collaborative and constructive interaction with registrants and stakeholders, forms the first step towards a full 
safety assessment of nanomaterials under REACH.
Nanomaterials risk assessment 
One of the main obligations under REACH is that manufacturers, importers and downstream users have to 
ensure the safe use of the substance they place on the market (in whatever form it is synthesized). Given 
the current status of scientific developments in the area of exposure and risk assessment of nanomaterials, 
industry, regulators and other stakeholders face a substantial challenge in adequately characterizing the risks 
to humans and to the environment. 
For regulatory purposes, appropriate characterization of manufactured nanomaterials is essential. Information on 
physicochemical parameters is important for synthesis, product formulation and toxicological testing. Hence, ECHA, 
in close collaboration with EU Member State competent authorities, the EC and stakeholders, is focusing substantially 
on assessing the type of information that is needed from industry in registration dossiers, in order to characterize 
the risks nanomaterials may pose to humans and to the environment. In initial stages, efforts concentrated on 
physicochemical parameters and processes that, when reported, can aid identifying nano-dossiers.
Activities on nanomaterials
There are a large number of REACH processes (e.g. registration, evaluation, authorization and restrictions) 
and CLP processes (e.g. classification and labelling) for which ECHA needs to be able to carry out its tasks 
for nanoforms, as for any other form of a substance. Therefore, since 2011, ECHA has gradually increased its 
activities in the area of nanomaterials, in order to properly address the regulatory, scientific and legal challenges 
and provide support and advice to industry and stakeholders. Some of the activities that have been conducted 
in 2012 include:
• ECHA has been providing feedback and advice (e.g. via webinars) to registrants that wish to register 
nanomaterials at the next registration deadline (2013). 
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• Guidance developments for nanomaterials have led to six new and eight corrigenda to appendices to 
chapters of the Information Requirements and Chemical Safety Report. 
• IUCLID updates incorporate several nanomaterial flags, and the IUCLID manual is also being updated to 
align it with the guidance updates. 
• Article 36 decisions have been sent to registrants to request further information on their substance. The 
decisions request information that the registrant should have already, and do not require further testing. 
• Three substances have been selected for the Community Rolling Action Plan (CoRAP) List of Substances based 
on initial grounds of concern. These are: silicon dioxide, silver and titanium dioxide.
• A nanomaterials working group (ECHA-NMWG) has been created to discuss scientific and technical 
questions relevant to REACH and CLP processes. ECHA-NMWG is an informal advisory group consisting 
of experts from EU Member States, the EC, ECHA and accredited stakeholder organizations. 
• A Group Assessing Already Registered Nanomaterials (GAARN), established by the EC Directorate-General 
for the Environment and chaired by ECHA, has the purpose of building a consensus in an informal setting 
on best practices for assessing and managing the safety of nanomaterials under the REACH regulation. 
This aims to increase confidence and mutual understanding among stakeholders so that nanomaterials can 
be sustainably developed.
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REACH implementation projects on nanomaterials: Outcomes and 
implementation
Dr Steve Hankin, Institute of Occupational Medicine
It is a continuing matter of debate whether current formal regulatory frameworks, including REACH, are well 
suited to identifying nano-specific issues. These issues include the relevance of notification triggers and 
information requirements, and important knowledge gaps in the toxicology, physicochemical characteristics 
and exposure data needed for highly-informed risk assessment and risk management. In the face of this 
uncertainty, a number of activities aim to improve REACH in relation to nanomaterials. One such activity, the 
REACH Implementation Projects on Nanomaterials (RIP-oN), sought to provide scientific and technical advice 
on key aspects of the implementation of REACH with regard to nanomaterials. The objectives of the RIP-oN 2 
and RIP-oN 3 projects, undertaken by a consortium led by the Institute of Occupational Medicine (IOM), were 
to develop specific advice on:
i. how REACH information requirements on intrinsic properties of nanomaterials can be fulfilled, including 
the appropriateness of the relevant test methods (and dosimetry) for nanomaterials; and outlining, when 
relevant, possible specific testing strategies (RIP-oN 2);
ii. the information that is needed for safety evaluation and risk management of nanomaterials and, in 
particular, if information is needed beyond or in addition to the current information requirements listed in 
REACH annexes VI–X (RIP-oN 2);
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iii. how to do exposure assessment for nanomaterials within the REACH context to cover (a) development 
of exposure scenarios, (b) evaluation of operational conditions (OC) and risk management and mitigation 
measures, and (c) exposure estimation (RIP-oN 3);
iv. how to conduct hazard and risk characterization for nanomaterials (RIP-oN 3).
These projects were carried out as an objective scientific review based on an informed and systematic gathering 
and consideration of evidence by experts who used their knowledge and professional judgement when considering 
the relevance and contribution of the scientific evidence towards delivering the projects’ objectives.
The final project reports summarize the key specific issues related to nanomaterials in a REACH context. 
They also recommend updates to the guidance in a form compatible with possible future integration into the 
existing REACH Guidance on Information Requirements and Chemical Safety Assessment. Clear reference to 
the existing REACH guidance was provided. For issues which were considered to be insufficiently technically 
mature for developing detailed guidance, the need for further research and development is indicated. All task 
reports were subject to review by the project’s EC Steering Group, constituting representatives of the EC Joint 
Research Centre, Directorate-General for the Environment, Directorate-General for Enterprise and Industry and 
the ECHA, and by a Stakeholder Consultation Group, consisting of the members of the REACH Competent 
Authorities Sub-Group on Nanomaterials and other relevant experts from EC Member States, industry and 
nongovernmental organizations nominated by the Competent Authorities for REACH and CLP (CARACAL). 
The assessment of the scientific evidence and subsequent recommendations are the considered opinion 
of the authors and were submitted for consideration by the EC, who have subsequently published the 
recommendations as appendices to existing guidance documents. 
The final reports for the RIP-oN projects3 and nanomaterial-specific appendices to ECHA Guidance4 are freely 
available to download.
Since the completion of the RIP-oN 2 and 3 projects, a number of additional and on-going activities continue 
to inform the discussion and development of nanomaterials regulation. These include publication of the 
EC definition of a nanomaterial, the EC Second Regulatory Review on Nanomaterials published in October 
2012, and their forthcoming assessment of regulatory options for nanomaterials under REACH expected 
in December 2013. Additional evidence gathering activities include the NanoSupport project5 and other EC 
sponsored projects underway including “Scoping possible modifications across the breadth of EU safety & 
health at work legislation for nanomaterials” and “Scoping the impact on industry, consumers, human health 
& the environment from possible options for changing the REACH regulation”. These can be expected to 
be complemented by contributions to the evidence-base from national, European and international research 
projects of relevance to nanomaterials risk assessment. 
Summary of findings from RIP-oN2
Of the existing information requirements reviewed, in general the guidance on physicochemical properties is 
considered to be applicable to nanomaterials, with the exceptions of the limited relevance and applicability of 
the properties and methods for surface tension, flash point and viscosity. Further evaluation of the suitability of 
existing methods for water solubility, partition coefficient, adsorption and desorption was also recommended. 
The existing guidance on toxicological data information requirements was considered applicable for the 
assessment of nanomaterials, although it was highlighted that attention needs to be given to measuring, dosing, 
3 http://ec.europa.eu/environment/chemicals/nanotech/index.htm#ripon
4 http://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment
5 http://ec.europa.eu/environment/chemicals/nanotech/pdf/jrc_report.pdf
Abstracts 25
delivery and tracking of nanomaterials in the test system. In general, the basic ecotoxicological properties and 
endpoints described in OECD test guidelines for the determination of potential effects of test substances in 
environmental compartments (aquatic, terrestrial, sediment) after acute or chronic exposure are considered 
adequate and relevant for nanomaterials. However, OECD acknowledge that the test guidelines were not 
specifically designed for the testing of nanomaterials, and the guidance provided on preparation, delivery of 
test substances to the test system, exposure quantifications, dose metrics, measurement, and metrology is 
considered to be insufficient for testing of nanomaterials. 
The potential additional relevant specific intrinsic properties, which have been identified from an objective 
review of published scientific sources of information, include:
• Physicochemical properties
 – particle shape
 – surface area
 – surface energy
 – surface chemistry
 – surface charge
 – redox potential
 – cell-free reactive oxygen species (ROS) and reactive nitrogen species (RNS) production capacity
 – state of dispersion
 – state of agglomeration
• Toxicological endpoints
 – cell uptake
 – cell viability
 – oxidative stress
 – inflammation
 – fibrosis
 – immunotoxicity (sensitization)
 – cardiovascular toxicity
• Ecotoxicological endpoints
 – ventilation rate
 – gill pathologies
 – mucus secretion
 – brain pathology
 – animal behaviour
 – oxidative stress biomarkers – superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) 
and glutathione-S-transferase (GST).
The value and feasibility of incorporating the identified potential additional relevant specific intrinsic properties 
into the REACH guidance was considered on the basis of the available scientific evidence. Notably, the 
published scientific evidence demonstrates a consensus that representative sample preparation and thorough 
and accurate physicochemical characterization (using multiple techniques) is an essential component of 
assessing the potential (eco)toxicity of nanomaterials. 
With regard to toxicity, a range of endpoints have been examined relating to some of the existing information 
requirements under REACH, including: acute toxicity, repeated dose toxicity, toxicokinetics, mutagenicity, 
carcinogenicity and reproductive toxicity. However, no material regarding other REACH information requirements 
(such as dermal and respiratory sensitization and irritation) was identified. Frequently, studies considered 
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the endpoints of cell viability, oxidative stress, and pro-inflammatory effects in vitro. Studies undertaken and 
reported to date have highlighted a number of key issues or gaps in existing testing strategies that may 
influence their outcome, and thus should be observed closely in the assessment of nanomaterials within 
the context of REACH. Factors such as the exposure method, dose selection, species used and cell type 
under investigation, all have the potential to impact on the assessed toxicity of nanoparticles, highlighting how 
experimental design can influence the resulting toxicological profile. 
A limited body of scientific evidence is available to inform the provision of specific practical advice with regard 
to the ecotoxicological information requirements in REACH, but a number of issues have been found to 
influence the ecotoxicologic responses observed in the study of nanomaterials. These include: (i) coating and 
functionalization of the surface and particle impurities, (ii) suspension preparation methods, (iii) release of free 
metal ions, (iv) particle aggregation, and (V) relevance of dose (concentration)-response for ecotoxicological 
studies of nanomaterials. The extent of influence of these factors on the ecotoxicological impact of 
nanomaterials is still emerging. Although at the time of writing this report, results from the OECD-WPMN 
Sponsorship Programme had not emerged, the limited information currently available from OECD-WPMN 
has been considered. Documents published or classified by the International Organization for Standardization 
and European Committee for Standardization as being at “Final Draft International Standard” or “Draft 
International Standard” stage were reviewed and commented upon. Those at an earlier stage of development 
(i.e. “Committee Draft” stage or lower) were reviewed and commented upon, to the extent possible. 
The gap analysis of relevant intrinsic properties for nanomaterials assembled and further developed the findings 
from (i) the examination of existing REACH guidance, (ii) the identification of additional relevant specific intrinsic 
properties for nanomaterials, and (iii) the assessment of relevance and applicability of testing, endpoints and 
methods described in the scientific literature and on-going international work. The framework used for the 
gap analysis considered physicochemical properties and toxicological and ecotoxicological endpoints. It 
integrated the existing and recognized additional properties and endpoints to identify those that may and may 
not be addressed by standard test guideline methods. It also sought to identify where further development 
of in vitro, in vivo or other methodologies is required. The gap analysis was structured by property and/or 
endpoint, and systematically assessed whether a property and/or endpoint is relevant and the respective 
characterization methods were applicable to nanomaterials. Commentary was provided on aspects including: 
whether the property and/or endpoint is applicable to substances, particles, or nanomaterials only; the method 
type (standard, nonstandard method or widely-accepted in research and development); the applicability 
and limitations of the method; information on the type of data provided by the method; and identification 
of research and development needs. The outcomes of the gap analysis have informed the development of 
specific guidance updates and recommendations for research and development. 
The relevance and applicability of the current Integrated Testing Strategies (ITS) to nanomaterials for properties and 
endpoints in the existing REACH guidance have been reviewed and any limitations identified. For each ITS , the 
relevance and applicability to nanomaterials has been indicated along reviewed, and the need for any update to the 
existing guidance text has been indicated, where this is considered feasible given the current state of knowledge. 
In general, only minor updates are necessary to some of the existing ITS for the properties and/or endpoints 
considered. This includes the general testing strategy for physicochemical properties, water solubility (reflecting a 
need to distinguish between solubilization and dispersion), and the need to justify scientifically the use of quantitative 
structure–activity relationship models and/or read-across in the toxicological endpoints. A substantive update to the 
ITS for granulometry is suggested, reflecting the recommended substantive update to the guidance for this property. 
Advice is provided on the scientific basis for the categorization of nanomaterials and application of in silico methods, 
read-across and category approaches for deriving hazard information for nanomaterials from the information on bulk 
substances or from comparison between nanomaterials. Whilst the lack of data across a wide range of structural 
and compositionally different nanomaterials precludes a fully prescribed category-based approach being developed, 
the suggested approaches for possible development indicate where such groupings may be applied. 
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Summary of findings from RIP-oN3
OC, risk management measures and the “hierarchy of control” concept that underpins much of the REACH 
guidance in this area were considered to be equally valid for nanomaterials as for other substances. There 
is evidence that control and risk management methodologies that are already known can provide levels of 
protection for workers from exposure to engineered nanomaterials. Whilst it was not indicated that new 
nano-specific risk management measures need to be developed, the protection provided against specific 
nanomaterials needs to be evaluated. Evidence indicates that emissions in the workplace are substantially 
reduced if a process involving engineered nanomaterials is performed in a properly designed enclosure or 
containment, although this was not universal. The situation is further amplified when considering what happens 
when containment is opened. Similarly, evidence indicates that worker exposure can be significantly reduced or 
prevented through the use of correctly designed and implemented extraction ventilation and filtration. Filtration 
theory indicates that filtration will be effective for particles in the nanometre size range. This also applies to 
personal protective equipment, where several studies clearly demonstrate the potential of respirator filters to 
capture nanoparticles. As for chemicals in general, further work is required to investigate human factors such 
as leakage around (rather than through) a face-piece filter. The situation is not as clear with protective suits and 
gloves, where much less work has been carried out. 
Control Banding (CB) may have use in relation to the selection of control approaches. Attempts are being 
made to develop this approach for nanomaterials, but they are at an early stage. However, given the current 
level of development, CB cannot be used to demonstrate that the risks are adequately controlled. As an 
interim measure, users might consider CB approaches to provide an initial selection of control measures, 
while collecting further information about exposure, toxicity and risk. Although preliminary medical surveillance 
activities, such as documentation of the presence of engineered nanoparticles and identification of potentially 
exposed workers, are likely to be beneficial in the long term, no clear guidance can be given at this time as 
to which specific medical endpoints should be examined. For safety data sheets (SDS), it is important that 
information provided for a nanomaterial is representative, valid and provides the protection needed for the 
forms addressed by the SDS. 
Other than in the case of filtration, no recommendations for risk management measures in REACH guidance 
relating to the environment can be made at this time, due to lack of evidence. Almost no work has been done 
on the effectiveness of consumer risk management measures. For OC, only limited information was found to 
be available in the public literature. Information is available on the risk management measures adopted, and 
in some cases the quantity of material produced and used on a daily or batch basis. Information concerning 
room sizes, ventilation rates, and temperature is almost entirely absent. 
Regarding exposure estimation, the key issues identified included: discrimination from background 
nanoparticles; measurement of size distribution; maximum relevant particle size; effect of high spatial and 
temporal variability; assessment of high aspect ratio nanomaterials; application of exposure models and choice 
of metric; and instrument and measurement strategy. Alternative approaches in dealing with background 
particle measurements included a time series approach, near- and far-field paralleled measurements and off-
line analysis to confirm whether peak concentrations observed correspond to an identified nanoparticle, either 
by composition, morphology or both.
Consideration of the use of size distribution data concluded that recommended methods should be able to 
account for complex distributions (e.g. bimodal distributions) and that the full size distribution curve should 
be reported. Particle size issues were concerned with aggregates and agglomerates and the need to identify 
and characterize these. Nanoparticles of interest may be present as primary particles, larger aggregates 
or agglomerates, and potentially background particles from which primary particles may subsequently be 
released. It was suggested that the respirable convention is the appropriate upper size limit. Given the effect 
of high spatial and temporal variability, measurements of workplace air concentrations are unlikely to represent 
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personal exposure. Therefore strategies which encourage comparison (even limited) between workplace air 
concentrations and personal exposure are recommended. At this time, it is not possible to make a definitive 
statement concerning which of the metrics are the most appropriate for nanoparticles. In relation to measuring 
exposure, the recommended practice at this time is that measurements should encompass assessment of at 
least mass, but where possible also number and/or surface area concentration. 
For high aspect ratio nanomaterials, the application of WHO approach has not yet been validated. Given an 
absence of measurement methods or terminology to describe “bundles” or “clumps” of high aspect ratio 
nanomaterials, no specific guidance can be given at this time for quantitative assessment of these entities. 
However, their presence should be noted in any assessment. The limited evidence of validation for occupational 
exposure indicates that model estimates should not be relied on alone without further confirmation of their 
validity in individual cases. In any case, model estimates should be used with caution and with further scientific 
justification. Detailed implications for these issues in relation to the REACH guidance has been developed in 
Task B4 and refined through discussions with the Stakeholder Consultation Group into proposals for guidance 
amendments, which have been fully elaborated in the Final Project Report. 
Consideration and evaluation of the REACH approach for deriving no-effect levels was made through the use 
of case studies for multiwalled carbon nanotubes (MWCNTs), nano-titanium dioxide and silver nanoparticles. 
In relation to the case studies, in all instances data gaps were observed that could hinder a full evaluation 
under REACH. Normally, the approach for dealing with deficiencies in data would be to look for other studies 
using similar materials, which may provide some knowledge of the likely effects of the materials (e.g. long-term 
effects, systemic effects, etc.). However, in relation to many nanomaterials, evidence is insufficient to apply 
such an approach. 
Where data was available, and a case study was performed, it emerged that a major question relating to 
the REACH guidance was the applicability of the current assessment factors for nanomaterials, as these 
assessment factors have been derived from classical (soluble substance) toxicity in relation to both human 
and environmental health. Considerations have been made regarding their applicability to nanoparticles and 
the impact that alternative metrics and other issues, such as agglomeration and aggregation state, could have 
on the different assessment factors. However, it was considered that, for the most part, the current guidance 
on deriving exposure limits provides sufficient flexibility to address areas of uncertainty, data gaps and, if 
justified, deviations from the default approach and assessment factors. It was considered unclear whether the 
aggregation and agglomeration of nanoparticles will result in higher or lower toxicities found in standard tests. 
However, the aggregation or agglomeration state could affect various parameters, such as deposition zone 
in the lung or uptake by organisms, and thus characterization of particles both within test systems and the 
exposure environment is important. 
Considerations were made of on-going hazard and risk characterization approaches, using the case study 
nanomaterials (MWCNTs, titanium dioxide, nanosilver). Evaluation of the identified alternative approaches 
for hazard and risk characterization under REACH revealed both merits and deficiencies in the derivation of 
exposure limits. This was very much the case in relation to extrapolating from experimental animals to humans 
for inhalation exposure (pertaining to both initial starting point modification and interspecies adjustments). 
Based on the information gathered and considered, in addition to the wider particle toxicology literature, 
an alternative approach for extrapolating from experimental animals to humans for inhalation exposure was 
suggested for possible future incorporation into guidance. 
Lastly, jointly between the RIP-oN 2 and RIP-oN 3 projects, the critical items on exposure and dose descriptors 
were identified and used to outline needs for adequate metrics and parameters, as appropriate for exposure 
assessment and compatible with those used for hazard assessment. The metrics currently used in risk 
assessment (both regulatory and otherwise) across the three elements of exposure, toxicology and risk, are 
based on mass or number. The most prominent emerging alternative or additional metric identified for use 
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in relation to the risk assessment of nanomaterials is surface area. This is based primarily on toxicological 
evidence relating particle surface area to inflammation, an indicator of toxicity. There are currently no definitive 
conclusions on the best metric. However, there is consensus that there should be sufficient characterization 
of the forms of a substance tested to allow the dose response to be expressed in the different metrics 
discussed: number, surface area and mass. It is important to note that there are other parameters that can act 
as modifiers of the toxicity, including particle size, size distribution, density, surface modification, aggregation 
and agglomeration state, and shape, but these parameters would not generally be considered as scalable 
quantities. They do not appear to conform to the current use of the term “metric” under REACH, and were 
therefore not considered further in relation to the metric issue. 
Nanomaterials in EU regulation
Andrej Kobe, Directorate-General for the Environment, European Commission
There are no specific EU regulations on nanomaterials. Two successful EC regulatory reviews, in 2008 and 
2012, have concluded that the existing EU regulatory framework covers nanomaterials in principle; however, 
individual pieces of legislation may require adaptation to ensure adequate and effective implementation. In 
2009 the European Parliament disagreed with the EC 2008 assessment and called for responsible use of the 
new technology and actions to ensure adequate information on safety and uses of materials on the market. It 
also prompted the introduction of some specific provisions in the enacting terms of legislation on biocides (EU, 
2012), cosmetics (EU, 2009) and food labelling (EU, 2011) in co-decision. In a 2012 review, the EC affirmed the 
need to strengthen market surveillance and improve information and labelling requirements for nanomaterials 
in consumer product safety legislation. It also concluded that principle risk assessment paradigms applied in 
existing legislation were adequate, with the proviso that risks arising from specific properties, challenges in 
application of methods and tools, and variation between different materials must be adequately addressed. No 
generalizations are possible at present so a case-by-case approach to risk assessment is required. There is 
still a general lack of data, although development since 2008 has been significant. A review of environmental 
legislation (e.g. air, water, waste) emphasized the challenges in assessing nanomaterials in the environment, 
the ineffectiveness of end-of-pipe measures and the strong dependence on upstream chemicals legislation 
(e.g. REACH and CLP) to generate appropriate data and classify hazardous nanomaterials. An assessment on 
workplace legislation will only be concluded in 2014.
At present, cosmetics, biocides and food labelling regulations include nano-specific provisions in enacting 
terms, to better ensure their specificity is taken into account in the respective risk assessment and/or labelling of 
product ingredients. The first step in revising REACH was improving guidance for implementation and set-up of 
the specific working group at the ECHA, while further steps, such as revision of its annexes are still in progress. 
All changes have been informed by a series of studies, stakeholder consultations and the opinions prepared by 
the EU scientific committees. In order to support coherent regulatory introduction of nano-specific provisions, 
in 2011 the EC published a recommendation on the definition of “nanomaterial” and invited Member States 
and EU agencies to apply it in their work. Practical aspects of the implementation of the recommendation are 
continuously being addressed (e.g. the 2012 Joint Research Centre report on measurement methods), while 
the definition itself will be reviewed in 2014. 
In 2012, France introduced a notification scheme to address the lack of knowledge regarding nanomaterials 
on the market. Several other Member States are considering similar schemes. In 2013, the EC is performing 
an impact assessment on establishing an inventory at EU level and will take into account national experiences. 
It also announced the third regulatory review in 2015. 
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Pulmonary effects of exposure to nanoparticles
Ulla Vogel, Anne T Saber, Nicklas R Jacobsen, Petra Jackson, Karin S Hougaard, Ismo K Koponen, Keld A 
Jensen, Håkan Wallin
Danish Centre for Nanosafety, National Research Centre for the Working Environment 
Nano-sized titanium dioxide and carbon black are both high-volume industrial chemicals. Airway exposure 
to nano-sized titanium dioxide and carbon black in the working environment is therefore likely. The potential 
risk of airway exposure to nanoparticles is of concern. Depending on primary and agglomerate particle size-
distributions, a significant fraction of inhaled nanoparticles may deposit in the alveolar region of the lungs where 
clearance is slow. Prolonged lung retention is likely to result in long-lasting inflammation, which is linked to 
several adverse health effects. Inflammation has been shown to be proportional to the total surface area of the 
pulmonary deposited particles (Duffin et al., 2007; Saber et al., 2011)
As an example, we have studied the hazard of two industrially relevant engineered nanoparticles: titanium 
dioxide nanoparticle UV-Titan L181, which is a surface coated rutile with an average crystallite size of 17 nm; 
and Printex 90, which is a carbon black nanoparticle with an average primary particle size of 14 nm. When 
aerosolized, the titanium dioxide had an average aerodynamic size of 97 nm (Hougaard et al., 2010) and the 
carbon black had an average agglomerate size of 45 nm (Jackson et al., 2012). Inhalation of the titanium 
dioxide and carbon black dusts for 1 hour daily for 11 days at about 40 mg/m3 increased influx of neutrophils 
in the lungs at both 5 and 25 days after exposure in mice (Hougaard et al., 2010; Jackson et al., 2012). 
Titanium dioxide retention in the lungs was assessed by measuring the titanium content in lung tissue 5 and 
25 days after exposure. Five days after exposure, 24% of the estimated lung titanium deposition could still be 
detected in lung tissue; after 25 days, 21% could be detected, indicating slow clearance of the nano-titanium 
dioxide from the lungs (Hougaard et al., 2010). Increased levels of DNA strand breaks in bronchiolar lavage 
fluid were observed following inhalation exposure to carbon black but not titanium dioxide (Hougaard et al., 
2010; Jackson et al., 2012). The doses correspond to half the daily exposure at the Danish OEL to titanium 
dioxide (9.75 mg/m3 for 8 hours) or 50% more than the daily exposure at the Danish OEL to carbon black (3.5 
mg/m3/8 hours).
In another series of studies, UV-Titan and Printex 90 were deposited in lungs of mice by intratracheal 
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instillation. The doses corresponded to the total pulmonary deposition following 1, 3 or 9 days of exposure at 
the Danish OEL for the studied carbon black, based on the observed size distribution when aerosolized; and 
1.5, 4.5 and 14 days at the Danish OEL for studied titanium dioxide. Exposure resulted in dose-dependent 
lung inflammation for both particles (Saber et al., 2012), and induction of DNA strand breaks in lung fluid 
cells, lung tissue and liver tissue for carbon black (Bourdon et al., 2012a). Thus, persistent inflammation and 
DNA damage was observed 28 days after instillation of doses corresponding to 3 and 1 day exposure to the 
Danish OEL of carbon black, respectively (Saber et al., 2012).
The Printex 90, but not the UV-Titan L181, was shown to induce reactive oxygen species in vitro (Jacobsen et al., 
2008; Saber et al., 2011). The carbon black is mutagenic in vitro and the observed mutation spectrum is consistent 
with the interpretation that the mutations are caused by oxidative damage (Jacobsen et al., 2007, 2011). Global 
gene expression was assessed in lung tissue. For Printex 90, the most differentially expressed gene was the acute 
phase protein, serum amyloid A (SAA)  (Bourdon et al., 2012b). Inhalation of UV-Titan L181 also increased pulmonary 
expression of acute phase proteins, with SAA3 as the most differentially expressed gene (Halappanavar et al., 2011). 
This links pulmonary exposure to cardiovascular risk, because it was recently shown that overexpression of SAA was 
sufficient to accelerate plaque progression in susceptible ApoE-/- mice (Dong et al., 2011).
CNTs represent another industrially relevant nanomaterial. As CNTs are high aspect ratio particles, that is long, thin, 
inhalable and insoluble fibres, they are suspected of having asbestos-like properties. Takagi et al. (2012) showed 
that intraperitoneal injection of the multiwalled carbon nanotube (MWCNT) Mitsui-7 resulted in mesothelioma in 
a susceptible mouse strain (p53 heterozygous mice) in a dose-dependent manner and at relatively low doses (1 
microgram [μg]/mouse or 106 fibres/mouse). However, another noncommercially available MWCNT (11 nm wide 
and 0.7 micrometres [μm] long) did not induce cancer following intraperitoneal injection in rats (Muller et al., 2009).
Subchronic inhalation studies of two different MWCNTs, Baytubes and Nanocyl NC7000, both identified 0.1 
mg/m3 as the lowest-observed-effect level or no-observed-effect levels (Ma-Hock et al., 2009; Pauluhn, 2010). 
The pulmonary retention time was estimated as 375 days (Pauluhn, 2010). 
Concerns are also raised regarding nanomaterial-based products, for example paint and lacquers. The potential 
hazards of sanding dust from paint nanocomposites were assessed by generating dust particles by sanding 
wall paint with and without UV-Titan L181 (Koponen et al., 2011). Toxicity was assessed by deposition of the 
sanding dust into the lungs of mice (Saber et al., 2012). There was no difference in the inflammatory response 
to paint with and without UV-Titan, and the inflammatory response was much lower than that observed for the 
pure UV-Titan (Saber et al., 2012). No induction of DNA damage was observed.
In summary, toxicological effects after pulmonary exposure to pure titanium dioxide- and carbon-based 
nanoparticles and CNTs were observed at doses well below or close to the OELs. This indicates that the 
present OELs do not protect against adverse effects following exposure to the studied nanomaterials. NIOSH 
has proposed an OEL of 7 μg/m3 for CNTs in air, and an OEL of 0.25 μg/m3 for the general population. Others 
have proposed an OEL of 1 μg/m3 (Aschberger et al., 2010). NIOSH has furthermore proposed a specific 
exposure limit for ultrafine (and nano-sized) titanium dioxide of 0.3 mg/m3.
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The IRGC Risk Governance Framework: Applications in food and cosmetics
Dr Antje Grobe, DIALOG BASIS, University of Stuttgart, Germany and University of St. Gallen, Switzerland
Nanotechnologies have been identified as one of the key technologies for innovation in the fields of sustainable 
energy, transport, medical treatment and water purification, to name but a few. Many consumer products using 
nanotechnologies are under development or already on the market, such as smart textiles, intelligent packaging, 
cosmetics, paints and construction materials. However, in the light of the debate about GMOs in Europe, with 
millions of euro disinvestment due to negative public perceptions the development of nanotechnologies is 
accompanied by an extended societal debate. The idea of an inclusion of societal issues in the full process of 
technology assessment was developed by the IRGC in 2006. The IRGC report, Appropriate risk governance 
strategies for nanotechnology applications in food and cosmetics (IRGC, 2008) analysed the communicational 
patterns of the nano-debate and the changes of risk awareness among the broader public in these special 
fields of interest. 
The authors recommended stakeholder dialogues as an early warning system in the pre-assessment phase, 
a systematic concern assessment in the risk appraisal phase, followed by a commonly shared tolerability 
judgement and adequate risk management measures. Each of the steps required the inclusion of stakeholders 
and a minimum of transparency and shared information. As discussed by Grobe and Rissanen (2012), we 
are still far from an application of the IRGC Risk Governance Framework for nanotechnologies in the food or 
cosmetics industries. The consequences are becoming more and more visible in public perception studies. For 
example, in Germany and Switzerland the quality of consumer knowledge about nanotechnologies decreased 
significantly between 2008 and 2011 (Grobe et al., 2012). Consumers know less about potential applications 
and benefits, but showed more detailed knowledge about risks. The data were interpreted as the result of two 
main factors: first the “non-communication” strategies of industry, and second, as the product of well connected 
and actively communicating environmental groups and consumer organizations. According to the first axiom of 
Paul Watzlawick: “One cannot not communicate” (Watzlawick et al., 1967), the absence of information about 
the benefits and the quality of nanotechnology products led to a transformation of concerns and uncertainties 
from former technology debates to the debate about nanotechnologies. The consumer’s requirements for more 
information and transparency were exemplified: industry should provide easily accessible information about 
the functionality and the added value of nanomaterials in consumer products, about their safety for humans 
and the environment, and whether the products have been tested by an independent organization. Over all, 
consumer attitudes and expectations are still positive. But if industry fails to build trust among regulators, civil 
society organizations and consumers, nanotechnologies will share the fate of GMOs. Therefore, innovation 
for responsible communication strategies on nanotechnologies is needed, in the same way as responsible 
innovation in nanomaterials themselves.
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Scope and Purpose
The use of nanotechnology and nanomaterials stands to offer great societal benefits in areas such as clean 
water and energy, medicine and manufacturing of novel products. Nanomaterials and products based on 
nanotechnological applications are being commercialized at an increasing pace and human and environmental 
exposure can occur either during manufacturing of goods, use and disposal of products.
Given the increasing use of nanotechnology, concerns have emerged about the potential adverse health 
effects of nanomaterials and nanoparticles. At present, in fact, it is not fully known which nanomaterials can be 
hazardous to human and the environment, nor is it fully understood which properties make nanomaterials more 
or less toxic. Although significant progress is being made in regard to studying and mapping the environmental, 
health and safety aspects of nanomaterials, the field is pervaded by scientific uncertainty (“we know what we 
do not know”) and ignorance (“we do not know what we do not know”).
At the Fifth Ministerial Conference of Environment and Health (Parma, Italy, 10-12 March 2010)1, the health 
implications of nanotechnology and nanoparticles were listed among the key environment and health challenges 
that Ministers in the WHO European Region committed to act on. Along with a call for an increase of research 
into the use of nanomaterials, the Ministers, acknowledging the complex nature of the question, pledged to 
develop and use improved health risk and benefit assessment methods.
Preliminary work carried out by WHO indicates that a rigorous risk assessment is currently not feasible and that 
a less structured model of “risk governance” is a preferable way to proceed. Such an approach must be based 
on the best available science and evidence in regard to possible biological and health effects, but also on 
what is known about the present and future uses of nanomaterials, as well as regulation and risk management 
strategies.
This consultation organized by the WHO Regional Office for Europe aims at reviewing and discussing the current 
state of knowledge concerning the health risks and impacts of nanotechnology, established, suspected, and 
potential. Research into the environmental, health and safety aspects of nanomaterials is vast and growing 
rapidly, and so are the systematic literature reviews.
Specific issues for discussion include: present and future use and diffusion of nanomaterials; human health 
toxicity; risk assessment limitations and strategies, and alternative approaches; current nanomaterial regulatory 
frameworks; nanomaterial risk governance experiences and needs. The main objective of the consultation is 
thus to take stock of the recent insights from research and outcomes of assessment exercises in order to 
further characterize the complex picture of the health implications of nanotechnology and provide European 
Member States with some suggestions on appropriate risk and benefit assessment methods and, ultimately, 
for developing appropriate policies.
1 Parma Declaration on Environment and Health. Copenhagen, WHO Regional Office for Europe, 2010 (http://www.euro.
who.int/__data/assets/pdf_file/0011/78608/E93618.pdf, accessed 2 October 2012).
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Executive summary
Nanotechnology is the science and application of 
materials with a size below 100 nanometres (nm) (10-
9 m). A number of substances, at this scale, acquire 
properties that are different both from those at an 
atomic or molecular level as well as at bulk scale. 
This has opened the way for a variety of applications 
in many different fields, from medicine to consumer 
products, from the creation of new materials to food 
additives. Research and commercial applications 
are already widespread, but nanotechnology is 
in its early days and the potential for developing 
and applying new generations of nanomaterials is 
huge. Harnessing the potential of current and future 
applications is the goal of nanotechnology, and the 
prospect of large benefits and returns has attracted 
considerable research and financial investment. 
At the same time, concerns have emerged with 
regard to the potential of nanomaterials, engineered 
nanoparticles in particular, to have unwanted or 
unexpected interactions with biological systems, 
resulting in adverse consequences for human and 
ecosystem health. The literature on these aspects 
is growing rapidly, but many areas of uncertainty 
remain, not least because nanotechnology is evolving 
fast and new research questions arise frequently. 
The issue will likely be surrounded by considerable 
uncertainty for some time.
This report aims to synthesize the current state of 
knowledge and the key evidence on possible health 
implications of nanomaterials, and identify options 
for risk governance and policy formulation. In this 
respect, it is important to underline that the term 
“nanotechnology” encompasses a very large and 
heterogeneous set of materials and applications 
which are difficult to classify, and impossible to 
discuss in their entirety. For the sake of discussing the 
health implications, it is convenient to consider the 
location of the nanoscale structure in the materials, 
i.e. whether nanostructures are in the bulk or on the 
surface, or if the material contains nanoparticles; 
in the latter case, most relevant for health effects, 
one can distinguish between the presence of 
nanoparticles bound to the surface, suspended in a 
liquid, suspended in a solid or airborne.
Humans have limited evolutionary experience of 
exogenous nanomaterials, with very few types of 
nanoparticles being present from prehistory, such as 
some inorganic nanoparticles from marine aerosols 
and viruses. As humans learnt to control fire, 
nanoparticles from combustion also became part of 
our evolutionary history. This may be a reason for the 
diminishing ability of cells to interact with particles 
(through the main mechanisms of dealing with 
them, phagocytosis and endocytosis), as their size 
decreases to nanoscale.
When they come into contact with humans, 
nanoparticles can enter the body relatively easily 
through inhalation, gastrointestinal assimilation and 
dermal absorption. They can also gain access to the 
central nervous system through the olfactory mucosa 
or through the blood–brain barrier, especially during 
the fetal stage and early life. These properties are of 
great interest for the targeted delivery of drugs.
Once inside the body, nanoparticles are highly mobile: 
they can access the circulation and be transported by 
the blood stream. How this happens in practice, the 
properties of nanoparticles as they travel the body 
and their dependence on particle size, however, is 
not well understood, as most of the evidence is based 
on animal models, with uncertain extrapolations to 
humans. Some degree of bioaccumulation due to 
incomplete excretion is known to occur, for example 
in the lung, gastrointestinal tract and the brain.
Evidence of the health effects of airborne particles, 
especially particulate matter (PM) of 2.5 micrometres 
(μm) and below PM2.5 (fine particles) is well 
established and includes severe and measurable 
impacts on mortality, morbidity, hospital admission 
and occurrence of symptoms. PM2.5 includes 
ultrafine and nanosized particles, whose role in 
determining the health effects is not well known. 
It is also clear that for nanoparticles, exposure 
metrics other than gravimetric concentrations (i.e. 
micrograms (μg) per cubic metre) are more relevant 
to assessing human exposure, for example the 
particle count or their total surface area.
Several mechanisms by which nanoparticles can 
induce cell damage have been reported, mainly of a 
chemical nature (e.g. oxidative stress, inflammation, 
protein misfolding), but also of a physical nature (e.g. 
direct physical damage, production of secondary 
photoelectrons), and involving the cell nucleus, 
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the membrane and cell organelles. Many of these 
mechanisms are known specifically for certain types 
of nanoparticles; they are often dependent on particle 
size, with a tendency to become more active as the 
particle size decreases.
The overall data and evidence on nanotechnology 
and health is far from conclusive. A cautionary 
approach is recommended by many evaluations, on 
the basis of the wide range of possible effects; the 
lack of effective defence mechanisms in the human 
body; the potential for damage; the possible extent of 
population exposure, for example through consumer 
products, cosmetics and food additives; the speed 
of technological development; and the projected 
proliferation of applications. The need for caution is 
reinforced by recent evidence of the asbestos-like 
action of carbon nanotubes in animal models and, to 
a lesser extent, by episodes of human health impacts 
following localized acute exposures.
Translating information about nanoparticle exposure 
and distribution in the human body, toxicological 
mechanisms and possible adverse health effects 
into assessment of the risks for human health is 
highly challenging. Traditional risk assessment 
methodology, for example as applied in chemical 
safety, has some important limitations. There is a 
need for the development of “nanotoxicology” as 
a specialized branch of toxicology that takes into 
account the property of materials at the nanoscale, 
similarly, approaches and methodology for describing 
the likelihood of human health impacts must take into 
account the unique complexities of the interaction 
between nanomaterials and the human body. Such 
complexities challenge all steps in traditional risk 
assessment: hazard identification is complicated by 
the diversity of nanomaterials and their properties, 
and by the variety of the possible relevant health 
endpoints. The few dose–response relationships 
known are based on experimental studies, especially 
in vitro, and interpretation and extrapolation of these 
data to human health is difficult; also some health 
effects may not depend on dose, but on other 
physical and chemical properties. As to exposure 
assessment, some attempts have been made in 
controlled circumstances in the occupational setting, 
but information is chronically lacking, due, among 
other things, to uncertain exposure metrics and 
technical difficulties in measuring concentrations.
Models and frameworks alternative to traditional risk 
assessment are thus being developed and applied 
to organize the available evidence on biological and 
health effects of nanomaterials in ways that can inform 
policy. Many of these approaches, developed by 
consortia of public and sometimes private agencies 
and expert groups, recognize the high degree of 
complexity and uncertainty. Thus, they are based 
on several steps (sequential or organized in flow 
charts), make provision for extended stakeholder 
consultation and some, rather than focusing on one 
agent, involve the consideration of alternatives, as in 
the case of comparative hazard assessment.
As no agency is currently in a position to formulate 
conclusive and reliable assessments of the 
health risks of nanomaterials, it is imperative that 
adequate mechanisms are put in place, at various 
levels, to ensure transparent and fair negotiation 
between stakeholders, and that evidence on health 
implications is used to inform the risk governance 
of nanotechnology. Profitable areas of discussion, 
in terms of policy action, include: the creation of 
regulatory bodies and their scope; the development 
of labelling schemes for consumer products (with a 
separate regime for pharmacological and medical 
applications); the most suitable means of providing 
information to the public for exercising informed 
choices; the relevance, at nanoscale, of licenses 
for production of materials at bulk scale; the criteria 
for identification of priority nanomaterials, for 
research and regulatory action; and the institution of 
monitoring and surveillance systems, possibly aimed 
with priority at vulnerable groups, for early detection 
of health consequences of nanomaterials.
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1. Remit
The purpose of this document is to provide an 
overview of the potential impacts of nanotechnology 
on human health, and discuss if such evidence can 
be used to inform processes of risk governance 
of nanotechnology. The review first focuses on the 
potential health sequelae that could result from 
exposure to engineered nanoparticles or products 
containing them. Since 2003, a large number of 
detailed reviews have been published examining the 
impacts of nanotechnology (e.g. ETC Group, 2003a; 
ETC Group, 2003b; Bucher, 2004; EU, 2004; Royal 
Society, 2004; Swiss Re, 2004; Allianz & OECD, 
2005; Oberdörster et al., 2005; Borm et al., 2006; 
DEFRA, 2006; FSA, 2006; Gwinn & Vallyathan, 
2006; HSE, 2006; Maynard, 2006a; DEFRA, 2007; 
IRGC, 2007; CCA, 2008; NNI, 2008; DEFRA, 
2009; Linkov & Steevens, 2009; Oberdörster, 2009; 
Seaton et al., 2009; Stone et al., 2010). Given this 
exhaustive background information, the aim is not 
to provide another extensive review, but rather 
to inform the policy debate in Member States of 
the WHO Regional Office for Europe by critically 
examining the current knowledge base from a toxico-
pathological viewpoint and discussing the likely 
disease patterns that could result from exposure. On 
the basis of the available evidence, the commentary 
addresses questions of risk assessment and risk 
governance in nanotechnology, by discussing pros 
and cons of different risk assessment strategies 
and other frameworks for dealing with the risks of 
nanomaterials. The report concludes with a set of 
points meant to develop a suitable risk governance 
framework. This document was prepared following 
consultation work begun by WHO in 2008, in the 
framework of the EU co-funded PAVEL Project 
(Enhanced policy advice in environment and health 
Grant Agreement 2006WHO01). Draft versions were 
compiled and updated by the authors, taking into 
account the outcome of the expert consultations and 
on the basis of selected specialized literature.
2. What is nanotechnology?
2.1 Evolution
Broadly speaking, nanotechnology consists of 
the study and use of substances and materials at 
the scale 1–100 nm (10-9 m) in size. At this scale, 
substances and materials acquire properties that 
differ from the properties at both the atomic or 
molecular level and from those at bulk size.
Controlling and taking advantage of such novel 
physical, chemical and biological properties is the 
objective of nanotechnology. This holds the prospect 
of considerable benefits, through the development 
of countless applications: from new drugs and 
therapies to water purification technologies, from 
photovoltaic devices to food additives (see Figure 1 
for some examples of existing applications). While 
many applications are already in use, including 
for health and the environment, and despite 
the substantial technological advances already 
achieved, nanotechnology is in its early stages, with 
an exceptionally rapid pace of innovation.
Four generations of nanotechnology development 
have been identified (Roco, 2003). The first 
generation, developed until the year 2000, consists 
of simple “passive” nanostructures. The second 
generation, undergoing development between 2000 
and 2005, includes the development of “active 
(evolving function) nanostructures” such as targeted 
drugs and chemicals, light-driven molecular motors, 
nanoscale fluidics, laser-emitting devices and 
adaptive structures. The third generation consists of 
“systems of nanosystems”. This generation, projected 
to range from 2005 to 2010, includes the use of 
various syntheses and assembling techniques such 
as bioassembling, networking at the nanoscale and 
multiscale and hierarchical architectures, robotics on 
surfaces, modular nanosystems, chemomechanical 
processing of molecular assemblies, and 
quantum-based nanoscale systems. From 2010 
to 2015/2020, a fourth generation was projected 
to involve the development of heterogeneous 
molecular nanosystems, where each molecule in 
the nanosystem has a specific structure and plays a 
different role (Roco & Renn, 2006).
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2.2 Types of application
The word “nanotechnology” is probably of limited 
usefulness as it encompasses a wide range of 
enabling technologies that will facilitate progress 
in a number of fields (often unrelated to the initial 
development). According to the British Standards 
Institution (BSI, 2007) the number of nanotechnology 
methods, processes and techniques exceeds 30. The 
catchall nature of the term “nanotechnology”, hence, 
may be confusing, as it can lead to a classification of 
a whole range of technologies as a single entity. In 
fact, the definition of “nanomaterial” or “nanoparticle” 
is still subject to debate 
A great number of different nanomaterials can be 
manufactured (using various techniques) including 
buckminsterfullerene, carbon nanotubes, micelles, 
self-assembled monolayers, dendrimers, and 
aerogels in all kinds of sizes and shapes. The 
nature and the properties of nanomaterials differ 
substantially, and so do the potential biological effects 
and possible health hazards; however, information on 
a particular aspect of nanotechnologies has tended 
to be applied to the whole spectrum, which can be 
misleading.
In order to facilitate hazard identification and to 
focus risk assessment, Hansen et al. (2007) suggest 
categorizing nanomaterials depending on the 
location of the nanoscale structure in the system. 
This leads to a division of nanomaterials into three 
main categories (see Figure A3.1 for examples):
1. materials that are nanostructured in the bulk
2. materials that have nanostructure on the 
surface 
3. materials that contain nanostructured 
particles.
A benefit of this categorization is that it provides a 
tool for dividing nanosystems into identifiable parts, 
thereby facilitating the evaluations and analysis 
ofexposure routes or effect studies. Others have 
proposed that nanomaterials are classified into 
different groups, depending on their chemical 
composition, for example the National Academy of 
Sciences (2008) grouped nanomaterials into metal 
oxides, nanoclays, nanotubes and quantum dots, 
while the United States Environmental Protection 
Agency (EPA) (2007) proposed groups of carbon-
based materials (nanotubes, fullerenes), metal-
based materials (metal oxides and quantum dots), 
dendrimers (nanosized polymers) and composites 
(including nanoclays).
While the scientific literature on nanomaterials 
toxicity and ecotoxicity is growing rapidly, a number 
of aspects of nanotechnology do not appear to pose 
an appreciable immediate health threat, although 
extensive uncertainties remain. For example, the 
use of nanostructured surfaces to produce self-
cleaning glass for use in buildings is a case of non-
pervasive application, unlikely to have major health 
implications. However, this will not apply during 
manufacture or subsequent breakdown, and indeed 
the nanotechnology industry is currently engaged 
in the production of powders consisting of these 
nanoparticles, potentially hazardous and locally or 
widely pervasive.
Nanoparticles, an important subset of nanomaterials, 
are defined as discrete particles with at least one 
dimension less than 100 nm (which includes thin 
enough fibres); for a fuller definition see ISO (2008). 
Nanoparticles can have various forms and shapes, 
and include quantum dots, fullerenes, nanotubes 
and nanowires (Maynard & Aitken, 2007). In the 
third category of the classification of nanomaterials 
described by Hansen et al. (2007) – materials that 
contain nanostructured particles – four subcategories 
can be identified, depending on the environment 
around the nanoparticles:
• subcategory IIIa: nanoparticles bound to the 
surface of another solid structure
• subcategory IIIb: systems where nanoparticles 
are suspended in a liquid
• subcategory IIIc: nanoparticles suspended in solids
• subcategory IIId: of airborne nanoparticles.
This report will mainly focus on the health 
implications of free nanoparticles (subcategory III; b, 
c and d) of the first generation of nanotechnology; 
newer generations might pose profoundly different 
challenges. Carbon nanotubes and titanium dioxide 
are specifically considered in this report, given their 
widespread use and the available toxicity data.
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Figure A3.1. Examples of nanomaterials and applications
Nanostructured materials Bulk material structure at the 
nanoscale (e.g. nanocrystals with 
large breaking strength)
Bulk consisting of several 
materials (e.g. porous pills of 
magnesium chloride for the 
storage of ammonia)
Surface-structured 
nanomaterials
Bulk material with structures at 
the nanoscale (e.g. cell-growth 
promoting plastics for implants)
Unpatterned nanofilm (e.g. dew 
free sunglasses)
Patterned nanofilm (e.g. 
magnetic film on hard disks)
Nanoparticles Surface bound platinum particles 
used in car catalysts
Carbon nanotubes incorporated 
into solid materials (e.g. ratchets, 
bikes)
Titanium dioxide suspended in 
liquids (e.g. sunscreens)
Airborne nanoparticles
Source: Hansen SF (2012). Reproduced by permission of DTU Environment.
3. Nanotechnology and health:  
 background
Despite the great potential of materials at the 
nanoscale, concerns also exist about their possible 
unintended adverse effects on human health and 
the environment. As substances acquire new, 
sometimes unexpected properties when engineered 
at nanoscale, and as the complexity of the 
nanomaterials’ structures and functions increases, 
their ability to interact with biological systems, their 
known toxic characteristics, and their potential to 
cause adverse health effects, can also change.
Concerns over the possible health effects of exposure 
to nanomaterials were somewhat heightened by 
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two episodes, in different settings, suggesting the 
occurrence of acute respiratory conditions . In 2006, 
80–100 people experienced respiratory problems and 
six were admitted to hospital with pulmonary conditions 
following use of “Nano Magic”, a glass sealant home 
product, which was recalled. In 2008, seven workers 
in a printing factory in China were admitted to hospital 
with severe respiratory problems and two of them 
died, following exposure to nanoparticles over several 
months. Both episodes made international news and 
stimulated the debate over nanotechnology safety, in 
the general population as well as in the occupational 
setting. While these episodes provide some warning, 
neither established a clear causal link between 
exposure and health effects: in the first case, it turned 
out that the sealant contained no nanomaterials, but 
was designed to produce a nanoscale layer on the 
treated surfaces through deposition of an aerosol, 
which may have affected the users’ lungs. In the 
second case, limited information on the nature and 
extent of the actual exposure to nanomaterials 
prevented the formulation of robust conclusions (see 
boxed text for further details).
3.1 Evolutionary perspective
To put in context the question of the possible 
adverse health effects of nanoparticles, it may be 
useful to examine the conditions that prevailed 
during human evolution. Seaton et al. (2009) provide 
a brief background on this topic in their review. It is 
likely that through evolutionary processes all species 
become adapted to prevailing conditions. However, if 
new agents or exposures are introduced, or marked 
changes in intensity of exposure occur, a lack of natural 
defences should cautiously be assumed, until it can 
be shown that there are no deleterious influences. An 
example can be made by considering environmental 
levels of heavy metals. The geochemical record 
indicates that traces of lead, cadmium, mercury etc. 
have always been present in the environment, albeit at 
very low levels. Thus, we have evolved mechanisms 
for their removal, which involve carrier proteins. 
However, these mechanisms evolved to cope with the 
pre-industrial levels to which we were exposed. When 
faced with higher levels of exposure, the performance 
of such systems is not optimal, and exposure to heavy 
metals is known to have deleterious health effects.
Humankind has always been exposed to some 
inorganic particles, possibly including some at 
nanoscale, mainly consisting of marine aerosols, 
minute crystals of soluble salts windblown from 
the action of the sea. However, the air contained 
relatively few other inorganic nanoparticles of less 
than 100 nm throughout our prehistory. The main 
biological objects at nanoscale were viruses and 
some other biological particles. This changed when 
humans harnessed fire about 150 000 years ago and 
combustion nanoparticles became a common feature 
of the human environment. Our defence mechanisms 
against nanoparticles probably evolved principally to 
cope with the biological threat posed by viruses.
The other evolutionary aspect that requires 
consideration is the propensity of cells to engulf 
particulate matter. Unicellular organisms, which 
evolved about 3.5 billion years ago, interact with 
their environment by internalizing matter through the 
cell wall and similarly externalizing waste materials. 
With the evolution of multicellular creatures some 
450 million years ago, this basic ability was kept, and 
is essential for many aspects of the functioning of 
complex multicellular organisms.
Two cellular mechanisms for handling nano- and 
microparticles are of relevance, phagocytosis and 
endocytosis. Phagocytosis is typically triggered 
by larger particles (1–2 μm) such as apoptotic cell 
remnants, bacteria and viruses. A pseudopodial 
outgrowth of the cellular membrane surrounds and 
engulfs the particle before internalization into a 
phagosome. This appears to be an “active” process 
and to operate under a molecular recognition system. 
It is interesting to note that alveolar macrophages 
appear to have “difficulty” recognizing foreign 
particles of a size less than 65 nm (Donaldson et al., 
1999). A number of studies support the hypothesis 
that alveolar macrophages are less efficient at 
engulfing nanoparticles than micron sized particles 
(Pratten & Lloyd, 1986; Oberdörster et al., 2002; 
Kreyling, 2002). This is probably indicative of the size 
range of particles that the body had to cope with 
through inhalation during our evolutionary history.
A second mechanism, endocytosis, is a basic property 
of cell membranes, which has evolved to transport much 
smaller objects, such as macromolecules, and is typified 
by an invagination of the cell membrane. It is divided 
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into: pinocytosis (cell drinking), caveolar endocytosis 
and receptor medicated endocytosis in clathrin coated 
pits. A review of nanoparticle mobility and endocytosis 
has been produced by Gumbleton (2001).
In parallel to the continuous process of endocytosis, the 
opposite mechanism of exocytosis is also operating. 
In the nervous system, this has become specialized in 
the telodendria for the regulation and release of neuron-
transmitter substances into the synaptic cleft. In other 
cell membranes, exocytosis is a continuous process.
Engineered nanoparticles are in the size range of 
objects that can cross biological membranes, in 
common with many viruses, by endo- and exocytosis. 
Therefore, the expectation is that their mobility within 
the body will be high once they have gained entry, 
because the mechanisms that they would “highjack” 
are rapid, continuous and unstoppable. Likewise, it 
should be expected that nanoparticles will also be 
easily expelled from cells by exocytosis.
Two episodes of intoxication and acute health effects
1. Death of Chinese workers
During January–April 2008, seven young female 
workers in a Chinese print plant were diagnosed 
with shortness of breath and excess of liquid 
in the lungs, following exposure to a cocktail of 
dust, fumes and polyacrylate nanoparticles (~30 
nm) for 5–13 months. All seven were admitted to 
hospital and eventually two of the women died. 
The incident was later investigated and described 
by Song et al. (2009). The women had been 
working 8–12-hour shifts in a 70 m2 room with no 
windows and no ventilation, spraying a polyacrylic 
ester paste onto a polystyrene substrate that 
was subsequently heat-cured. Five months prior 
to the incidents, the local exhaust ventilation in 
the facility had broken down and had not been 
repaired (Maynard, 2009; Song et al., 2009). 
The women underwent a number of tests, including 
immunologic tests, internal thoracoscopy and 
video-assisted thoracic surgery; a survey of the 
workplace was also conducted (Song et al., 
2009). Pathological examinations of patients’ 
lung tissue displayed nonspecific pulmonary 
inflammation, pulmonary fibrosis and foreign-body 
granulomas of the pleura. Using transmission 
electron microscopy, nanoparticles were found 
in the cytoplasm and caryoplasm of pulmonary 
epithelial and mesothelial cells, and located in 
the chest fluid. Particles of ~30 nm diameter 
were found in the fluid surrounding the patients’ 
lungs and in the cell linings inside and outside the 
lungs. Similar sized nanoparticles were found in 
the polyacrylic ester paste, and in the workplace 
ventilation system, leading Song et al. (2009) to 
conclude that their study might be the “… first 
study on the clinical toxicity in humans due to 
long-term exposure to nanoparticles …”
As in the case of Nano Magic, the study by Song et 
al. (2009) made internationals news, but was also 
questioned by the scientific community. The main 
areas of criticism focused on the lack of exposure 
data and that no details were reported about the 
nature of exposure (i.e. the combination of fumes, 
dust and nanoparticles) and its magnitude and 
duration. Furthermore, it was not reported how 
the nanoparticles were produced and whether 
they were inhaled as single species or as large 
agglomerates or aggregates; chemical analysis of 
the nanoparticles identified in the women’s lungs 
was limited (Maynard et al., 2009; Brain et al., 
2010). Also, while nanoparticles were identified as 
the causative agent, no assessment was made of 
other plausible causes of the symptoms. Thus, one 
should be careful in extrapolating the conclusions of 
this study into recommendations on the handling of 
nanoparticles in general (Maynard et al., 2009; Brain 
et al., 2010). Some have argued that the study by 
Song et al. (2009) should never have been published 
due these deficiencies. Others have suggested 
that appropriate workplace hygiene needs to 
implemented in the nanotechnology industry, as 
in other industries, in order to avoid preventable 
tragedies (Maynard et al., 2009; Brain et al., 2010).
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2. Nano Magic
In late March 2006, a protective glass and 
bathroom tile sealant known as “Nano 
Magic” was recalled in Germany after 80–100 
consumers experienced severe breathing 
problems after using it in confined spaces 
(Maynard, 2006b; Glaza, 2010). Six people 
had to be hospitalized with pulmonary oedema 
(water in the lungs). The recall made news 
headlines around the world. The product, made 
by Kleinmann GmbH, was sold in a pump 
spray container in supermarkets and discount 
stores, but was pulled from the market by 
the manufacturers after the German Federal 
Institute for Risk Assessment (BfR) issued a 
product warning. It later turned out that the 
product did not contain any nanoparticles. The 
manufacturer attributed the nanotechnological 
element of their product to the nanoscale layer 
of silicon dioxide that the product creates on 
surfaces (Bulls, 2006; Pescovitz, 2006). One 
major element of controversy was that neither 
the German government nor the manufacturer 
could provide clear information on what was 
in the product and whether appropriate safety 
testing had been performed. It took the BfR 
about 2 months to establish the absence of 
nanoparticles in the product (Elvin, 2006; von 
Bubnoff, 2010). It was later speculated that the 
effects observed where due to the tiny droplets 
produced via the aerosol liquid spray, which 
enabled the solvent to penetrate deep into the 
lungs. At the time, the incident was seen as an 
early warning on the risks of nanotechnology. 
In hindsight, it does seem to have led to 
greater attention on the potential health and 
environmental threats of this new technology 
(Maynard, 2006b).
3.2 Human exposure to nanomaterials
One of the key issues, from a public health 
viewpoint, is to establish the extent to which the 
population is exposed to nanomaterials. More 
precisely, it is important to know distributions of 
exposure to different types of nanomaterials in 
different population subgroups. This information 
seems to be quite elusive. Apart from airborne 
ultrafine and nanoparticles from combustion 
processes (e.g. from transport or industrial 
sources), some nanopowders, such as titanium 
dioxide, carbon black and fumed silicas, have been 
in industrial production for decades. Other newer 
nanopowder products are moving from research 
to industrial-scale production and may become 
more widespread, for example single-walled 
carbon nanotubes (SWCNT) (Aitken et al., 2006; 
Next Big Future, 2007; Thayer, 2007; NNI, 2008). 
However, the current exposure of the general 
population to the newer types of nanoparticle is 
largely unknown. Table A3.1 summarizes available 
data on exposure to nanoparticles from different 
sources. Some kinds of engineered nanoparticles 
have limited use and exposure to them is likely to 
be minimal. However, possible exceptions include 
cosmetics and personal care products containing 
titanium and zinc oxide nanoparticles (absorption 
through the skin), food additives (by ingestion) 
and fuel additives (such as ceria, by inhalation). 
Also, the workforce employed in nanoparticle 
production could well experience substantial 
exposure. In any case, given the paucity of data 
on exposure, it is currently not possible to attempt 
estimates of risk or health impacts of different 
types of nanomaterials for the general population.
Nanotechnology and human health: Scientific evidence and risk governance56
Table A3.1. Available data on nanoparticle exposure 
Setting/scenario Nanoparticle Air Water Soil
Worker exposure
Maynard et al. (2004) Production (research) SWCNT < 53 μg/m3 
Han et al. (2008) Research lab MWCNT 172.9–193.6 MWCNT/cm3
Bello et al. (2008a) Research lab MWCNT ND
Bello et al. (2008b) Research lab CNT carbon ≤2–5e6 (i)/380.7 (ii) particles/cm3
CNT alumina ≤2–5e4 particles/cm3 (i)
Fujitani et al. (2008) Production/bagging operation Fullerene 1.0e4–2.0e4 particles/cm3
Tsai et al. (2008a) Research lab Aluminium oxide < 4.6e5
Tsai et al. (2008b) Production/compounding Aluminium 50 000–150 000 particles/cm3
Demou et al. (2008) Pilot-scale production Metal-based 59 100 particles/cm3 (+20%)a
Hsu & Chein (2007) Tile Titanium dioxide 629.2 particles/cm3 (iii)
Wood Titanium dioxide 478.5 particles/cm3 (iii)
Polymer Titanium dioxide 378.9 particles/cm3 (iii)
Methner (2008) Pilot-scale production Manganese 150 μg/m3 after LEV (3 600 μg/m3 without LEV)
 Silver 1 700 μg/m3 after LEV (6 700 μg/m3 without LEV)
 Cobalt 41 μg/m3 after LEV (710 μg/m3 without LEV)
Methner et al. (2007) Production (research) Caron nanofibers < 4.5E+04 p/cm3
Peters et al. (2009) Production (commercial) Lithium titanate metal oxide 0.118 +/- 0.023 mg/m3
  0.035 +/- 0.006 mg/m3
  0.026 +/- 0.007 mg/m3
  0.039 +/- 0.016 mg/m3
  0.036 +/- 0.015 mg/m3
  0.028 +/- 0.012 mg/m3
Kuhlbusch et al. (2004) Production (commercial) Carbon black PM1 Bag filling area, no bagging 14–24 μg/m3 (Plant 1 & 2)
  PM1 Bag filling area 33–41 μg/m3 (Plant 1–3)
  Bag filling fluffy 18–37 μg/m3 (Plant 2)
  PM1 Bag filling (small bags) 46–52 μg/m3 (Plant 3)
  PM1 Bag filling (large bags) 181–280 μg/m3 (Plant 3)
Worker exposure continued
Kuhlbusch & Fissan (2006) Production (commercial) Carbon black PM10 18 ± 20 μg/m3 (Plant 1 Reactor 1) 
 PM10 29 ± 25 μg/m3 (Plant 1 Reactor 2) 
 PM10 29 ± 25 μg/m3 (Plant 1 Reactor 2) 
 PM10 38 ± 35 μg/m3 (Plant 1 Pelletizer 1) 
 PM10 47 ± 39 μg/m3 (Plant 1 Pelletizer 2)
 PM10 24 ± 7 μg/m3 (Plant 2 Reactor) 
 PM10 50 ± 50 μg/m3 (Plant 2 Pelletizer)
 PM10 21 ± 12 μg/m3 (Plant 3 Reactor) 
 PM10 2080 ± 1 613 μg/m3 (Plant 3 Pelletizer)
Yeganeh et al. (2008) Research lab Fullerenes 4 Aug 05: Fume hood 150 ± 29 μg/m3
 4 Aug 05: Work zone 123 ± 7 μg/m3
 9 Aug 05: Fume hood 85 ± 122 μg/m3
 9 Aug 05: Work zone 36 ± 3 μg/m3
 21 Jun 06: Fume hood 52 ± 4 μg/m3
 21 Jun 06: Work zone 52 ± 11 μg/m3
 25 Jun 06: Fume hood 81 ± 116 μg/m3
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Table A3.1. Available data on nanoparticle exposure 
Setting/scenario Nanoparticle Air Water Soil
Worker exposure
Maynard et al. (2004) Production (research) SWCNT < 53 μg/m3 
Han et al. (2008) Research lab MWCNT 172.9–193.6 MWCNT/cm3
Bello et al. (2008a) Research lab MWCNT ND
Bello et al. (2008b) Research lab CNT carbon ≤2–5e6 (i)/380.7 (ii) particles/cm3
CNT alumina ≤2–5e4 particles/cm3 (i)
Fujitani et al. (2008) Production/bagging operation Fullerene 1.0e4–2.0e4 particles/cm3
Tsai et al. (2008a) Research lab Aluminium oxide < 4.6e5
Tsai et al. (2008b) Production/compounding Aluminium 50 000–150 000 particles/cm3
Demou et al. (2008) Pilot-scale production Metal-based 59 100 particles/cm3 (+20%)a
Hsu & Chein (2007) Tile Titanium dioxide 629.2 particles/cm3 (iii)
Wood Titanium dioxide 478.5 particles/cm3 (iii)
Polymer Titanium dioxide 378.9 particles/cm3 (iii)
Methner (2008) Pilot-scale production Manganese 150 μg/m3 after LEV (3 600 μg/m3 without LEV)
 Silver 1 700 μg/m3 after LEV (6 700 μg/m3 without LEV)
 Cobalt 41 μg/m3 after LEV (710 μg/m3 without LEV)
Methner et al. (2007) Production (research) Caron nanofibers < 4.5E+04 p/cm3
Peters et al. (2009) Production (commercial) Lithium titanate metal oxide 0.118 +/- 0.023 mg/m3
  0.035 +/- 0.006 mg/m3
  0.026 +/- 0.007 mg/m3
  0.039 +/- 0.016 mg/m3
  0.036 +/- 0.015 mg/m3
  0.028 +/- 0.012 mg/m3
Kuhlbusch et al. (2004) Production (commercial) Carbon black PM1 Bag filling area, no bagging 14–24 μg/m3 (Plant 1 & 2)
  PM1 Bag filling area 33–41 μg/m3 (Plant 1–3)
  Bag filling fluffy 18–37 μg/m3 (Plant 2)
  PM1 Bag filling (small bags) 46–52 μg/m3 (Plant 3)
  PM1 Bag filling (large bags) 181–280 μg/m3 (Plant 3)
Worker exposure continued
Kuhlbusch & Fissan (2006) Production (commercial) Carbon black PM10 18 ± 20 μg/m3 (Plant 1 Reactor 1) 
 PM10 29 ± 25 μg/m3 (Plant 1 Reactor 2) 
 PM10 29 ± 25 μg/m3 (Plant 1 Reactor 2) 
 PM10 38 ± 35 μg/m3 (Plant 1 Pelletizer 1) 
 PM10 47 ± 39 μg/m3 (Plant 1 Pelletizer 2)
 PM10 24 ± 7 μg/m3 (Plant 2 Reactor) 
 PM10 50 ± 50 μg/m3 (Plant 2 Pelletizer)
 PM10 21 ± 12 μg/m3 (Plant 3 Reactor) 
 PM10 2080 ± 1 613 μg/m3 (Plant 3 Pelletizer)
Yeganeh et al. (2008) Research lab Fullerenes 4 Aug 05: Fume hood 150 ± 29 μg/m3
 4 Aug 05: Work zone 123 ± 7 μg/m3
 9 Aug 05: Fume hood 85 ± 122 μg/m3
 9 Aug 05: Work zone 36 ± 3 μg/m3
 21 Jun 06: Fume hood 52 ± 4 μg/m3
 21 Jun 06: Work zone 52 ± 11 μg/m3
 25 Jun 06: Fume hood 81 ± 116 μg/m3
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Setting/scenario Nanoparticle Air Water Soil
 25 Jun 06: Work zone 85 ± 48 μg/m3
Bello et al. (2009b) Research lab CNT composites Wet cutting (at source), arithmetic mean PM10 dust = 0.054 (mg/m3)
 Dry cutting base-alumina (at source), AM PM10 dust = 1.19 (mg/m3)
 Base-alumina (at personal breathing zone), AM PM10 dust = 0.73 mg/m3
 Dry cutting CNT-alumina (at source), AM PM10 dust = 2.11 (mg/m3)
 CNT-alumina (at personal breathing zone), AM PM10 dust = 0.80 mg/m3
 Dry cutting base-carbon (at source), AM PM10 dust = 5.61 (mg/m3)
 Base-carbon (at personal breathing zone), AM PM10 dust = 5.41 mg/m3
 Dry cutting CNT-carbon (at source), AM PM10 dust = 8.38 (mg/m3)
 CNT-carbon (at personal breathing zone), AM PM10 dust = 2.40 mg/m3
Vorbau et al. (2009) Mixed coating with zinc oxide < 100 nm
Human exposure
Hansen et al. (2008) Sunscreen lotion Titanium dioxide 26 μg/kg bw/yearb  
Fluid product Not specified 15 μg/kg bw/year  
Spray product Not specified 44 μg/kg bw/year  
Park et al. (2008) Car emissions in the United Kingdom Cerium oxide 161 kg/year < 0.01 mg/kg
Car emissions in the EU by 2020 Cerium oxide < 1255 tonnesc 0.28—1.12 μg/g**
Environmental exposure
Kaegi et al. (2008) Exterior paint discharge Titanium dioxide 3.5e8 particles/L   
Mueller & Nowack (2008) Textiles, cosmetics, etc. Silver 1.7e-3–4.4e-3 μg/m3 0.03–0.08 μg/L 0.02–0.10 μg/kg
Sporting good, cosmetics, etc. Titanium dioxide 1.5e-3–4.2e-2 μg/m3 0.70–16.00 μg/L 0.40–4.80 μg/kg
Plastics and electronics CNT 1.5e-3–42.3e-3 μg/m3 0.5e-3–0.8e-3 μg/L 0.01–0.20 μg/kg
Luoma (2008) Socks Silver  < 2 790 kg d  
Washing machines Silver  2 850 kg e  
Swimming pools Silver  30 tonnesf  
Blaser et al. (2008) Biocidal plastics and textiles Silver  320 ng/Lg 14 mg/kg
Boxall et al. (2008) Laundry detergents Latex  103–1 025 μg/Lh 4.30–43.00 mg/kg
Paints, sunscreens, etc. Zinc oxide  76.00–760.00 μg/Lh 3 194 μg/kg
Paints, sunscreens, etc. Titanium dioxide 7 mg/m3g 24.50–245.00 μg/Lh 1 030 μg/kg
Toothpaste Hydroxyapatite  10.1μg/L 422 μg/kg
Cosmetics Buckminsterfullerene    
 Organo-silica  0.000 5 μg/L 4 307 μg/kg
 Silicon dioxide  0.000 7 μg/L 0.03 μg/kg
Fuel additive Cerium oxide 6,00E-07j <0.000 1 j < 0.01 j
CNT = carbon nanotube, LEV = local exhaust ventilation, MWCNT = multiwalled carbon nanotubes, ND = not determined, 
PM = particulate matter, SWCNT = single-walled carbon nanotubes. 
a) Particle number retention 97–100% 
b) Sunscreen contains 2% titanium dioxide  
c) Assuming that all cerium is emitted to atmosphere 
d) Assuming that 10% and 30% of the population in the United States use silver 
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Setting/scenario Nanoparticle Air Water Soil
 25 Jun 06: Work zone 85 ± 48 μg/m3
Bello et al. (2009b) Research lab CNT composites Wet cutting (at source), arithmetic mean PM10 dust = 0.054 (mg/m3)
 Dry cutting base-alumina (at source), AM PM10 dust = 1.19 (mg/m3)
 Base-alumina (at personal breathing zone), AM PM10 dust = 0.73 mg/m3
 Dry cutting CNT-alumina (at source), AM PM10 dust = 2.11 (mg/m3)
 CNT-alumina (at personal breathing zone), AM PM10 dust = 0.80 mg/m3
 Dry cutting base-carbon (at source), AM PM10 dust = 5.61 (mg/m3)
 Base-carbon (at personal breathing zone), AM PM10 dust = 5.41 mg/m3
 Dry cutting CNT-carbon (at source), AM PM10 dust = 8.38 (mg/m3)
 CNT-carbon (at personal breathing zone), AM PM10 dust = 2.40 mg/m3
Vorbau et al. (2009) Mixed coating with zinc oxide < 100 nm
Human exposure
Hansen et al. (2008) Sunscreen lotion Titanium dioxide 26 μg/kg bw/yearb  
Fluid product Not specified 15 μg/kg bw/year  
Spray product Not specified 44 μg/kg bw/year  
Park et al. (2008) Car emissions in the United Kingdom Cerium oxide 161 kg/year < 0.01 mg/kg
Car emissions in the EU by 2020 Cerium oxide < 1255 tonnesc 0.28—1.12 μg/g**
Environmental exposure
Kaegi et al. (2008) Exterior paint discharge Titanium dioxide 3.5e8 particles/L   
Mueller & Nowack (2008) Textiles, cosmetics, etc. Silver 1.7e-3–4.4e-3 μg/m3 0.03–0.08 μg/L 0.02–0.10 μg/kg
Sporting good, cosmetics, etc. Titanium dioxide 1.5e-3–4.2e-2 μg/m3 0.70–16.00 μg/L 0.40–4.80 μg/kg
Plastics and electronics CNT 1.5e-3–42.3e-3 μg/m3 0.5e-3–0.8e-3 μg/L 0.01–0.20 μg/kg
Luoma (2008) Socks Silver  < 2 790 kg d  
Washing machines Silver  2 850 kg e  
Swimming pools Silver  30 tonnesf  
Blaser et al. (2008) Biocidal plastics and textiles Silver  320 ng/Lg 14 mg/kg
Boxall et al. (2008) Laundry detergents Latex  103–1 025 μg/Lh 4.30–43.00 mg/kg
Paints, sunscreens, etc. Zinc oxide  76.00–760.00 μg/Lh 3 194 μg/kg
Paints, sunscreens, etc. Titanium dioxide 7 mg/m3g 24.50–245.00 μg/Lh 1 030 μg/kg
Toothpaste Hydroxyapatite  10.1μg/L 422 μg/kg
Cosmetics Buckminsterfullerene    
 Organo-silica  0.000 5 μg/L 4 307 μg/kg
 Silicon dioxide  0.000 7 μg/L 0.03 μg/kg
Fuel additive Cerium oxide 6,00E-07j <0.000 1 j < 0.01 j
e) Households in the United States that are wealthy enough will buy silver washing machines  
f) 1 million pools in the United States use silver as a biocide  
g) Removal in the STP was assumed to be 99–85% of wastewater  
h) 10% and 100% market penetration 
i) All diesel fuel doped with 10 ppm will lead to an emission rate of 10 ppm
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4. Health effects of airborne   
 particles
For other preceding novel technologies, such as 
genetically modified food crops, little toxicological 
research existed when they were introduced. In the 
case of nanomaterials and nanoparticles in particular, 
some literature already exists on exposure and adverse 
health effects of particulate matter. Therefore, before 
considering the possible health effects of engineered 
nanoparticles, it is important to consider what is 
known of the adverse effects of particulate pollution. 
The earliest understanding that particle exposure 
could harm health came from the “dust diseases” of 
silicosis (Agricola, 1556), pneumoconiosis, byssinosis 
and, more latterly, asbestosis. These were high-
dose exposures associated with particular industrial 
activities.
They all resulted in lung destruction and fibrosis 
and were the result of high levels of exposure. The 
realization that poor air quality alone could cause 
acute morbidity and mortality became manifest during 
the Great Smog of London in December 1952, which 
caused 4000 acute deaths and a further 8000 deaths 
in the subsequent weeks, principally from acute (on top 
of pre-existing chronic) respiratory and cardiovascular 
disease. It led to the passing of the Clean Air Acts of 
1956 and 1968 in the United Kingdom.
Particles in aerosols are defined with respect to their 
size: “coarse” particles, particulate matter (PM)10 
(i.e. particles of 10 μm); “fine”, PM2.5; and “ultrafine”, 
PM0.1. In each case, the suffix refers to the upper 
size limit of the mean aerodynamic diameter of the 
particle population, in μm (Maynard and Howard, 
1999). The ultrafine fraction has the same size range 
as defined for nanoparticles, i.e. 1–100 nm. The 
size distribution of particles in the atmosphere is not 
uniform, but tends to be trimodal (Harrison, 1999). 
This is associated with their mode of formation. 
• Nucleation mode particles are generally < 100 
nm diameter and are mainly the result of primary 
combustion particle production such as from 
traffic fumes. They are not particularly long-lived 
in the atmosphere in their initial form because of 
agglomeration and condensation mechanisms.
• Accumulation mode particles are typically 
found with sizes between 100 nm and 2.5 μm 
diameter and arise because of the growth of 
nucleation mode particles. They tend to consist 
of secondary particles, predominantly sulphate 
nitrates of ammonium. Their lifetime in the 
atmosphere is longer than for nucleation mode 
particles and can typically be over 1 week. They 
are thus subject to undergo long-range transport.
• Coarse particles are the result of grinding 
mechanical processes and resuspension 
processes from the surface of the land or sea. 
Their size is 2.5–10.0 μm. 
The ultrafine range of atmospheric particles varies 
considerably from location to location. Urban 
ultrafine composition has been addressed by Cass 
et al. (2000). The average chemical composition of 
ultrafine particles in southern California, for example, 
was found to include:
• 50.0% organic compounds
• 14.0% trace metal oxides
• 8.7% elemental carbon
• 8.2% sulphate
• 6.8% nitrate
• 3.7% ammonium ion
• 0.6% sodium
• 0.5% chloride.
Mobile or stationary fuel combustion sources 
predominated, with an estimated consistency that 
includes:
• 65% organic compounds
• 7% elemental carbon
• 7% sulphate
• 4% trace elements.
The health hazard created by airborne particles is 
among the main concerns in environmental health, and 
the size of the particles is of key importance. Particles 
larger than 10 μm generally get caught in the nose 
and throat, and don’t enter the lungs. Particles smaller 
than 10 μm can get into the large upper branches just 
below the throat, where they are caught and removed 
(by coughing and spitting or by swallowing). Particles 
smaller than 5 μm can get into the bronchial tubes, 
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at the top of the lungs. Particles smaller than 2.5 μm 
in diameter can get down to the deepest (alveolar) 
portions of the lungs, where gas exchange occurs 
between the air and the blood stream, oxygen moving 
in and carbon dioxide moving out.
Although the toxicological mechanisms are not 
completely clear, the epidemiological evidence on 
the association between exposure to fine particulate 
air pollution and adverse health effects is strong. 
Both WHO Air Quality Guidelines (WHO, 2006) and 
United States EPA air quality criteria for particulate 
matter (2004) point to a strong association between 
fine particulate matter (particle size less than 2.5 μm) 
and (i) chronic mortality due to long-term exposure 
(all-cause mortality, lung cancer and cardiovascular 
causes); (ii) acute mortality due to short-term exposure 
(respiratory and cardiovascular admissions, asthma, 
bronchitis); and (iii) a series of less severe but more 
frequent cardiovascular and respiratory morbidity 
effects or symptoms (restricted activity days, work 
days lost, etc.). For most of the health outcomes the 
relationship between pollutant exposure and outcome 
is linear and without threshold (WHO, 2006). This 
has been reinforced by more recent studies (Pope & 
Dockery, 2006; Brook, 2007; Chen et al., 2008).
Particles smaller than 0.1 μm in diameter are potentially 
the most hazardous, because the deepest (alveolar) 
portions of the lung have no efficient mechanisms 
for removing them. If these particles are soluble in 
water, they pass directly into the bloodstream within 
minutes. If they are not soluble in water, they are 
collected by macrophages (scavenging cells) and 
then transported to lymph nodes, where they are 
retained in the deep lung for long periods (months or 
years) (NRC, 1979).
About 60% of PM10 particles (by weight) have a 
diameter of 2.5 μm or less. Ultrafine particles are 
more penetrative than larger particles, and buildings 
do not offer complete protection from exposure (Rim 
et al., 2010). In a modern city or major town, on many 
days, the air will contain 100 billion (1011) particles of 
1 nm diameter in each cubic meter of air, including 
indoors. By weight, these 100 billion particles will 
only amount to 0.00005 μg (one ten-thousandth of 
1% of 50 μg/m3, a limit value used in legislation), yet 
they may be implicated in the health damage created 
by fine particle pollution. For this reason, in 1979, the 
United States National Research Council suggested 
that measuring particles by weight, without regard to 
particle size, has “little utility for judging effects” (NRC, 
1979). The continued validity of this statement, 30 
years on, is supported by Maynard & Aitken (2007).
Research is underway to clarify the health effects 
of ultrafine particles, given their relevant chemical–
physical and toxicological characteristics. However, 
the epidemiologic studies specifically investigating 
the health effects of exposure to ultrafine particles 
are still few as compared to those available for the 
coarser fractions of particulate matter. This is mainly 
due to the scarce availability of specific and valid 
environmental data and to technical difficulties in 
measuring them. The current epidemiologic evidence 
is, however, compatible with a role for ultrafine 
particles in the health effects of particulate matter, 
which is also corroborated by toxicological studies 
and biological plausibility. It is possible, in other words, 
that part of the health effects documented for fine 
particles is due to the ultrafine fraction. However, the 
lack of studies based on measurements of exposure 
to ultrafine- or nanoparticles for sizeable populations 
limits the evaluation of such hypothesis. Identification 
of the role of the ultrafine fraction in determining 
known health impacts is further complicated by the 
choice of metric for concentration and exposure.
4.1 Relevant dose metric
There is some debate as to the most suitable 
metric to use for human exposure to ultrafine 
particles; this has been discussed by Seaton et al. 
(2009) and Oberdörster (2010). The classical dose 
metric for measurement and regulation of particle 
concentration has been gravimetric. For many 
decades, the accepted fraction for particles, used 
as standard for air quality, was PM10. More recently, 
some jurisdictions have adopted the standards 
for PM2.5, in consideration of its higher relevance 
for health effects. With regards to nanoparticles, 
consideration should be given to the question of 
the most relevant metric for PM0.1, in terms of 
concentrations, exposures and dose.
Particle number seems to be a more informative 
metric than particle mass, when the interest is in 
ultrafine particles, as is illustrated by figures A3.2 
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and A3.3. The majority of the particles that are of 
concern in the ultrafine and nanoscale range, weigh 
practically nothing. Figure A3.2 shows two frequency 
distributions made from measurements on one 
population of particles. The  area (integral) under the 
black curve (number weighted) will result in the total 
number of particles within that size range.The  area 
under the grey curve (mass weighted) will give the 
the total mass of all particles within that size range.
Figure A3.2. Typical particle number (N) and mass (M) distribution averages from approximately 10 000 single 
measurements, Erfurt.
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This distribution is also shown in Figure A3.3 in a 
simplified form. The upper-left image represents a 
set of arbitrarily selected particles. In the upper-right 
image, the particles have been binned according 
to their size in arbitrary units of volume (which is 
directly related to mass). In the bottom-left graph, the 
number of particles in each bin is represented on the 
y-ordinate, while in the bottom-right graph they are 
binned according to volume (mass). The influence of 
the larger particles is illustrated in this hypothetical 
example by the fact that nearly 20% of the total 
volume (mass) is represented by a single particle.
Despite its advantages, particle count may make it 
difficult to compare concentrations when different 
sizes and types of particle are present, and other 
metrics have been proposed. Total particle surface 
area appears to be a most promising metric. Other 
parameters of possible interest as dose metrics, but 
still to be elucidated, include biologically available 
surface area and surface reactivity (Oberdörster 
2009). Cedervall et al. (2007) demonstrated that 
nanoparticles’ surface characteristics and size 
determine the protein binding properties of plasma 
proteins. Maynard and Aitken (2007) have published 
a review of what is possible to measure with current 
technologies and what would be the most desirable 
metric to use when considering nanoparticles. They 
considered number-, length-, surface- and mass-
weighted distributions of size. These are illustrated 
graphically for various classes of particle size. Clearly, 
the best option would be to have the capability to 
capture the multiple dimensions of concentration, 
exposure and dose, and monitor all weightings 
simultaneously. This would permit the collection of a 
large amount of additional information about particle 
shape, in addition to higher order extrapolations 
about particle size variability, convexity and surface 
roughness, etc.
The measurement of ultrafine particles has 
implications in terms of air pollution abatement. 
The ultrafine fraction of particulate aerosols is the 
most stubbornly resistant to abatement through 
regulation. This is illustrated in Figure A3.4, which 
shows a reduction in PM10 in Erfurt, Germany 
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during 1991–1999. Inspection of the breakdown of 
the size fractions of the overall PM10 shows that 
while the larger particles were abated, the smallest 
fraction remained constant and therefore increased 
proportionally in its contribution to the total PM10. In 
urban areas, the major source of particulate emissions 
is motorized vehicles, with contributions from heating 
systems and from industrial sources. It is well known 
that reduction in particulate concentrations through 
appropriate transport policies leads to tangible health 
benefits, but the role of ultrafine particles is not clear. 
In particular, primary emissions from diesel engines 
and industrial processes tend to be monitored on 
the basis of coarse and fine particles, while ultrafine 
particle emissions are not well known.
Figure A3.3. Illustration of the difference between the number-weighted and volume (mass)- weighted 
distributions of size
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Figure A3.4. Mass concentration of fine particles in Erfurt, Germany (1991–1999)
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5. Nanoparticle toxicity
When bulk materials are made into particles, the 
surface to volume ratio of the material increases. When 
this process reaches the nanoscale, the proportion of 
“surface” atoms or molecules in the material increases 
exponentially and the surface chemistry also changes, 
with the material tending to become more chemically 
reactive. This is the basis for the production of 
heterogeneous catalysts in the chemical industry. 
Platinum, for example, in the bulk state is particularly 
chemically unreactive. In the form of ultrafine particles, 
however, it can facilitate a number of chemical 
reactions. Jefferson & Tilley (1999) demonstrated 
that nanoscale platinum particles take on crystalline 
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forms with facets and isolated atoms at vertices, and 
discuss the implications of this morphology to the 
surface chemistry.
The special properties of nanomaterials must then 
be considered when studying their interactions 
with biological systems and when assessing their 
potential health effects. Because the surface 
chemistry of nanoparticles is different from that of 
the bulk materials that they were derived from, their 
toxicological properties differ, in many cases, from 
both the bulk and atomic or molecular forms of the 
materials. In fact, many aspects of nanoparticle 
interactions with biological systems are different, 
including transport, reactivity and excretion. These 
aspects are further elaborated and described in 
subsequent sections.
The term nanotoxicology, first used by Donaldson 
et al. (2004), indicates the fact that such differences 
require an ad hoc form of toxicology. The essential 
nature of the nanotoxicological problem was 
captured by Myllynen et al. (2008): “There are 
basically two questions to address: (1) what is the 
fate of nanoparticles? (i.e. where do they get to) and 
(2) if they get to a particular location, does it matter?”.
The following sections aim to provide some key 
points in terms of the mechanisms of action of 
nanoparticle toxicity, as shown in the available 
literature (e.g. Oberdörster et al. 2005; Balbus et 
al., 2007; Helland et al. 2007; Singh & Nalwa, 2007; 
Elder et al., 2009; Genaidy et al., 2009; Isaacson et 
al., 2009; Oberdörster G., 2009; Seaton et al., 2009; 
Stone et al., 2010).
5.1 Mechanisms of toxicity
A number of mechanisms by which nanoparticles can 
induce cell damage have been reported, including, for 
example:
• oxidative damage through catalysis (Foley et al., 
2002)
• lipid peroxidation (Kamat et al., 2000)
• surfactant properties (Cottingham et al., 2002; 
Cottingham et al., 2004)
• protein misfolding (Billsten et al., 1997)
• direct physical damage (Lam et al., 2004)
• enzyme poisoning (Nel et al., 2009).
These are known mechanisms mainly operating at a 
chemical level and have been reviewed in Nel et al. 
(2009). However, more data on the purely physical 
mechanisms of nanoparticle toxicity is needed. A 
recent article by Tickell (2008) has drawn attention 
to another possible route to harm, that of secondary 
photoelectron production, discussed in section 5.1.1.
Another source of vulnerability in an organ or tissue 
happens when it cannot repair itself by replacing 
damaged or dying cells, which makes it more 
susceptible to chronic, low-dose toxicity. Many tissues 
have the ability to repair through cellular proliferation. In 
mammals, for example, the liver is the organ with the 
highest regenerative capacity. Other functions, such 
as haemopoiesis and the renewal of the continually 
shedding gut lining, rely on lifelong cellular proliferation. 
However, in the central nervous system (CNS), the 
functional neurons that differentiate and mature during 
selective stabilization lose the ability to replicate and 
have to remain functional for the whole of life (Jontes & 
Phillips, 2008). Therefore in considering mechanisms of 
action, chronic effects on degenerative processes must 
also be considered.
5.1.1 Oxidative stress and inflammation
A common thread in nanoparticle research is the 
induction of oxidative stress and inflammation. 
This may happen via a number of mechanisms. 
The link between pro-inflammatory influences such 
as transcription factors, nuclear factor kappa beta 
(NF-kB) and activating protein 1 (AP-1), highlight the 
central role of oxidative stress in the inflammatory 
process (Meyer et al., 1993). Seaton et al. (1995) 
developed the biologically plausible hypothesis that 
the inflammation induced in the lung by ultrafine 
particles could increase blood coagulability, 
which in turn was associated with the increase in 
cardiovascular deaths during pollution episodes.
Also, catalytic activity can cause ionization events 
in what is, basically, an aqueous medium, leading 
to free radical production. This has been shown, 
for example, with certain nanoparticles, e.g. titania 
in sunlight (Barker & Branch, 2007). In vitro studies 
on living cells have confirmed the increased ability of 
ultrafine particles to produce free radicals, which then 
cause cellular damage (Rahman et al., 2002; Uchino 
et al., 2002; Li et al., 2003). This damage can be 
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manifested in different ways, including genotoxicity 
(Rahman et al., 2002) and altered rates of cell death, 
including apoptosis (Afaq et al., 1998; Kim et al., 
1999; Rahman et al., 2002; Uchino et al., 2002).
A recent development in nanotechnology has been 
the application of buckminsterfullerene (C60), a 60+ 
atom form of carbon in the shape of a geodesic 
sphere, hence the nickname, “buckyball” (Johnston, 
2010). These objects are very small, being about 
1 nm in diameter and are therefore likely to be 
extremely mobile in biological systems. Kamat et 
al. (2000) demonstrated the ability of fullerenes to 
induce the production of reactive oxygen species 
and cause lipid peroxidation. However, Sayes et 
al. (2004) have demonstrated that the cytotoxic 
potential of fullerenes can be altered by over 7 orders 
of magnitude by changing their surface properties. 
Oberdörster E. (2004) has demonstrated the effects 
of Buckminsterfullerene in causing oxidative stress 
in fish, though more recently it has been suggested 
that the effect may have been due to residual 
tetrahydrofuran, used to solubilize the particles (Zhu 
et al., 2006).
Oxidative stress can induce inflammation. The cellular 
responses to nanoparticles have been reviewed 
by Unfried et al. (2007). The various pathways 
for free radical production leading to mitogen 
activated protein kinase (MAPK)-linked signalling 
are discussed in detail. There is increasing interest 
in the scientific literature in innate inflammosome 
interactions, see for example Dostert et al. (2008). 
It appears that a mechanism has evolved for coping 
with naturally occurring biological nanoparticles such 
as viruses. It is biologically plausible that engineered 
nanoparticles may be able to trigger such innate 
mechanisms and lead to the commonly observed 
inflammatory response of tissues to nanoparticle 
challenge. However, very little is known of the 
potential interactions with important immune system 
receptors, such as toll-like receptors and scavenger 
receptors. With the additional complexity, due to 
the protein “corona” that internalized nanoparticles 
garner on entry to the body, such interactions need 
to be further examined.
The toxicity and the ability of ultrafine particles 
to cause inflammation tend to increase as the 
particle size becomes smaller. This has been 
shown by a series of experiments with laboratory 
rodents; by Oberdörster G. (2000) using ultrafine 
particle inhalation; and by Donaldson et al. (1999, 
2000) using nanoparticle instillation. For example, 
Donaldson et al. (1999) showed that 14 nm carbon 
black was roughly three times more toxic than 50 
nm carbon black, and 10 times more toxic than 
250 nm carbon black on a mass basis. Other 
experiments (Donaldson et al., 2000) showed that 
materials as dissimilar as titanium dioxide and latex 
demonstrated similar levels of toxicity, dependent on 
size and surface area rather than on composition. 
Oberdörster G.’s (2000) experiments with exposure 
to polytetrafluoroethylene fumes showed low-dose 
toxicity (50 μg/m3 for 15 minutes led to very high 
mortality). However, the instillation experiments must 
be considered as having been conducted at high 
dose, compared to the levels of particles normally 
present in ambient air.
More recently, some in vivo investigations have been 
conducted into the effects of engineered nanoparticles. 
Lam et al. (2004) instilled nanotubes into the tracheas 
of mice and found resulting pathological changes 
persisting up to 90 days post-exposure. 
Another potential mechanism gaining some attention, 
involves the toxicology of heavy metals, which is not 
yet fully explained. As mentioned above, a number 
of hypotheses based on chemical processes have 
been put forward, but less consideration has been 
given to physical rather than chemical processes. 
One possible explanation for genotoxic damage 
by induction of oxidative stress is through the 
production of secondary photoelectrons. When a 
material is irradiated with electromagnetic radiation, 
it will produce photoelectrons, the amount being 
a function of the fifth power of the atomic number 
(Einstein, 1905). The escape depth for photoelectrons 
from a bulk material is about 5 nm. Therefore, in bulk 
materials the majority of photoelectrons generated 
will be internally absorbed within the material. When 
an equivalent mass of bulk material is transformed 
into nanoparticles, the number of photoelectrons 
escaping into the surrounding environment of the 
particle increases greatly. This has been modelled by 
Elsaesser et al., (2008), who demonstrated a 25 000-
fold amplification in photoelectron production, with a 
plateau at a particle size of 10 nm, which is consistent 
with the known escape depth. The population is 
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continuously exposed to background radiation and 
therefore, if high atomic number nanoparticles are 
internalized, they will give rise to photoelectrons that 
will enter surrounding tissues.
The main known mechanism for damage from 
photoelectrons is through the production of reactive 
oxygen species (ROS) in the main body constituent, 
water. On average, for every 60 electronvolts of energy 
lost by a photoelectron along its track there will be an 
ionization event, which will produce ROS. Counter-
intuitively, therefore, the photoelectrons produced by 
low energy “soft” x-rays are predicted to be much more 
damaging to biological systems than those produced 
by high energy cosmic or gamma rays. High energy 
photoelectrons will leave the body with relatively few 
ionization events, while low energy photoelectrons will 
have a short intracorporeal course, which will give rise 
to thousands of ionization events. This could well be 
a significant mechanism for the induction of oxidative 
stress. It is interesting to note that the element with 
the highest atomic number occurring as part of natural 
biochemistry is iodine and that the thyroid gland, which 
contains almost all the body’s iodine, is the most 
radiosensitive organ in the body.
5.1.2 Cellular toxicity
Possible targets for nanoparticle induction of cellular 
toxicity include the following:
Membranes
The integrity of cellular membranes is essential for 
many cellular processes involving fluid transport, 
maintenance of differential ionic concentrations 
and partitioning of various intracellular processes. 
Damage to phospholipid bilayer membranes 
through surfactant and lipid peroxidation effects will 
lead to cellular dysfunction and, if severe enough, 
to cell death. In particular, the vulnerability of cells 
that display electrical activity, such as neurons and 
cardiac muscle, requires further investigation.
Macromolecules
Fully functional proteins are essential for normal 
activity. When proteins misfold, they can become non-
functional or produce oligomers, which themselves 
may be toxic. For a fuller discussion of nanoparticles 
and protein misfolding, see section 6.1. 
Mitochondria
It appears that mitochondria may be a major target 
organelle for nanoparticle toxicity. The process of 
oxidative phosphorylation in the mitochondria is vital for 
cell function. Damage to the permeability of the outer 
mitochondrial membrane can precipitate apoptosis 
through the release of cytochrome c. Fullerenes have 
been shown to preferentially localize in mitochondria 
(Foley et al., 2002) as have MWCNT (Zhu et al., 2006). 
Salnikov et al. (2007) have shown that 3 nm gold 
particles can enter mitochondria via voltage dependent 
channels, while 6 nm particles cannot.
Air pollution can also interfere with mitochondrial 
activity: Li et al. (2003) showed that ultrafine air pollution 
particles, as opposed to coarse, are commonly found 
within mitochondria and cause vacuolar changes. 
Xia et al. (2006) have found mitochondrial mass loss 
and apoptosis in RAW264.7 macrophages. They 
have also shown that ambient ultrafine particles 
and cationic polystyrene nanoparticles cause 
mitochondrial damage with increased calcium uptake 
and ROS production (Xia et al., 2006). Hussain et al. 
(2005) have compared the mitochondrial impact of a 
number of different types of metallic nanoparticles. 
They found silver nanoparticles to be the most potent 
in disrupting mitochondrial function. A comparison of 
the mitochondrial toxicity of CNTs and fullerenes was 
made by Jia et al. (2005). They found SWCNTs to be 
the most toxic on a mass basis.
The nucleus
Damage to DNA within the nucleus can result in 
mutation and transmissible disease. The genotoxicity 
of silica particles has recently been studied in a 
multicentre in vitro investigation using the “comet 
assay” (Barnes et al., 2008), and no genotoxic 
activity was detected. However, there are questions 
about the sensitivity of the comet assay in detecting 
clastogens and therefore its suitability in this context.
Unfried et al. (2007) report on the work of a 
number of studies that have examined intranuclear 
nanoparticles. One portal of entry could be from 
nanoparticles coated in phospholipids interacting 
with the nuclear membrane (Godbey, 1999) or 
nanoparticles diffusing through the nuclear pores. 
Panté & Kann (2002) reported the passage of 24–39 
nm gold particles coated in cargo receptors, and 
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Hoshino et al. (2004) detected quantum dots in cell 
nuclei within 15 minutes of incubation.
5.2 Nanoparticle assimilation, absorption, 
fate and mobility within the body
Nanoparticles can gain entry to the body by a 
number of routes, including inhalation, ingestion and 
across the skin, and can then travel around the body 
into various organs, including across the blood–
brain barrier (Gumbleton, 2001; Elder et al., 2009; 
Oberdörster G., 2010). These properties are being 
positively harnessed by the pharmaceutical industry 
to improve the efficiency of drug delivery; however, 
there is growing recognition that the same properties 
could apply to ambient nanoparticles resulting from 
pollution or from manufactured products.
5.2.1 Inhalation
The airways of the respiratory system are lined with 
a pseudostratified columnar ciliated epithelium from 
the nose downwards to the respiratory bronchioles, 
except for a part of the lower pharynx and upper 
larynx, which have a stratified squamous epithelium. 
The surfaces of the epithelia are kept moist by 
secretions of mucus from goblet cells and, more 
importantly, submucosal glands. The lining of 
the major airways of the trachea and bronchi are 
covered with a “mucociliary escalator”. The cilia 
move the mucus slowly upwards to the larynx, 
where it is swallowed and ingested. Beyond the 
respiratory bronchioles is the alveolar air space, 
which has a simple epithelium with no cilia, onto 
which a surfactant is secreted. The alveolar surface 
is patrolled by alveolar macrophages, living within 
the layer of surfactant, which engulf foreign matter 
arriving at the alveolar surface. Particle deposition 
may occur within the airways via three different 
mechanisms: sedimentation, inertial impaction and 
diffusion.
• Sedimentation occurs under the influence of 
gravity and tends to increase with increasing 
particle size.
• Inertial impaction occurs when a particle is 
being carried in air and the direction of the air 
changes, the momentum of the particle carrying 
it forward on its initial path. Particles have a 
tendency to impact at bifurcations in the bronchial 
tree. Deposition is usually determined by the 
momentum (weight and speed) of the particle. 
Increased flow tends to increase impaction, 
especially of larger particles. This turbulent 
impaction is more common in the upper, larger 
airways and predominantly affects particles 
greater than 1 μm in diameter.
• Diffusion (or Brownian motion) occurs with very 
small particles, as a result of being bombarded 
by other molecules, similar to the behaviour of 
gas molecules. Movement of these particles is 
completely random. Therefore, if they are close 
to a wet mucosa they are likely to deposit. Re-
suspension does not happen subsequently. 
Diffusion is the method of deposition for the smaller 
ultrafine particles with a diameter less than 10 nm 
and happens predominantly in the nasal and upper 
pharyngeal parts of the respiratory tract.
The relative deposition of particles according to their size 
is shown in Figure A3.5 (Wichmann & Peters, 2000). 
Note that the very smallest particles tend to deposit 
in the upper airways by diffusion, while the bulk of the 
ultrafine particles deposit predominantly in the alveolar 
region of the lung by impaction. Other particles which 
deposit on the lining of the trachea and bronchi are 
usually ingested.
The animal literature on translocation of nanoparticles 
to the pulmonary circulation is not univocal.
Evidence has been found of accumulation of 13C 
nanoparticles (20–29 nm) in the rat liver within 30 
minutes of inhalational exposure, with a further five-
fold increase in the following 24 hours (Oberdörster 
et al., 2002). Earlier work also indicated nanoparticle 
uptake from the lung (Patrick and Stirling, 1992). This 
suggests a rapid translocation, although questions 
concerning confounding by ingestional exposure 
have been addressed in Stern and McNeil (2008). 
Kreyling et al. (2002) showed a very low (< 1%) rate 
of translocation from rat lung to liver, spleen, heart 
and brain when dosing with 80 and 15 nm iridium 
nanoparticles by instillation. The study did, however, 
report that the smaller particles showed a higher rate 
of translocation.
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The results for human studies are also mixed. While 
Brown et al. (2002) and Mills et al. (2006) did not 
demonstrate any significant translocation of radio 
labelled carbon nanoparticles, Nemmar et al. (2001) 
showed 3–5% uptake within a few minutes of 
exposure in the blood, and subsequent deposition in 
the liver. The latter paper attracted some comment 
that the possibility of label removal from nanoparticles 
was not controlled for.
On the evidence available at the time, Hoet et al. 
(2004) concluded that endocytosis by epithelial 
and endothelial cells and phagocytosis by alveolar 
macrophages were the most important routes for 
nanoparticle translocation.
Figure A3.5. Predicted deposition of inhaled particles of different sizes of unit density in the human respiratory 
tract during nose breathing, light exercise
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5.2.2 Dermal absorption
Another possible portal of entry into the body is via 
the skin. The findings in scientific papers are mixed, 
some showing dermal nanoparticle assimilation, 
others not. The question is a key one, because the 
skin is the largest organ in the body and the quantity of 
nanoparticles that crosses per unit area of skin would 
not have to be large to achieve a substantial internalized 
dose. In addition, because a number of commercial 
skincare products containing nanoparticles are already 
on the market, including sunscreens, their application 
to a large proportion of the skin surface area may 
contribute to high levels of exposure.
A number of sunscreen preparations are now 
available which incorporate nanoparticle titanium 
dioxide. Tan et al. (1996) showed the presence of 
titanium in the epidermis and dermis after the use 
of sunscreen. Schulz et al. (2002) and Gamer et al. 
(2006) could not reproduce Tan’s results; however, 
they did not address confounders such as movement 
of the skin or the charge of the particle.
Tinkle et al. (2003) have shown in an animal model 
that beryllium particles of 0.5 and 1.0 μm diameter 
(i.e. within the category of “fine” particles) can get 
deep enough into the skin to be taken up into the 
lymphatic system, while larger particles did not. The 
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lymphatics are a system of blind capillary vessels 
which drain the spaces between cells of interstitial 
fluid and then drain into bigger vessels, eventually 
returning the lymph to the general circulation. The 
implication is that nanoparticles can be assimilated 
into the body through the skin. The exact proportion 
of deposited particles which will be absorbed 
remains unknown. Tinkle et al. (2003) have studied 
the penetration of dextran beads into postmortem 
human skin and demonstrated that 0.5 μm and 1.0 
μm beads can penetrate the stratum corneum of skin 
being flexed. This affected over 50% of samples if the 
process continued for 1 hour. In a small proportion 
of cases, the beads got as far as the dermis. More 
recently, Rouse et al. (2007) demonstrated that 
buckminsterfullerene  amino acid penetrated the skin 
after mechanical flexing, thus supporting the findings 
of Tinkle et al. (2003). Lademann et al. (1999) 
demonstrated that microparticles of titanium dioxide 
contained in sunscreen penetrated into the stratum 
corneum and hair follicle orifices.
Particle charge appears to be a significant factor. 
Kohli & Alpar (2004) found that positively charged 
or neutral latex particles of 50 and 500 nm could 
not penetrate the dermis, while negatively charged 
particles could. The size and shape of quantum dots 
was shown by Ryman-Rasmussen et al. (2006) to be 
significant in the penetration of intact skin.
A comprehensive, industry-funded review of skin 
absorption of nanomaterials has recently been 
published (Nohynek et al., 2007). This indicated that 
most studies on the skin absorption of metal oxide 
nanoparticles (both in vitro and in vivo) showed no 
significant absorption into the systemic circulation. 
However, the relevance of some in vitro models has 
been questioned, as the role of flexing may be more 
important with nanomaterials (EC, 2007). The effect 
of abrasion of rat skin causing a small increase in 
the penetration of quantum dots is reported in Zhang 
& Monteiro-Riviere (2008). However, the effect on 
skin damaged by other mechanisms (e.g. through 
sunburn), or on infant skin, remains unknown.
5.2.3 Gastrointestinal assimilation
Particles enter the gut through ingestion. 
Nanotechnology applications in the food industry 
include the use of ingredients processed or 
formulated to form nanostructures, and nanosized 
or nano-encapsulated additives. Also, food can 
be a source of nanoparticle ingestion owing to 
nanotechnology applications in coating, packaging 
and filtering. These involve organic and inorganic 
nanomaterials (WHO/FAO 2010).
An additional source is the constant swallowing of 
mucus produced by the mucociliary escalator of 
the respiratory system, which will contain impacted 
particles. Lomer et al. (2002) have estimated that 
1012–1014 particles of up to 3 μm are ingested each 
day, per person in developed countries. These are 
predominantly in the form of titanium dioxide, food 
colorants and silica.
Persorption is a process in the gut whereby quite 
large particles, of up to 20 μm, can be assimilated 
into the lymphatics and portal capillaries across 
Peyer’s patches in the ileum (Volkheimer, 1974; 
Hodges et al., 1995). In contrast, Kreyling et al. 
(2002) found that no 192IrCl 18 nm particles were 
absorbed across the gut wall in rats. This was a 
similar result to that obtained with the same material 
in their respiratory exposure studies.
Another mechanism that has been demonstrated is 
via intestinal enterocytes (Jani et al., 1990; Florence, 
2005). Positive charge of particles appears to 
enhance their uptake in the gut (Florence, 2005). 
Jani et al. (1990), using polystyrene particles (50 nm, 
100 nm, 500 nm, 1 μm and 10 μm) found a size 
effect: the smaller the particle, the higher the uptake.
5.2.4 Translocation to and assimilation by 
the central nervous system
Oberdörster et al. (2005) reviewed three ways in 
which nanoparticles can potentially gain access 
to the CNS: absorption by the olfactory mucosa, 
assimilation via the peripheral nervous system and 
traversing of the blood–brain barrier. Virtually the 
first thing that vertebrates do during ontogeny is 
“internalize” their CNS during gastrulation (i.e., they 
turn a piece of the skin on the dorsum “inside-out” 
and sink it under the integument), which brings it 
under the influence of the homeostatic robustness 
of the internal milieu. However, this system has an 
“Achilles heel” – the olfactory mucosa. The olfactory 
mucosa is the only part of the CNS to remain in direct 
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contact with the external milieu. It is an absorptive 
“sampling” mucosa, operating by endocytosis. It is 
widely recognized that this is a portal of entry to the 
CNS for some viruses, as demonstrated by Bodian 
& Howe (1941a, 1941b) for the 30 nm polio virus in 
a primate model. They showed that the virus was 
moved by anterograde axonal transport at 2.4 mm/
hr. de Lorenzo (1970) used 50 nm silver-coated 
colloidal gold nanoparticles in squirrel monkeys 
and showed uptake in the olfactory bulb. He also 
observed trans-synaptic propagation to reach mitral 
cell dendrites. Oberdörster et al. (2004) reported 
on the translocation of inhaled ultrafine particles to 
the brain. They exposed rats to 13C nanoparticles 
(35 nm) by inhalation. They observed a significant 
increase in 13C in the olfactory bulb on day 1 with a 
further continued increase up to day 7 post exposure.
The second route of entry, assimilation via the 
peripheral nervous system, is again achieved by 
retrograde axonal transport. A number of viruses 
are known to be able to travel via the trigeminal 
nerve to the semilunar ganglion in the middle cranial 
fossa. Herpes viruses can use both anterograde 
and retrograde axonal transport via branches of 
the trigeminal nerve (Kennedy & Chaudhuri, 2002). 
Non-biological nanoparticles have also been 
observed to undergo retrograde axonal transport 
from the peripheral nervous system. Hunter & Dey 
(1998) demonstrated the uptake of rhodamine 
labelled microspheres of 20–200 nm in rats and 
Hunter & Undem (1999) used the same method in 
guinea pigs.
The third route is for nanoparticles to traverse the 
blood–brain barrier. The blood–brain barrier does 
not become fully competent until about 6 months 
after birth. Therefore, a window of vulnerability 
exists for the ingress of nanoparticles into the 
CNS during fetal and early postnatal life. The 
blood–brain barrier has specialized tight junctions 
which help minimize paracellular transport. 
It stops most small molecules and nearly all 
macromolecules from entering the CNS (de Boer 
& Galliard, 2007). The pharmaceutical industry is 
conducting a large amount of active research into 
nanoparticle preparations to increase drug delivery 
to the CNS by crossing the blood–brain barrier. 
This has been extensively reviewed by Kabanov 
& Gendelman (2007). Candidate nanoparticles 
under consideration include liposomes, polymeric 
micelles, nanogels, dendrimers and insoluble 
nanoparticles. Kreuter et al. (2001, 2002) have 
shown that poly(butyl cyanoacrylate) nanoparticles 
pre-coated with polysorbate 80 can be used to 
enhance the delivery of apolipoproteins to the 
brain. Alyaudtin et al. (2001) have demonstrated 
that similar ultrafine particle mediate delivery of 
[3H]-dalargin to the brain. Furthermore, Foley et al. 
(2002) have established that fullerenes can cross 
the membranes of living cells and accumulate 
preferentially in the mitochondria.
5.2.5 Nanoparticle distribution in the body
The kinetics of nanoparticles in the body has been 
reviewed by Hagens et al. (2007). Once nanoparticles 
have been assimilated, if they can gain access to the 
circulation they can be transported throughout the body. 
Several authors have demonstrated the presence of 
nanoparticles in the blood stream (Hillyer and Albrecht, 
2001; Gatti et al., 2004), and a number of studies have 
shown distribution of nanoparticles to the liver, spleen, 
heart and brain (Hillyer & Albrecht, 2001; Nemmar et al., 
2002; Oberdörster et al., 2002; Ji et al., 2006). When 
nanoparticles enter the circulation, they can interact 
with elements of the blood, plasma proteins, cells 
and factors affecting coagulation; however, the exact 
mechanism of this interaction is unknown. Evidence 
suggests that nanoparticle interactions with plasma 
proteins can reduce their toxicity. Lovric et al. (2005) 
showed that bovine serum albumin reduced the toxicity 
of quantum dots in vitro. Apolipoprotein-A1 has been 
shown to bind to silica (Barrett et al., 1999); although, 
little appears to be known about the stability of such 
binding or the proportion of nanoparticles likely to be so 
bound. Human studies are not conclusive, as they may 
suffer a lower level of sensitivity, compared to animal 
experiments.
After oral dosing with colloidal gold in mice, 
Hillyer & Albrecht (2001) demonstrated that 4 nm 
nanoparticles spread to distant organs, including the 
brain. However, 58 nm nanoparticles remained in the 
gut, suggesting a size dependent phenomenon.
Oberdörster et al. (2002) showed in animals that 
after inhalation there was a small but measurable 
redistribution of radio-labelled nanoparticles to 
distant organs, suggesting haematogenous spread.
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5.2.6 Nanoparticle excretion
The kidney forms urine as an ultrafiltrate of blood, 
through the glomerular wall, whose pores are ~8 nm 
in size. Small positively charged ions such as sodium 
and potassium can pass easily through the kidneys, 
while larger molecules, particularly those with a 
negative charge, such as proteins, hardly pass at all. If 
nanoparticles cannot be completely removed from the 
body then, however slowly they enter, some degree of 
bioaccumulation will occur. It is evident from the literature 
that non-soluble particulate matter can sequester for 
years in the lungs, gastrointestinal tract or brain.
There is evidence of translocation of nanoparticles 
from the lung and gut to the vascular system. 
Nigavekar et al. (2004) report that poly(amidoamine) 
dendrimers 5 nm in diameter have been shown 
in a mouse model to be excreted in urine, with 
accumulation in the kidney observed. Borm et al. 
(2006) describe unpublished observations (Curtis) 
that suggested it is conceivable that nanoparticles of 
an appropriate size could block the renal fenestrae 
and precipitate acute renal failure. There is clearly a 
large data gap in this topic.
Nanoparticles can also be excreted in the bile 
(Nefzger et al., 1984); the process of transcytosis 
is involved. Lowe et al. (1985) studied the transport 
of horse radish peroxidise, a high molecular weight 
protein into the bile. Their studies suggested that 
in the presence of liver damage paracellular routes 
of excretion into the bile became more significant. 
Sweat and cell shedding are other possible routes of 
nanoparticle excretion.
This topic is of critical importance to the 
pharmaceutical industry, which needs to know the 
pharmacokinetics of nanomedicine products. A 
review of nanoparticle clearance has been published 
by Longmire et al. (2008).
5.3 Internally produced nanoparticles
Internally produced nanoparticles cause a number of 
“co-pathologies”, which should be considered because 
they can inform hazard identification from engineered 
nanoparticles. In addition, these pathologies could 
be affected by interactions between nanoparticles 
produced by the human body and engineered ones. 
Examples include:
• Acute glomerulonephritis. In the post-beta 
streptococcal infection variety the pathology is 
caused by the deposition of nanoscale protein 
immune complexes which obstruct the pores in 
the glomerular basement membrane.
• Disseminated intravascular coagulopathy is an acute 
pathological activation of coagulation mechanisms 
which can be activated by the appearance in the 
blood of nanoscale lipopolysaccharide complexes. 
The latter can be a consequence of a gram negative 
bacterial infection.
• Amyloid precursor protein oligomer toxicity.  The 
presence of this oligomer is associated with 
Alzheimer’s disease.
6. Target organ susceptibility
6.1 The brain and protein misfolding
Over 40 human protein misfolding diseases are 
known. The majority of these result in damage to 
the CNS as shown in Table A3.2. The spectrum of 
sequelae associated with protein misfolding include 
non-functioning proteins, insoluble proteins or protein 
fractions and/or the production of toxic oligomers 
(Cottingham et al., 2002). However, through evolution 
the CNS has developed a system for coping with 
a basal level of such misfolding by internalizing such 
products in specialized endosomes. The occurrence 
of lipofuscin granules, for example, increases with 
age. Some specific proteins have their own distinctive 
endosomes, for example the protein associated with 
Parkinson’s disease, alpha-synuclein  accumulates in 
Lewy bodies.
The mechanisms that have evolved throughout pre-
industrial history to deal with misfolded protein fragments 
can be expected to have the capacity to cope over a 
lifetime without major adverse effects. However, if the 
rate of misfolding is increased, it may result in adverse 
consequences. The possible sequelae might be an 
increase in the incidence of protein misfolding disease in 
the general population and an earlier average age onset.
Some literature exists on the ability of nanoparticles 
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to disrupt protein folding, termed “chaperone effects”. 
Billsten et al. (1997) showed that 9 nm silica particles can 
alter the configuration of the enzyme human carbonic 
anhydrase II. Akiyoshi et al. (1999) have demonstrated 
the chaperone-like activity of nanoparticles with the 
beneficial effect of facilitating the thermal stabilization 
with refolding of carbonic anhydrase B. Ishii et al. (2003) 
have shown that semiconductor nanoparticles can be 
stabilized by chaperoning molecules, and then their 
release can be mediated by Adenosine triphosphate 
(ATP). This is presented as a possible basis for bio-
mediated devices in the future. Protein misfolding 
mechanisms and cellular recognition systems have 
been reviewed by Goldberg (2003).
In vitro work  by Linse et al. (2007) has demonstrated 
that the rate of fibrillation of amyloid protein can be 
perturbed by nanoparticles. Chen & von Mikecz 
(2005) have reported that silicon dioxide nanoparticle 
induced protein aggregates have a similar composition 
to intracellular inclusions that are diagnostic markers 
for protein misfolding diseases such as Huntington’s 
chorea and muscular dystrophy.
It is clear that more data are needed about the degree 
of translocation of nanoparticles into the brain and 
the interactions of nanoparticles with critical proteins 
such as amyloid precursor protein, Parkin, alpha 
synuclein and tau.
Table A3.2. List of proteopathies
Proteopathy Major aggregating protein
Alzheimer's disease Amyloid β peptide (Aβ); Tau protein (see tauopathies)
Cerebral β-amyloid angiopathy Amyloid β peptide (Aβ)
Retinal ganglion cell degeneration in glaucoma[38] Amyloid β peptide (Aβ)
Prion diseases (multiple) Prion protein
Parkinson's disease and other synucleinopathies (multiple) α-Synuclein
Tauopathies (multiple) Microtubule-associated protein tau (Tau protein)
Frontotemporal lobar degeneration (FTLD) (Ubi+, Tau-) TDP-43
FTLD–FUS Fused in sarcoma (FUS) protein
Amyotrophic lateral sclerosis (ALS) Superoxide dismutase, TDP-43, FUS
Huntington's disease and other triplet repeat disorders 
(multiple) 
Proteins with tandem glutamine expansions
Familial British dementia ABri
Familial Danish dementia ADan
Hereditary cerebral hemorrhage with amyloidosis (Icelandic) 
(HCHWA-I) 
Cystatin C
CADASIL Notch3
Alexander disease[39] Glial fibrillary acidic protein (GFAP)
Seipinopathies[40] Seipin
Familial amyloidotic neuropathy, Senile systemic 
amyloidosis 
Transthyretin
Serpinopathies (multiple) Serpins
AL (light chain) amyloidosis (primary systemic amyloidosis) Monoclonal immunoglobulin light chains
AH (heavy chain) amyloidosis Immunoglobulin heavy chains
AA (secondary) amyloidosis Amyloid A protein
Type II diabetes Islet amyloid polypeptide (IAPP; amylin)
Aortic medial amyloidosis Medin (lactadherin)
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Proteopathy Major aggregating protein
ApoAI amyloidosis Apolipoprotein AI
ApoAII amyloidosis Apolipoprotein AII
ApoAIV amyloidosis Apolipoprotein AIV
Familial amyloidosis of the Finnish type (FAF) Gelsolin
Lysozyme amyloidosis Lysozyme
Fibrinogen amyloidosis Fibrinogen
Dialysis amyloidosis Beta-2 microglobulin
Inclusion body myositis/myopathy Amyloid β peptide (Aβ)
Cataracts Crystallins
Retinitis pigmentosa with rhodopsin mutations[41] rhodopsin
Medullary thyroid carcinoma Calcitonin
Cardiac atrial amyloidosis Atrial natriuretic factor
Pituitary prolactinoma Prolactin
Hereditary lattice corneal dystrophy Keratoepithelin
Cutaneous lichen amyloidosis Keratins
Mallory bodies Keratin intermediate filament proteins
Corneal lactoferrin amyloidosis Lactoferrin
Pulmonary alveolar proteinosis Surfactant protein C (SP-C)
Odontogenic (Pindborg) tumor amyloid Odontogenic ameloblast-associated protein
Seminal vesicle amyloid Semenogelin I
Cystic Fibrosis cystic fibrosis transmembrane conductance regulator 
(CFTR) protein
Sickle cell disease[42] Hemoglobin
Critical illness myopathy (CIM) Hyperproteolytic state of myosin ubiquitination
Source: Proteopathy [web page]. San Francisco, Wikimedia Foundation Inc. (http://en.wikipedia.org/
wiki/Proteopathy, accessed 8 October 2013).
6.2 Vascular and respiratory systems
As discussed earlier, epidemiological studies 
demonstrate the links between air pollution and 
cardiovascular and respiratory mortality and morbidity 
(Schwartz & Dockery, 1992; Dockery et al., 1993; 
Peters et al., 2001; Clancy et al., 2002). Particulate 
aerosols have also been associated with changes 
in heart physiology (Brook et al., 2002; Devlin et 
al., 2003). The fact that tobacco smoke damages 
the arterial endothelium, and increases incidence of 
atherosclerosis, myocardial infarction and stroke is 
widely known (Auerbach et al., 1965). Particle research 
is uncovering the mechanisms for these observations; 
Donaldson et al. (2005) have reviewed this topic. 
The current hypothesis is that combustion derived 
nanoparticles (i) on gaining the blood stream, disrupt 
platelet and endothelial cell function, destabilizing 
plaque, leading to plaque rupture and thrombogenesis; 
and (ii) in the lung interstitium, nanoparticles cause lung 
inflammation, which produces cytokines and induces 
systemic inflammation, leading to destabilization 
of atheromatous plaques, plaque rupture and 
thrombogenesis.
The lung is also a major target for direct consequences 
of nanoparticle aerosol exposure. Donaldson et al. 
(1996) showed that, for titanium dioxide instilled into rat 
lungs, the smaller the size of particle the more intense 
the inflammation. Stone et al. (1998) have shown that 
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installation of carbon black induced a similar particle 
size related inflammation. Furthermore, it appeared 
that the material used was of less significance than 
the particle size. Oberdörster et al. (2005) showed 
acute lung inflammation in rats following inhalation 
of freshly generated polytetrafluoroethylene fumes. 
In all cases, the most intense inflammation, assessed 
by the loading of bronchoalveolar lavage fluid with 
neutrophils, was associated with exposure to particles 
in the ultrafine fraction. The common denominator 
was inflammation and the implications for systemic 
disease have been discussed by Seaton (1995).
6.3 The fetus
A suitable model for the study of nanoparticles on 
rapidly dividing cells is provided by the fetus, where at 
certain stages cells around the notochord are dividing 
every 3.5 hours, many times faster than in the most 
malignant tumours. In addition, epigenetic phenomena 
involving apoptosis in the selective stabilization of a 
number of systems makes the intrauterine part of life 
very vulnerable to damage.
Myllynen et al. (2008) have recently shown, on a 
human placenta perfusion model, that PEGylated 
gold nanoparticles of 5, 10 and 15 nm did not cross 
the materno–fetal barrier into the fetal circulation 
after a 6 hour perfusion. However, a dispersion of 
nanoparticles took place and these were found in the 
syncytiotrophoblast. The result of a more prolonged 
perfusion in vivo in human placenta remains unknown.
Tsuchiya et al. (1996) exposed pregnant mice to 
buckminsterfullerene. At high dose (137 mg/kg) 
all embryos died. At a lower dose, (25–50 mg/
kg) teratogenesis was observed, particularly in the 
head region. Although the nanoparticles may have 
crossed the placenta, an intraperitoneal route of 
exposure could not be ruled out. The dosages used 
were extremely high. An in vitro study on mouse 
embryos (Bosman, 2005) showed that polystyrene 
nanoparticles were internalized by the embryo, but 
no hindrance of development was detected.
Developmental toxicity of nanoparticles would be 
dependent on their potential to have effects either on 
placental function or by direct migration to the fetus. 
Very little data is available on this.
6.4 The anticipated spectrum of 
pathology from nanoparticle exposure
Some general conclusions can be drawn from the 
previous sections, concerning known pathogenic 
mechanisms, which can inform the formulation of 
policy. The likely unwanted consequences of human 
exposure to engineered nanoparticles will fall into 
two main categories, depending on whether or not 
particles can get inside cells. For nanoparticles that 
can be fully internalized by cells, the predominant 
hazard will involve cytotoxicological effects at the 
cellular level and/or inflammatory effects at the tissue 
level. Fibres, when they reach a length at which they 
become “indigestible” by the cell (generally accepted 
as being in the region of 20 μm), tend to give rise 
to a different spectrum of disease, associated with 
chronic inflammation and oxidative stress of the 
interstitial regions between cells. The demonstration 
of mesothelioma-like activity in certain varieties of 
carbon nanotubes suggests that human exposure 
may have important consequences. For those 
particles that cannot be fully internalized, usually high 
aspect ratio fibres, the additional complication of 
extracellular “foreign body” type of reactions exists. 
This is particularly the case for those associated 
with “frustrated phagocytosis”, where the cell tries 
to engulf the particle but because of its dimensions 
only partially achieves this.
The acute response of tissues to nanoparticles 
has been more widely studied than chronic long-
term endpoints. The common factor for the acute 
response is oxidative stress leading to inflammation 
(Unfried et al., 2007), which is detectable and the 
sequelae of which are well understood. However, the 
possibility of longer-term phenomena, not necessarily 
involving inflammation, has to be considered. The 
growing literature on the ability of nanoparticles to 
interfere with normal protein folding raises questions 
about the possibility that chronic low-dose exposure 
of particles over a lifetime may contribute to 
degenerative diseases, particularly of the nervous 
system. While acute effects such as inflammation 
are more likely to be detected, particularly with 
modern nitric oxide measurement equipment, and 
associated with nanoparticles exposure, chronic 
low-dose toxicity leading to degenerative disease is 
much less likely to be identified. 
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Thus, the health consequences of human exposure 
to nanomaterials might include diseases that: are 
aspecific (i.e. admit several risk factors of a different 
nature, for example linked to lifestyle); are possibly 
more powerful; have long-term latency; and are not 
easily predictable given the complex causal chain, 
or possible synergistic effects with other exposures. 
The combination of these characteristics would make 
some of the health effects particularly difficult to detect 
and may produce some “unknown unknowns”.
7. Consideration of two 
  nanomaterials produced in   
  industrial quantities
7.1 Titanium dioxide
Titanium dioxide has been widely used for decades, 
for instance as an ultraviolet (UV) filter in sunscreens. 
Originally the particle size for use in sunscreens was 
~200 nm and sunscreen creams where opaque and 
white in appearance. More recently the particle size 
has been reduced to the nanoscale of ~30–60 nm, 
making creams transparent. Due to these applications, 
nanosized titanium dioxide may be among the most 
widespread nanoparticles to be encountered in the 
daily human environment. Various effects have been 
observed in different strains of rodents after exposure 
to titanium dioxide, and several studies report 
differences in the responses for particles smaller 
than 100 nm compared to those for larger particles 
(Ferin et al., 1992; Baggs, et al. 1997; Oberdörster 
et al., 2005). Difference in the toxicological profile in 
rodents has also been observed to be dependent of 
the surface area of titanium dioxide particles rather 
than mass dose. When comparing anatase (one of 
the three mineral forms of titanium dioxide) particles 
of 20 and 250 nm, Oberdörster G. (2000) found that 
the former generated a much greater pulmonary-
inflammatory response in rats after exposure to equal-
mass doses. With dose expressed as a function of 
mass and surface particle number, marked differences 
in the dose-response curve of the two materials were 
found; however, when dose was expressed in terms 
of particle surface area, both forms of titanium dioxide 
followed a similar dose-response curve. Donaldson 
et al. (2002) reported observing a similar correlation 
for carbon black, when studying the ability of nano- 
and microparticles to cause inflammatory effect in rats 
(Donaldson et al., 2002). In contrast, Warheit et al., 
(2006) and Sayes et al. (2007) reported no association 
with surface area when evaluating biological response 
in rats after exposure to nanosized titanium dioxide, 
silicon dioxide and other particles.
A number of factors have been hypothesized to 
influence the toxicity of titanium dioxide besides 
surface area. These include crystalline structure, 
shape, coated versus non-coated type, as well as 
exposure routes (e.g. intratracheal, oral, inhalation) 
(Oberdörster et al., 1992; Osier & Oberdörster, 
1997; Höhr et al., 2002; Warheit et al., 2007). The 
cytotoxicity of titanium dioxide has also been found to 
be dependent on crystalline structure, size and purity. 
For instance Sayes et al. (2006) observed a time-
dependent decrease in human dermal fibroblasts 
for anatase titanium dioxide (30 μg/mL/1–48 h) and 
found a 50% lethal concentration  (LC50 = 3.6 μg/
mL). However, for rutile titanium dioxide (another 
mineral form), the LC50 was substantially higher 
and equal to 550 μg/mL, with LC50 of anatase/rutile 
titanium dioxide falling between the two. Limbach et 
al. (2007) found promoted increase of ROS in human 
lung epithelial A459 cells that increased with the purity 
of the particles (30 μg/mL/4 h). This observation was 
supported by Long et al. (2006) who observed a 
rapid (< 5 minute) and sustained (120 minute) release 
of ROS at non-cytotoxic concentrations (2.5–120 
ppm/1–18 h) in BV2 brain microglia. This work has 
also been reviewed by Stone et al. (2010). 
The UV reactivity of titanium dioxide has been the 
subject of several studies. Uchino et al. (2002) 
and Gurr et al. (2005) found no additional effect of 
photoactivation against human bronchial epithelial 
BEAS-2B cells and Chinese hamster ovary cells; 
however, evidence indicates that the cytotoxicity of 
titanium dioxide is influenced by UV irradiation (Sayes 
et al., 2006). Recent graphical evidence concerning 
titanium dioxide and ROS production can be found 
in Oberdörster (2010).
7.2 Carbon nanotubes 
CNTs are fibrous nanoparticles, already being 
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produced in industrial quantities, with annual 
production rising sharply since 2005. Current 
applications include materials and components for 
a variety of industries (sports, construction, textiles, 
scientific laboratories); the remarkable characteristics 
in terms of strength, lightness, flexibility, conductivity 
and thermal properties make CNTs likely to become 
very widely used in the near future. Their health 
effects have been thoroughly reviewed by Genaidy 
et al. (2009). In addition, their toxicology is discussed 
in Stone et al. (2010) and Oberdörster (2010). As 
with titanium dioxide, the widespread use of CNTs 
creates a greater likelihood of generalized exposure 
than with other nanoparticle types. Thus, the 
available knowledge on CNTs’ nanotoxicology is of 
special importance.
The publication of two papers (Poland et al., 2008; 
Takagi et al., 2008) indicating that CNTs have 
mesothelioma-like activity in animal models, acts as 
a serious warning in the risk assessment of these 
novel materials. The paper by Poland et al. examined 
the effect of long MWCNT on the peritoneal cavity 
of mice; the results indicated an asbestos-like, 
length-dependent, pathogenic behaviour. Takagi et 
al. (2008), reported that MWCNT with a fibrous or 
rod-shaped length around 10–20 μm, with an aspect 
ratio of more than three, induced mesothelioma when 
administered intraperitoneally to p53-heterozygous 
mice that had been reported to be sensitive to 
asbestos – although the doses used were high. A 
positive control, crocidolite (blue asbestos) was used 
for comparison. The results point out the possibility 
that carbon-made, fibrous or rod-shaped micrometre 
particles may share the carcinogenic mechanisms 
postulated for blue asbestos. Thus, CNTs of similar 
dimensions and durability as asbestos fibres may be 
of concern.
This result was predictable from in vitro studies by 
Kaiser et al. (2008) investigating bundles of SWCNT. 
Findings are also consistent with the review conducted 
by Tomatis et al. (2007) on the association between 
asbestos fibre size and mesothelioma. This review 
concluded that stiffer, high aspect ratio fibres are 
also positively associated, and rejected suggestions 
that only short, low aspect ratio asbestos fibres 
could traverse the pleura and cause mesothelioma 
(Chiappino, 2005).
8. Risk assessment of    
 nanomaterials
Risk assessment (mainly of chemical or physical 
agents) traditionally consists of the following four 
steps:
1. hazard identification
2. hazard characterization
3. exposure assessment 
4. risk quantification.
The quality of the final step, the risk quantification, 
is entirely dependent on the quality of the first 
three steps. Current risk assessment procedures 
with corresponding regulations for nanomaterials 
have been based on procedures extrapolated 
from chemical risk assessment, (Rocks et al., 
2008). This section briefly describes the basic risk 
assessment procedures used for nanomaterials, and 
gaps in knowledge, relevance and usefulness. The 
limitations of chemical risk assessment when applied 
to nanomaterials are also briefly described in later 
sections.
8.1 Hazard identification and 
characterization and exposure assessment 
in nanomaterial risk assessment
The diversity of nanomaterials and their properties 
makes it hugely challenging to conduct in vitro and 
in vivo evaluations of their biological effects (CCA, 
2008). End-points usually considered include acute 
toxicity, repeated dose toxicity, irritation, sensitization 
potential, mutagenicity, clastogenicity (i.e. propensity 
to cause a point mutation as compared to disrupting 
a chromosome), carcinogenicity and reproductive 
toxicity (Rocks et al., 2008). However, as discussed 
in this report, there is not enough knowledge to 
exclude the possibility of other, potentially unknown, 
endpoints. Preliminary results suggest that in vitro 
testing may not always accurately predict hazards, 
and large in vivo studies are few and difficult to 
reproduce.
Hazard identification of chemical or physical agents 
is traditionally based on inherent physical, chemical, 
biological and toxicological properties, whereas 
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hazard characterization involves the establishment 
of a dose (concentration)–response (effects) 
assessment. 
Several studies – for example on buckminsterfullerene, 
single- and multiwalled CNTs, and various forms of 
metal nanoparticles – have reported dose–response 
relationships. Based on these, some predicted “no 
effect concentrations” have even been estimated 
(Mueller & Nowack, 2008; Park et al., 2008).
Interpreting these results and extrapolating to the 
wide variety of nanomaterials is difficult, since the 
nanomaterials that have been tested differ substantially 
from other nanomaterials with regard to: (i) physical–
chemical properties such as chemical composition, 
shape, etc. and (ii) endpoints tested for, duration 
of exposure, methods (e.g. assays) and standards 
used (Hansen et al., 2007). In addition, based on the 
knowledge from studies on nanoparticles detailed in 
sections 5 and 6 of this report, it has been suggested 
that the biological activity of nanoparticles might not 
always be dose-dependent, but rather dependent 
on physical and chemical properties not routinely 
considered in toxicity studies (Oberdörster et al., 2005). 
This creates serious challenges for all steps of risk 
assessment of nanomaterials.
Exposure assessment is another key step in risk 
assessment, invariably challenging, and the case of 
nanomaterials is no exception. Unfortunately, exposure 
data are lacking and no full exposure assessment has 
so far been published for any type of nanomaterial or 
group of nanomaterials. This is partly due to technical 
difficulties in measuring nanomaterial exposure in 
the workplace and/or the environment, and partly 
because the biological and environmental pathways 
of nanomaterials are still largely unexplored in detail 
(NIOSH, 2006; Owen & Handy, 2007; CCA, 2008). 
However, some efforts have been made to estimate, 
predict and assess occupational, consumer and 
environmental exposure levels (e.g. Boxall et al., 2008; 
Mueller & Nowack, 2008; Wijnhoven et al., 2009; 
Gottschalk et al., 2010). The applicability of current 
exposure assessment methods and guidelines has also 
been discussed (OECD, 2009; SCENIHR, 2009). These 
efforts have been hampered by the lack of information 
(or access to it), e.g. about manufacturing conditions, 
levels of production, industrial applications and uses, 
consumer products, environmental behaviour and 
environmental fate and distribution (Maynard et al. 
2004; Boxall et al. 2008, Hansen et al., 2008).
8.2 Current status of risk assessment of 
nanomaterials
In 2007, the EC Scientific Committee on Emerging 
and Newly Identified Health Risks (SCENIHR) 
concluded that the current chemical risk assessment 
framework was most likely to be sufficient for 
nanomaterials, but may need to be modified in 
some cases (SCENIHR 2007, 2009; Grieger et al., 
2010). However, since then only a few attempts 
have been made to complete risk assessments of 
nanomaterials, which are described below.
In 2009, Shinohara et al. published a number of 
interim reports on risk assessments of manufactured 
nanomaterials, i.e. buckminsterfullerene, CNTs 
and titanium dioxide. Based on a limited number 
of inhalation exposure studies, the authors present 
several procedures to establish a provisional 
value for an acceptable exposure concentration 
in the occupational environment, as well as the 
general environment. When deriving the provisional 
no-observed-adverse-effect level (NOAEL) for 
buckminsterfullerene, inflammatory responses in the 
lung was selected as the critical endpoint, based on 
the assumption that inhalation is the primary route 
of human exposure. The occupational NOAEL was 
estimated to be 116 μg/m3 and the general NOAEL 
49.6 μg/m3. In the case of buckminsterfullerene, 
the uncertainty factor was reported to be 6 in the 
occupational environment and 60 in the general 
environment. Shinohara et al. (2009) found that the 
acceptable and estimated exposures to CNTs were 
quite close to each other, but concluded that the risk 
cannot be determined since the estimated exposure 
values have a wide range, and vary greatly with 
different work processes at individual sites. Using lung 
inflammation as the critical endpoint, the acceptable 
amount of deposited titanium dioxide on the alveoli per 
day, per body weight was found to be 18 μg/kg/day. 
Worst-case exposure was estimated at 5.9 μg/kg/day, 
and following that, a hazard quotient was calculated 
as 0.3 (i.e. < 1), indicating that titanium dioxide is 
safe to use. Shinohara et al. (2009) subsequently 
concluded that the provisional values presented in 
the interim reports must be treated as preliminary 
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due to a number of challenges and uncertainties in 
the estimated values, including: whether the amount 
deposited on the alveoli should be based on mass 
concentration; the influence of surface area, primary 
particle size, and aggregation/agglomeration size; 
limited information from toxicity tests; and diversity of 
types of titanium dioxide nanomaterials.
In 2010, Stone et al. published a scientific report 
including an exploration of key questions associated 
with risk assessment of nanomaterials. They 
carried out qualitative risk characterizations for 
buckminsterfullerene, CNTs, nanosilver and titanium 
dioxide, and concluded that a quantitative risk 
assessment was not possible due to “a significant 
lack of measured and modelled exposure data 
of nanoparticles, for humans (occupational and 
consumer exposure) and for the environment”. In 
terms of human health, Stone et al. (2010) sought to 
establish “exposure values for the various routes of 
exposure (inhalation, dermal and oral) for consumers 
and workers and the establishment of a Derived-No-
Effect Level (DNEL), typically based on extrapolation of 
animal data to the human situation by using appropriate 
assessment factors”. In relation to environmental risk 
assessment, the authors developed the predicted 
exposure concentration (PEC) and the predicted no 
effect concentration (PNEC) for each environmental 
compartment (e.g. water, air, soil) and derived a risk 
quotient. If the risk quotient is greater than one, this 
is interpreted as an indicator of risk. Based on the 
available data, Stone et al. (2010) found that risk does 
not seem to be adequately controlled for fullerenes and 
CNTs in the workplace, as there may be a potential 
risk after prolonged inhalation exposure to nanosilver, 
as well as a chronic risk associated with occupational 
nano-titanium dioxide exposure. However, they note 
that this risk characterization is based on sparse 
information and includes many uncertainties. For 
instance, with regard to the buckminsterfullerene, 
there are information gaps and areas of uncertainty 
concerning:
• the availability of reliable exposure measurements 
of fullerenes in mass/volume, identification of 
fullerenes or fullerene types, distinction from 
background levels in the workplace, and also as 
released from consumer products and possibly in 
the environment; 
• toxicokinetics (with consideration of detection 
methods and their influence on the results):
 – absorption of fullerenes via the different 
exposure routes (inhalation, dermal and oral);
 – metabolism/elimination via alveolar 
macrophages, Kupffer cells or other pathways;
• repeated dose toxicity studies via inhalation at 
concentrations relevant for the workplace to detect 
local and possible systemic effects; discussion is 
required to decide whether a 28-day or 90-day 
study would be more appropriate to see early/
prolonged effects, but also not to be affected by 
recovery; dependent on the results from these 
studies (e.g. low toxicity confirmed) no guideline 
acute inhalation study might be necessary;
• dermal studies:
 – dermal uptake with a skin model;
 – local/systemic dermal effects (depending on 
results of dermal uptake);
• irritation (skin/eye);
• sensitization (skin, respiratory tract);
• genotoxicity: further in vitro and in vivo 
investigations to decide on primary and/or 
secondary genotoxic effects;
• carcinogenicity: depending on results from 
genotoxicity tests and subacute/subchronic 
studies, a testing strategy for carcinogenicity 
might be developed;
• reproductive toxicity: depending on results from 
absorption studies (systemic availability) and 
indications of effects on reproductive organs/
hormones from a repeat dose toxicity study.
With regard to environmental risk assessment, Stone 
et al. (2010) were not able to perform a quantitative 
risk assessment of buckminsterfullerene and CNTs 
due to the lack of data. For instance, in order to 
“estimate the risk of C60 [buckminsterfullerene] for 
the aquatic environment, it would be necessary to 
measure/estimate fullerenes concentrations in water, 
and to study any toxic effect under realistic exposure 
conditions, considering the use of well characterized 
natural waters. Moreover, the effect of different 
functionalizations in relation to both biotic and abiotic 
factors should be studied case by case.”
Additional gaps identified in regard to environment 
risk assessment are:
• lack of information on production volumes of 
buckminsterfullerene, in its many forms;
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• lack of information on the number of 
buckminsterfullerene products, market penetration 
and amounts of the nanoparticles in these products;
• lack of information on behaviour of 
buckminsterfullerene during wastewater treatment;
• lack of exposure and monitoring data on 
buckminsterfullerene in environmental compartments;
• very little information about environmental fate, 
limited to aggregation in natural water;
• general lack of toxicity data, but especially 
for algae, sediment organisms and terrestrial 
organisms;
• lack of long-term toxicity studies for the aquatic 
compartment, i.e. long-term studies on fish and 
Daphnia;
• lack of information concerning interaction 
between organisms and buckminsterfullerene 
(adsorption, uptake, bioaccumulation, etc.).
Interaction of fullerenes with chemicals should also 
be considered in a full risk assessment, since it can 
increase the bioavailability and accumulation of organic 
and inorganic chemicals, increasing their toxicity.
For nanosilver and nano-titanium dioxide, a 
quantitative risk assessment was carried out for 
the aquatic compartment, but due to limited data it 
considered freshwater only. Normally, sediment and 
the food chain would be included as well. The PEC/
PNEC ratio for the aquatic compartment of nanosilver 
was found to be 0.25–2.00, and for nano-titanium 
dioxide 0.10–4.00. As these ranges include 1, Stone 
et al. (2010) state that refinements are needed.
Some of the limitations summarized above are 
specific to the application of nanomaterials, while 
others may also be problematic in other areas, 
such as chemical safety. Such limitations have been 
identified over the past 20–30 years, through the use 
of risk assessment. These issues raise a number 
of challenging questions in the practice of human 
health risk assessment:
• To obtain complete risk assessments (of chemicals 
as well as nanomaterials), simplifications like 
lab-to-real world extrapolations and worst-case 
assumptions are made and some uncertainties 
are dealt with by using prudential correction 
factors. Even with these simplifications, chemical 
risk assessments have turned out to be very 
time- and resource intensive and their real 
influence on risk management decisions can be 
questioned (Tickner, 2007). Although not specific 
to nanomaterials, these limitations are important 
to consider when doing risk assessment of 
nanomaterials.
• There are no established standards for risk 
assessment of nanomaterials and there are no 
standard procedures or widely accepted methods 
for assessing nanomaterials safety hazards. 
When looking at the individual steps in the risk 
assessment procedure, it becomes apparent that 
even at the starting point – hazard identification 
– applying internationally consolidated practices 
from other fields is not straightforward. For 
example, a set of hazard-relevant physical and 
chemical parameters still needs to be identified 
by the scientific community and no standardized 
toxicity test guidelines are in use. For exposure 
assessments, no standards exist on how to 
measure nanoparticle dose in the body, or exposure 
in the workplace or the environment, which present 
additional complications in monitoring, detection 
and procedures. Assessment of health effects 
is hampered by the lack of basic toxicological 
test methods, and a lack of established health 
endpoints to investigate. Although standardization 
work in the field of risk assessment of nanomaterials 
is currently underway on an international scale, it 
is important to remember that standardization of 
chemical risk assessment procedures (including 
toxicity tests and related exposure/effect 
assessment protocols) took more than 20 years 
(Halffman, 1998).
• The current risk assessment paradigm is not ideal 
for taking into consideration the many sources 
and types of uncertainty involved in determining 
exposures and health effects of nanomaterials. 
Many different data or research gaps need to be 
addressed in order to analyse more accurately 
the risks of nanomaterials, and traditional 
means of dealing with these uncertainties 
may not adequately reflect the true degree of 
uncertainty. The United Kingdom Department for 
Environment, Food and Rural Affairs (DEFRA) has 
recommended that these uncertainties should be 
further clarified. Furthermore, Grieger et al., (2009) 
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concluded that recognized knowledge gaps exist 
in nearly all aspects of the environmental and 
health risks of nanomaterials. Further research 
will likely reduce these uncertainties, although the 
process will be time- and resource expensive.
• It is often stated that the risk of nanoparticles needs 
to be assessed on a case-by-case basis in order 
to take the unique properties of any nanomaterials 
into consideration (e.g. SCENIHR, 2007, 2009; 
Stone et al., 2010). Even with well defined data 
demands, the experience from chemical risk 
assessments tell us that this will be very time- 
and resources intensive. For nanomaterials, this 
situation is further complicated by the fact that 
hazard characteristics will not only be linked to 
chemical identity but also to a large number of 
other characteristics, and their combinations. 
For instance, there are 20 different structural 
types of SWCNT alone, and their length can vary 
from 5 to 300 nm. According to Schmidt (2007) 
four different processes exist for manufacturing 
SWCNTs, five methods for purifying them, and 
10 surface coatings are typically applied. Hence, 
up to 50 000 potential combinations of SWCNT 
exist, and each version may have different 
chemical, physical and biological properties that 
determine their overall hazard. Although not all of 
them are expected to be of commercial relevance, 
the numerous kinds of nanoparticles – such 
as fullerenes, quantum dots, metal and metal-
oxide nanoparticles – imply a great complexity in 
performing case-by-case risk assessments.
8.3 Other frameworks for dealing with 
nanomaterial risk
In addition to the traditional risk assessment 
paradigm, and in consideration of its limitations, other 
frameworks have been proposed which attempt 
to analyse the human and environmental risks 
associated with nanomaterials (Grieger et al., 2010). 
There has also been interest in alternative tools such 
as multicriteria decision analysis (Linkov et al., 2007) 
or life-cycle analysis (Shatkin, 2008), to help assess 
some of the potential health risks. Although none of 
the tools or frameworks listed below are currently 
used on a systematic basis, they may provide some 
important insights into developing alternative ways 
to address the potential risks of nanomaterials given 
the complexity and degrees of uncertainty involved.
8.3.1 Nano Risk Framework
Environmental Defense and DuPont Corporation 
have published a “Nano Risk Framework” describing 
a process for ensuring the responsible development 
of nanoscale materials (Environmental Defense and 
DuPont, 2007). The intent of the framework is to 
define a systematic process for identifying, managing 
and reducing potential environmental, health and 
safety risks of engineered nanomaterials across all 
stages of a product’s life-cycle. The objective is to 
offer a voluntary scheme to facilitate the responsible 
development of nanomaterials by companies 
and private and public research institutions. The 
framework informs DuPont’s  decision-making over 
nanotechnology and on how to direct research and 
development of various applications of nanomaterials 
(e.g. surface-treated, high-rutile phase titanium 
dioxide, and the use of nano-iron(II) oxide to destroy 
contaminants in groundwater). The framework is 
designed to be used iteratively at different stages 
of development advancement (i.e. basic research 
and development, prototyping, pilot testing, test 
marketing and full commercial launch) and as new 
information becomes available. The framework 
consists of six distinct steps:
1. Develop a general description of the 
nanomaterial in question and its intended uses, 
based on information already available, and 
identify analogous materials and applications 
that may help fill data gaps in this and other 
steps.
2. Develop profiles of the nanomaterial’s 
properties, inherent hazards and associated 
exposures, considering all the elements of the 
nanomaterial’s full life-cycle and considering 
that a material’s properties, hazards and 
exposures may change during its life-cycle.
3. Evaluate all the information generated in the 
profiles and identify and characterize the 
nature, magnitude and probability of risks of 
the nanomaterial and its application. Gaps in 
the life-cycle profiles should be prioritized and 
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a decision should be made on how to address 
them.
4. Evaluate the available risk management 
options and recommend a course of action 
including engineering controls, protective 
equipment, risk communication strategies 
and product or process modifications.
5. Decide alongside key stakeholders, experts 
and decision-makers whether or in what 
capacity to continue development and 
production, and document these decisions 
and their rationale and share appropriate 
information with the relevant stakeholders.
6. Update and re-execute the risk evaluation 
regularly or as necessary to ensure that 
risk management systems are working as 
expected, and adapt in the face of new 
information or conditions, and document and 
share appropriate information with relevant 
stakeholders (Environmental Defense and 
DuPont, 2007).
Environmental Defense and DuPont have developed 
a system to help guide information generation and 
update assumptions, decisions and practices as 
new information becomes available (Figure A3.6). At 
various stages in the product development process 
a worksheet is provided to help participants:
• organize, document and communicate the 
information they have about their material
• recognize where and how information is 
incomplete
• explain how information gaps were addressed 
• explain the rationale behind the user’s risk 
management decisions and actions.
The amount of information required in the framework 
is directly related to the potential extent and degree of 
exposure of the specified application. Environmental 
Defense and DuPont recommend that a broad range 
of stakeholders have access to such information as 
products move into commercialization in order to 
facilitate understanding (Environmental Defense and 
DuPont, 2007).
8.3.2 SCENIHR’s staged approach
SCENIHR has recommended a tiered approach 
to assessing the potential risks from engineered 
nanoparticles (Figure A3.7). In order to put in place 
a process that is both scientifically valid and cost 
effective, and minimizes the use of animals, SCENIHR 
suggests a four stage process:
1. identify whether the manufacture, use and/or 
end of use disposal or recycling could result in 
exposure of humans or environmental species 
and ecosystems;
2. characterize the nature, level and duration of 
any exposure;
3. identify the hazardous properties of any 
forms of the nanomaterial to which significant 
exposure is likely;
4. characterize the hazard and make the final 
risk assessment.
Each stage involves specific steps, illustrated in 
Figure A3.7. The staged approach could also be 
used as a guide for the safe and sustainable handling 
of nanoparticles at various stages of their life-cycle. 
However, SCENIHR notes that a full implementation of 
this framework will require substantial methodological 
developments, for instance in regard to validated 
in vitro tests and portable equipment for exposure 
monitoring for nanoparticles (SCENIHR, 2007).
8.3.3 Weight-of-evidence appraisal
In a DEFRA project (2009), 19 research objectives 
were identified, including 6 on human health effects of 
nanomaterials. The scientific literature was assessed, 
through expert judgement, against these objectives. 
Each of 293 studies included in a database and 
selected for evaluation was rated on its relevance, 
quality and contribution using a weight-of-evidence 
framework, considering the nature of the study, 
the quality of characterization of nanomaterials, 
peer review and publication procedures, specificity, 
relevance and reliability. After studies were ranked, 
a threshold was identified, for each research 
objective, over which studies were considered to 
be of the most scientific value. Among the research 
objectives, one was “human health hazard and risk 
assessment”, which was based on data on the 
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toxicity (hazard) of nanoparticles and on nanoparticle 
physical-chemical characteristics and exposure 
(occupational, environmental, consumer). Eighteen 
studies on toxicology (including toxicokinetics), 
hazard identification (i.e. particle characterization), 
exposure and risk assessment were identified as 
relevant, and 17 reached a weight-of-evidence 
score high enough to be considered to have made 
(or be making) a contribution towards the objective. 
However, none of the studies involved humans, and 
data was lacking on occupational, environmental and 
consumer exposure. The authors conclude that “we 
are still some way from meeting the … objective”.
Figure A3.6. Environmental Defense and DuPont framework for assessment of risks from nanomaterials
Describe 
material and 
application
Evaluate risks Assess risk management
Decide, 
document and 
act
Review and 
adapt
Profile 
life-circle(s)
Properties
Hazards
Exposure
Iterate
Assess, prioritize and generate data
Source: Environmental Defense and DuPont (2007). Reproduced with permission.
8.3.4 Comparative hazard assessment
Comparative hazard assessment (CHA) is another 
means of prioritizing chemical substances for 
regulation. As outlined above, exposure assessment 
is complicated, expensive and often uncertain, and 
requires many model-based assumptions. Since 
hazard identification and characterization has many 
research needs and knowledge gaps, the deployment 
of ambitious exposure assessment exercises may be 
premature or not very cost effective, and CHA may 
be an alternative option. When using CHA, the step of 
exposure assessment is omitted. Substances or agents 
are ranked by hazard, and less hazardous materials 
are then substituted for more hazardous ones. This 
strategy has been successfully applied to reducing the 
number of hazardous pesticides in use. Pesticides lend 
themselves well to this approach, because some are 
relatively well characterized toxicologically. However, 
CHA can be applied in other situations.
The use of CHA for nanoparticles has been proposed 
by Howard & de Jong (2004). They developed a 
hazard trigger algorithm (EU, 2004). The majority of the 
hazard trigger values were unknown at that time, but 
progress has been made since. As a result, despite 
large knowledge gaps, this tool may be pragmatically 
used in regulatory work, as it allows the prioritization 
of nanoparticles to undergo regulatory scrutiny. Figure 
A3.8 illustrates such a CHA approach.
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Figure A3.7. A staged approach to identifying the human and environmental risks from nanoparticles
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Background Document 85
Figure A3.8. Proposed hazard trigger algorithm for nanoparticles 
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8.3.5 IRGC’s risk Governance Framework
The Risk Governance Framework developed by 
the International Risk Governance Council (IRGC), 
provides another approach to nanomaterials risk 
analysis. Unlike the previously described frameworks 
the IRGC’s framework is a broad framework for risk 
governance, which combines some aspects of the 
traditional risk assessment framework with societal 
and ethical aspects (Figure A3.9). This framework was 
considered particularly relevant for nanotechnology 
due to the large and extensive data gaps and 
uncertainties surrounding the potential health and 
environmental risks, and hence the need to involve a 
wide range of stakeholders when making decisions 
regarding nanotechnology’s use and implementation. 
For example, the IRGC’s framework includes an 
important step early in the process, which frames the 
problem according to societal values, establishing the 
risk “question” to be addressed by the subsequent 
risk appraisal step. Factors within the traditional 
risk assessment paradigm (hazard identification, 
exposure assessment, etc.) are then included within 
the risk appraisal section of the framework. Risks 
are evaluated during the tolerability and acceptability 
judgement phase, which is placed in a societal context. 
Finally, the identified risks are managed and decisions 
are made from the data collected in the process. 
Communication between the different steps plays an 
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integral part of the framework. The Risk Governance 
Framework has been applied to nanomaterials used 
in foods and cosmetics (IRGC, 2007).
Figure A3.9. The IRGC Risk Governance Framework
Management Sphere: 
Decision on & Implementation of Actions
Assessment Sphere: 
Generation of Knowledge
To be defined before most 
nanoproducts are known
Multidimensional in 
nanotechnology
Communication
Specific to 4 nanoproduct 
generations
Risk Management
Implementation
• Option Realisation
• Monitoring & Control
• Feedback from Risk Mgmt. Practice
Decision Making
• Option Identification & Generation
• Option Assessment
• Option Evaluation & Selection
• Option Risk Reduction
Specific to 4 natural, manufactured and bi-products NS
Tolerability & Acceptability Judgement
Risk Evaluation
• Judging the Tolerability & 
Acceptability
• Need for Risk Reduction 
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Risk Characterisation
• Risk Profile
• Judgement of the 
Seriousness of Risk
Applied to specific NT areas
Risk Appraisal
Risk Assessment
• Hazard identification & Estimation
• Exposure & Vulnerability Assessment
• Risk Estimation
Concern Assessment
• Risk Perceptions
• Social Concerns
• Socio-Economic Impacts
Two frames for NT
Pre-Assessment
• Problem Framing
• Early Warning
• Screening
• Determination of Scientific 
Conventions
Knowledge development is 
critical for nanotechnology
Source: IRGC (2007). Reproduced by permission.
9. Risk governance of    
 nanotechnology
Assessing the health effects of nanotechnology poses 
significant challenges. As discussed throughout this 
report, many distinctions must be made between types 
of nanomaterials, the possible nature of biological 
and health endpoints, and the route and likelihood 
of exposure. The extent to which humans come into 
contact with nanomaterials is only vaguely known, and 
so are the mechanisms of biological interaction. Many 
knowledge gaps exist, and the technology is in rapid 
evolution. Against this background, the role of scientific 
knowledge on nanotechnology and health effects, 
and the kind of advice that the research community 
can offer (in particular on health implications), must 
be realistic: it is virtually impossible that univocally 
determined, evidence-based recommendations on 
safe and unsafe types of nanomaterials and no-dose 
effects can be produced. The lack of such clear cut 
statements should not be misinterpreted as indicating 
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lack of effects, or conversely, suggestive of the need to 
ban all sorts of applications. Rather, it is important that 
health considerations, based on available scientific 
knowledge, are formulated as clearly as possible, and 
taken into full consideration through mechanisms of 
risk governance that ensure that an open, accountable, 
fair debate takes place. In essence, health advocates 
should contribute to ensuring that a fair process of 
negotiation occurs, between all relevant stakeholders, 
and results in reflective, legitimate deliberation, as 
mindful of health as possible.
Why is it unlikely that clear-cut, evidence-based 
standards and univocal risk assessments are 
produced? Nanotechnology and health presents 
a scenario that is rather typical of our era: high-
stakes, systemic uncertainty, great complexity and 
conflicting values and cultural positions. The stakes 
are high in several respects, as many benefits are 
already being gained and many more likely to accrue 
from developments in the field of nanoscience. This 
has attracted large industrial investment, financial 
(and human) capital and expertise, involving not only 
the private sector but also academia, research and 
development. Several such investors stand to reap 
substantial benefits, financially and otherwise, so 
“positive” stakes are high. “Negative” stakes are also 
high, however, though perhaps more uncertain: while 
adverse effects on human health and ecosystems 
have not been clearly established, some factors are 
of concern and suggest that a cautionary approach 
should be followed. 
Use of the precautionary principle has, in general, 
been endorsed in consultations around science and 
policy in environment and health (WHO, 2008), where 
complex risk factors are involved. Some specific 
factors related to nanomaterials also support this view: 
1. the human evolutionary experience of 
nanomaterials is essentially limited to 
combustion nanoparticles and viruses. 
The very reason for the great technological 
potential of substances aggregating at sizes 
between molecular and bulk level (i.e. the 
appearance of completely different properties) 
has a mirroring potential for creating unwanted 
biological interactions for which we may have 
no defence mechanisms in place. 
2. Similarly, nanomaterials have unfamiliar 
biokinetic properties within the human body. 
Nanoparticles have easy access to virtually 
all tissues and compartments of a biological 
system, including highly “protected” ones 
like the human central nervous system, at 
all stages of human development, beginning 
from preconception. 
3. Some still sporadic observations should 
be interpreted as possible warning signals, 
notably the asbestos-like properties of 
carbon nanotubes, which have produced 
mesothelioma in animal models. 
4. Such an observation, together with the variety 
of possible mechanisms of action outlined 
in this report, suggests that nanomaterials 
could result in adverse health effects of very 
different nature: some could be specific, like 
mesothelioma, and more easily detectable; 
other effects, occurring for example through 
inflammatory responses or oxidative stress, 
could be aspecific, and have other strong 
competing determinants. If a certain 
nanoparticle increased cardiovascular or lung 
cancer risks even modestly, for example, 
widespread exposure would produce a sizable 
impact, but would be extremely difficult to 
detect given the influence of other powerful 
risk factors, and against background trends. 
The time dimension could be problematic: asbestos-
like properties of nanofibres, for example, could 
produce health effects that require a long latency 
time to become manifest; exposures accrued over 
decades by a large enough population could then 
create the condition for irreversible epidemics. 
Thus, stakes around nanotechnology are high, both 
in terms of what we stand to lose by relinquishing 
certain benefits, or delaying them, and in terms of 
the potential detrimental consequences. Wrong 
decisions would have costly corollaries.
A second, related element, besides the high stakes, 
is that uncertainty and complexity are clearly of very 
high order. For a start, “nanotechnology” is a term 
that is too broad to be of use, in virtually all phases, 
from hazard identification to risk communication. 
It needs to be focussed and segmented for the 
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purpose of research and regulation, and for allowing a 
meaningful and accessible public debate. This would 
be in the interests of both producers and consumers. 
Uncertainty around the health implications 
of nanomaterials involves both recognized 
uncertainties, such as incomplete knowledge on 
the biological interaction of a given material, or on 
the choice of an appropriate exposure metric, but 
also ignorance, i.e. not knowing what we don’t 
know. Complex systems interactions can produce 
unexpected responses, which cannot be ruled 
out given the largely unknown properties of newly 
developed nanomaterials. Given the multiplicity of 
the nanomaterial types, variants, applications, target 
organs and mechanisms of action, such uncertainty 
is likely to be irreducible and be a permanent feature 
of research in this domain. Uncertainty will also be 
fuelled by the speed of technological development, 
which in many cases outpaces advancement of 
scientific evidence. Thus, it is necessary to apply 
modern methodology to characterizing and dealing 
with systematic uncertainty and complexity, and take 
policy decisions under such uncertainty. The popular 
demand on science to reduce uncertainty may be 
problematic and result in delaying the formulation 
of the most urgent questions. The problem may 
be compounded by a misconception, consisting of 
confusing accuracy, or abundance of information, 
with relevance. Given the magnitude of the scientific 
efforts, the number of dedicated programmes 
and published scientific papers, one may be lead 
to overestimate the available knowledge, and 
overlook the possibility that crucial questions are not 
addressed, or that substantial knowledge gaps exist.
Thirdly, underlying ethical questions, involving values, 
are entwined with scientific considerations and their 
policy implications. Apart from a possible ideological 
divide between “technophiles” and “technophobes”, 
it is very likely that some controversy may arise 
from issues of procedural as well as distributional 
justice. Procedurally unjust steps may occur, or be 
perceived to occur, if processes of governance are 
not fully transparent; if information is withheld from 
public circulation; if participatory decisions are not 
attended by a balanced and representative set of 
stakeholders; if vested interests unduly influence 
decisions; and ultimately, if the knowledge base 
and the policy course of action does not carry the 
necessary legitimacy. Distributional justice may 
be a subtle but important issue, at least on two 
accounts: (i) overall exposure to a certain type of 
nanomaterials may be low, but unevenly distributed 
among the population. If there are established or 
suspected health impacts, albeit small, they will be 
concentrated on a subgroup (perhaps a minority) 
receiving the majority of the overall exposure (such 
a subgroup may also happen to coincide with other 
vulnerabilities, adding to the problem). As seen in 
many other cases of environmental risk factors, such 
skewed distribution will substantially complicate 
decision-making and requires carefully managed 
negotiations. (ii) It may be of limited value to compare 
overall costs and benefits (monetary or otherwise) 
of a given nanotechnology or application. The most 
relevant issue may be who bears the costs and who 
reaps the benefits. If the discrepancy between the 
beneficiaries and those carrying the disbenefits (for 
example in terms of exposure) is marked, controversy 
will remain even if overall benefits outweigh overall 
costs. The aggregate, society-wide level of analysis, 
often used in economic assessments, may thus not 
be the most appropriate one.
9.1 Conclusions
Developing a prescriptive course of action for the 
risk management of nanotechnology is not feasible 
for any health agency. Rather, arrangements should 
be made to ensure that health considerations are 
fully appraised and given a high prominence in 
all deliberations. This is likely to be a continuous 
process, which needs to be set up and managed in 
consultation with a variety of stakeholders, and must 
address the most relevant questions. In particular:
• Consultative bodies and mechanisms on the 
risk governance of nanotechnology should be 
established, or strengthened where they exist, 
at the level where strategic decisions are made. 
Such bodies should be set up and/or run in a fair 
and transparent way, with the involvement of all 
legitimate stakeholders, to the extent possible. 
Consultation should be periodic, and held early 
enough in the process to meaningfully influence 
decisions. Leeway should be given to the phase 
of framing and formulating questions, i.e. avoiding 
situations where past decisions are presented as 
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fait accompli. Outcomes from such consultations 
should also inform the research agenda, towards 
the most policy-relevant objectives. Health 
agencies and health advocates should always 
be part of such bodies. Agencies in the United 
Nations system such as WHO should, in addition: 
facilitate the dialogue between stakeholders; 
ensure an appropriate use of available scientific 
evidence; and prevent the occurrence of unfair 
commercial or industrial practices between 
different regions of the world. Mechanisms 
should be identified to finance such efforts in a 
sustainable way.
• Given the multiplicity of different stakeholders, 
facilitating the necessary dialogue between 
commercial developers and regulators will be 
challenging, because technological progress is 
usually in advance of regulatory control. Yet, such 
dialogue should be continuous and accessible to 
other interested parties.
• Regulatory bodies have a role to play in exercising 
some level of control on the manufacture and 
commerce of some classes of nanoproducts. 
Regulatory schemes for products containing 
nanoparticles, possibly different from ordinary 
products, should be considered.
• Specific options to be considered include the 
following:
 – A full declaration of nanoscale ingredients 
should be made available in any consumer 
product (with the exception of medical 
products and devices, which will likely 
require a separate regime), with priority 
given to products with high exposure and/
or intake potential, such as food, cosmetics 
and household chemicals. Arrangements 
should be made that ensure that commercial 
confidentiality does not become a reason for 
non-compliance. This requirement obviously 
demands that manufacturers be fully aware 
of the nanomaterials present in their products;
 – Pre-existing licences, granted to manufacture 
or use materials at larger than nanoscale, 
should not automatically allow the manufacture 
or use of the same material at nanoscale, 
without requiring further assessment. 
 – Nanoscale materials should have a Chemical 
Abstracts Service Registry Number (CAS RN) 
which is distinct from the one for the bulk material.
• Identifying the priority nanomaterials for regulatory 
control and the priorities for research is critical:
 – This goal would be facilitated by the 
development of public databases bringing 
together available information on types and 
properties of nanomaterials. For example, 
the collation of data from all countries, using 
large volume air samplers to monitor trends 
of engineered nanoparticles in ambient air 
samples and assess changing patterns in 
population exposure is likely to be informative.
 – Such information would in turn enable the 
development and refinement of schemes of 
classification and taxonomy of nanomaterials, 
manufacturing processes, applications and 
products. It might be useful to include multiple 
criteria for classification, including criteria 
for classifying nanomaterials against their 
human exposure potential, for example as 
highly pervasive, pervasive or non-pervasive. 
The different categories could be subject to 
differing levels of regulation, hence improving 
cost–effectiveness of regulatory action.
• Nanomaterials that show the highest potential for 
health damage, or that can be expected to do so, 
on the basis of their chemical–physical properties, 
or for which existing toxicological evidence is a 
reason for concern, should be the highest priority 
candidates for regulation and research. However, 
because of the large scientific uncertainty, priorities 
should be based on other factors:
 – the extent of the current or anticipated 
population exposure; 
 – its distribution, notably the possible 
concentration of exposure on vulnerable 
subgroups, such as children or people with 
existing health conditions; 
 – a possible escalation of production and 
diffusion due to anticipated commercial driving 
forces, such as wider mass applications; 
 – the degree of availability of alternative 
materials, of lesser damaging potential 
(e.g. as established by comparative hazard 
assessment); 
Nanotechnology and human health: Scientific evidence and risk governance90
 – the expected nature of possible adverse 
health effects (e.g. how easily detectable 
it might be, over what time effects might 
become manifest);
 – the nature of the technological application 
(e.g. a purely commercial application on 
recreational equipment will invite a more 
restrictive attitude than a medical application 
meant to increase the effectiveness of a drug).
• Setting the research agenda to include 
key questions on the health implications of 
nanotechnology is crucial. Encouragement and 
incentives should be given to the development 
of suitable methodology to complement risk 
assessment, such as nanotoxicology and 
comparative hazard assessment and other 
methods developed ad hoc. This will require the 
sponsoring of targeted research programmes to fill 
in missing data needed for the setting of standards 
and norms. International collaboration to this 
effect should be encouraged. Generally speaking, 
public funding of research and development 
efforts should be balanced and always include a 
component dedicated to investigating possible 
health risks and impact. During 2004–2009, the 
proportion of funding for environment, health and 
safety research in the United States of America 
and the EU was 0.9–5.0% (Balbus et al., 2005; 
EC, 2005, 2008; Hullmann, 2007; NNI, 2008, 
2009), the latter figure being a better reflection of 
the current knowledge gaps.
• Governments and international agencies should 
consider instituting mandatory monitoring 
schemes and health surveillance systems, 
perhaps aimed with priority at vulnerable groups. 
Attention should be paid also to workers, possibly 
following the model of the nuclear industry in 
many countries. These populations, or some 
representative subgroups, should be monitored 
for diseases relevant to their potential exposures. 
For example, long-term longitudinal studies 
into the incidence of inflammatory diseases, 
cardiovascular disease and early-onset protein 
misfolding diseases.
10. References
Afaq F et al. (1998). Cytotoxicity, pro-oxidant effects and 
antioxidant depletion in rat lung alveolar macrophages 
exposed to ultrafine titanium dioxide. Journal of Applied 
Toxicology, 18(5):307–312.
Agricola (1556). De Re Metallica. Basel, Froben.
Aitken RJ et al. (2006). Manufacture and use of 
nanomaterials: current status in the United Kingdom and 
global trends. Occupational Medicine, 56(5):300–306.
Akiyoshi K, Sasaki Y, Sunamoto J (1999). Molecular 
chaperone-like activity of hydrogel nanoparticles of 
hydrophobized pullulan: thermal stabilization with refolding 
of carbonic anhydrase B. Bioconjugate Chemistry, 
10:321–324.
Allianz, OECD (2005). Small sizes that matter: opportunities 
and risks of nanotechnologies. Munich, Allianz Group, 
and Paris, Organisation for Economic Co-operation 
and Development (http://www.oecd.org/science/
nanosafety/44108334.pdf, accessed 15 April 2013).
Alyaudtin RN et al. (2001). Interaction of 
poly(butylcyanoacrylate) nanoparticles with the blood-
brain barrier in vivo and in vitro. Journal of Drug Targeting, 
9(3):209–221.
Anderson HR et al. (2004). Meta-analysis of time-series 
studies and panel studies of particulate matter (PM) and 
ozone (O3): report of a WHO task group. Copenhagen, 
WHO Regional Office for Europe (http://www.euro.who.
int/__data/assets/pdf_file/0004/74731/e82792.pdf, 
accessed 16 April 2013).
Auerbach O, Cuyler Hammond E, Garfinkel L (1965). 
Smoking in relation to atherosclerosis of the coronary 
arteries. New England Journal of Medicine, 273:775–779.
Baggs RB, Ferin J, Oberdörster G (1997). Regression of 
pulmonary lesions produced by inhaled titanium dioxide in 
rats. Veterinary Pathology, 34(6):592–597.
Balbus JM et al. (2005). Getting nanotechnology right 
the first time. Issues in Science and Technology, Summer 
2005:5–71.
Balbus JM et al. (2007). Meeting report: hazard assessment 
for nanoparticles – Report from an interdisciplinary 
workshop. Environmental Health Perspectives, 
115(11):1654–1659.
Barker PJ, Branch A (2007). The interaction of modern 
sunscreen formulations with surface coatings. Progress in 
Organic Coatings, 62:313–320.
Background Document 91
Barnes CA et al. (2008). Reproducible comet assay of 
amorphous silica nanoparticles detects no genotoxicity. 
Nano Letters, 8(9):3069–3074.
Barrett EG et al. (1999). Silica binds serum proteins 
resulting in a shift of the dose–response for silica-induced 
chemokine expression in an alveolar type II cell line. 
Toxicology and Applied Pharmacology, (2):111–122.
Bello D et al. (2008a). Particle exposure levels during CVD 
growth and subsequent handling of vertically-aligned 
carbon nanotube films. Carbon, 46:974–981.
Bello D et al. (2008b). Exposure to nanoscale particles and 
fibres during machining of hybrid advanced composites 
containing carbon nanotubes. Journal of Nanoparticle 
Research, 11:231–249.
Billsten P et al. (1997). Adsorption to silica nanoparticles of 
human carbonic anhydrase II and truncated forms induce 
a molten-globule-like structure. FEBS Letters, 402:67–72.
Blaser S et al. (2008). Estimation of cumulative aquatic 
exposure and risk due to silver: contribution of nano 
functionalized plastics and textiles. Science of the Total 
Environment, 390:396–409.
Bodian D, Howe HA (1941a). Experimental studies on 
intraneural spread of poliomyelitis virus. Bulletin of the 
Johns Hopkins Hospital, 69:248–267.
Bodian D, Howe HA (1941b). The rate of progression of 
poliomyelitis virus in nerves. Bulletin of the Johns Hopkins 
Hospital, 69:79–85.
de Boer AG, Gaillard PJ (2007). Drug targeting to the brain. 
Annual Review of Pharmacology and Toxicology, 47:323–
355.
Borm PJ et al. (2006). The potential risks of nanomaterials: 
a review carried out for ECETOC. Particle and Fibre 
Toxicology, 14(3):11.
Bosman SJ et al. (2005). Development of mammalian 
embryos exposed to mixed-size nanoparticles. Clinical and 
Experimental Obstetrics and Gynecology. 32(4):222–224.
Boxall ABA et al. (2008). Current and future predicted 
environmental exposure to engineered nanoparticles. York, 
Central Science Laboratory.
Brain JD, Kreyling W, Gehr P (2010). To the Editor. 
European Respiratory Journal, 35(1):226–227.
BSI (2007). Nanotechnologies – Part 2: Guide to safe 
handling and disposal of manufactured nanomaterials. 
British Standards Institution (PD 6699-2).
Brook RD (2007). Is air pollution a cause of cardiovascular 
disease? Updated review and controversies. Reviews on 
Environmental Health, 22(2):115–137.
Brook RD et al. (2002). Inhalation of fine particulate air 
pollution and ozone causes acute arterial vasoconstriction 
in healthy adults. Circulation, 105:1534–1536.
Brown JS, Zeman KL, Bennett WD (2002) Ultrafine particle 
deposition and clearance in the healthy and obstructed 
lung. American Journal of Respiratory and Critical Care 
Medicine, 166:1240–1247.
Bucher J et al. (2004). Developing experimental approaches 
for the evaluation of toxicological interactions of nanoscale 
materials. Gainesville, University of Florida.
Bulls K (2006). “Nano” safety recall [web site]. Cambridge, 
MA, MIT Technology Review (http://www.technologyreview.
com/NanoTech/wtr_16681,318,p1.html, accessed 16 
April 2013).
Cass GR et al. (2000). The chemical composition of 
atmospheric ultrafine particles. Philosophical Transactions 
of the Royal Society of London A: Mathematical, Physical 
& Engineering Sciences. 358(1775):2581–2592.
CCA (2008). Small is different: a science perspective on 
the regulatory challenges of the nanoscale. Report of the 
Expert Panel on Nanotechnology. Ottawa, Council of 
Canadian Academies.
Cedervall T et al. (2007). Understanding the nanoparticle-
protein corona using methods to quantify exchange rates 
and affinities of proteins for nanoparticles. Proceedings of 
the National Academy of Sciences, 104(7):2050–2055.
Chen H, Goldberg MS, Villeneuve PJ (2008). A systematic 
review of the relation between long-term exposure to 
ambient air pollution and chronic diseases. Reviews on 
Environmental Health, 23(4):243–297.
Chen M, von Mikecz A (2005). Formation of nucleoplasmic 
protein aggregates impairs nuclear function in response 
to SiO2 nanoparticles. Experimental Cell Research, 
305(1):51–62.
Chiappino G (2005). Mesotelioma: il ruolo delle fibre 
ultrafini e conseguenti riflessi in campo preventivo e 
medico legale [Mesothelioma: the role of ultrafine fibers 
and consequences for prevention and legal medicine]. La 
Medicina del Lavoro, 96:3–23. 
Clancy L et al. (2002). Effect of air-pollution control on 
death rates in Dublin, Ireland: an intervention study. Lancet, 
360:1210–1214.
Cottingham MG, Bain CD, Vaux DJT (2004). Rapid method 
for measurement of surface tension in multiwell plates. 
Laboratory Investigation, 84:523–529.
Cottingham MG, Hollinshead MS, Vaux DJ (2002). Amyloid 
fibril formation by a synthetic peptide from a region of 
human acetylcholinesterase that is homologous to the 
Alzheimer’s amyloid-beta peptide. Biochemistry, 41(46): 
13539–13547.
Nanotechnology and human health: Scientific evidence and risk governance92
DEFRA (2006). Characterising the potential risks posed 
by engineered nanoparticles. UK Government research – 
a progress report. London, Department for Environment, 
Food and Rural Affairs.
DEFRA (2007). Characterising the potential risks posed 
by engineered nanoparticles – A second UK Government 
Research Report. London, Department for Environment, 
Food and Rural Affairs.
DEFRA (2009). A review of completed and near completed 
environment, health and safety research on nanomaterials 
and nanotechnology. London, Department for Environment, 
Food and Rural Affairs.
Demou E, Peter P, Hellweg S (2008). Exposure to 
manufactured nanostructured particles in an industrial pilot 
plant. Annals of Occupational Hygiene, 52(8):695–706.
Devlin RB et al. (2003). Elderly humans exposed to 
concentrated air pollution particles have decreased heart 
rate variability. European Respiratory Journal, (Suppl.) 
40:76–80.
Dockery DW et al. (1993). An association between air-
pollution and mortality in 6 United-States cities. New 
England Journal of Medicine, 329:1753–1759.
Donaldson K, Beswick PH, Gilmour PS (1996). Free radical 
activity associated with the surface of particles: a unifying 
factor in determining biological activity? Toxicology Letters, 
88(1–3):293–298.
Donaldson J, Stone V, MacNee W (1999). The toxicology 
of ultrafine particles. In: Maynard RL, Howard CV, eds. 
Particulate matter: properties and effects upon health. 
Oxford, BIOS Scientific Publishers Ltd:115–129.
Donaldson K et al. (2000). Ultrafine particles: mechanisms 
of lung injury. Philosophical Transactions of the Royal 
Society of London A: Mathematical, Physical & Engineering 
Sciences. 358(1775):2741–2749.
Donaldson K et al. (2002). The pulmonary toxicology of 
ultrafine particles. Journal of Aerosol Medicine, 15:213–220.
Donaldson K et al. (2004). Nanotoxicology. Occupational 
and Environmental Medicine, 61:727–728.
Donaldson K et al. (2005). Combustion-derived 
nanoparticles: a review of their toxicology following 
inhalation exposure. Particle and Fibre Toxicology, 2:10.
Dostert C et al. (2008). Innate immune activation through 
NALP3 inflammasome sensing of asbestos and silica. 
Science, 320(5876):674–677.
EC (2005). Some figures about nanotechnology R&D in 
Europe and beyond. Brussels, European Commission (ftp://
ftp.cordis.europa.eu/pub/nanotechnology/docs/nano_
funding_data_08122005.pdf, accessed 16 April 2013).
EC (2007). Draft commission recommendation on 
the definition of the term “nanomaterial”. Brussels, 
European Commission (http://ec.europa.eu/environment/
consultations/pdf/recommendation_nano.pdf, accessed 
16 April 2013).
EC (2008). EU nanotechnology R&D in the field of health 
and environmental impact of nanoparticles. Brussels, 
European Commission (ftp://ftp.cordis.europa.eu/pub/
nanotechnology/docs/final-version.pdf, accessed 16 April 
2013).
Einstein A (1905). Ueber einen die Erzeugung und 
Verwandlung des Lichtes betreffenden heuristischen 
Gesichtspunkt. Annalen der Physik, 6:132–148.
Elder A et al. (2009). Human health risks of engineered 
nanomaterials: critical knowledge gaps in nanomaterials 
risk assessment. In: Linkov I, Steevens J, eds. 
Nanotechnology. Risks and benefits. Dordrecht, Springer, 
3–29. 
Elsaesser A et al. (2008). Personal communication.
Elvin G (2006). No nano in Magic Nano. nanotechbuzz [web 
site], 27 May (http://www.nanotechbuzz.com/50226711/
no_nano_in_magic_nano.php, accessed 16 April 2013).
Environmental Defense, DuPont (2007). Nano Risk 
Framework (http://www.nanoriskframework.com/
files/2011/11/6496_Nano-Risk-Framework.pdf, accessed 
16 April 2013).
ETC Group (2003a). The big down: atomtech: technologies 
converging at the nanoscale. Winnipeg, ETC Group (http://
www.etcgroup.org/content/big-down, accessed 16 April 
2013).
ETC Group (2003b). No small matter II: the case for a 
global moratorium. Size matters! Occasional Paper Series, 
7:1, Winnipeg, ETC Group (http://www.etcgroup.org/
content/size-matters, accessed 16 April 2013).
EU (2004). Nanotechnologies: a preliminary risk analysis on 
the basis of a workshop organized in Brussels on 1–2 March 
2004 by the Health and Consumer Protection Directorate 
General of the European Commission. Brussels, European 
Union (http://ec.europa.eu/health/ph_risk/documents/
ev_20040301_en.pdf, accessed 16 April 2013).
Ferin J et al. (1992). Pulmonary retention of ultrafine and 
fine particles in rats. American Journal of Respiratory Cell 
and Molecular Biology, 6:535–542.
Florence AT (2005). Nanoparticle uptake by the oral route: 
fulfilling its potential? Drug Discovery Today: Technologies, 
2(1):75–81.
Foley S et al. (2002). Cellular localization of a water-soluble 
fullerene derivative. Biochemical and Biophysical Research 
Communications, 294:116–119.
FSA (2006). Draft report of FSA regulatory review. A 
Background Document 93
review of potential implications of nanotechnologies for 
regulations and risk assessment in relation to food. United 
Kingdom Food Standards Agency.
Fujitani et al. (2008). Measurement of the physical properties 
of aerosols in a fullerene factory for inhalation exposure 
assessment. Journal of Occupational and Environmental 
Hygiene, 5(6):380–389.
Gamer AO, Leibold E, van Ravenzwaay B (2006). The in 
vitro absorption of microfine zinc oxide and titanium dioxide 
through porcine skin. Toxicology In Vitro, 20(3):301–307.
Gatti AM et al (2004). Detection of micro- and nano-sized 
biocompatible particles in the blood. Journal of Materials 
Science: Materials in Medicine, 15(4):469–472.
Genaidy A et al. (2009). Health effects of exposure to 
carbon nanofibers: systematic review, critical appraisal, 
meta-analysis and research to practice perspectives. 
Science of the Total Environment, 407(12):3686–3701.
Glaza P (2010). Industry should take lead with media when 
an event like a recall occurs. Electroiq [web site], 5 January 
(http://www.electroiq.com/articles/stm/print/volume-6/
issue-3/opinion/guest-column/industry-should-take-lead-
with-media-when-an-event-like-a-recall-occurs.html, 
accessed 16 April 2013).
Godbey WT, Wu KK, Mikos AG (1999). Tracking the 
intracellular path of poly(ethylenimine)/DNA complexes for 
gene delivery. Proceedings of the National Academy of 
Sciences, 96(9):5177–5181.
Goldberg AL (2003). Protein degradation and protection 
against misfolded or damaged proteins. Nature, 426:895–
899. 
Gottschalk F et al. (2010). Possibilities and limitations 
of modeling environmental exposure to engineered 
nanomaterials by probabilistic material flow analysis. 
Environmental Toxicology and Chemistry, 29:1036–1048.
Grieger K, Hansen SF, Baun A (2009). The known 
unknowns of nanomaterials: describing and characterizing 
uncertainty within environmental, health and safety risks. 
Nanotoxicology, 3(3):1–12.
Grieger K, Baun A, Owen R (2010). Redefining risk research 
priorities for nanomaterials. Journal of Nanoparticle 
Research, 2(2):383–392.
Gumbleton M (2001). Caveolae as potential macromolecule 
trafficking compartments within alveolar epithelium. 
Advanced Drug Delivery Reviews, 49:281–300.
Gurr JR et al. (2005). Ultrafine titanium dioxide particles 
in the absence of photoactivation can induce oxidative 
damage to human bronchial epithelial cells. Toxicology, 
213(1–2):66–73.
Gwinn MR, Vallyathan V (2006). Nanoparticles: health 
effects – pros and cons, Environmental Health Perspectives, 
114:1818–1825.
Hagens et al. (2007). What do we (need to) know about the 
kinetic properties of nanoparticles in the body? Regulatory 
Toxicology and Pharmacology, 49:217–229.
Halffman W (1998). Standardization as a trust device. 
In: Bal R, Halffman W, eds. The politics of chemical risk. 
Scenarios for a regulatory future. Dordrecht, Kluwer 
Academic Publishers, 265–292.
Han JH et al. (2008). Monitoring multiwalled carbon 
nanotube exposure in carbon nanotube research facility. 
Inhalation Toxicology, 20:741–749. 
Hansen SF et al. (2007). Categorization framework to aid 
Hazard Identification of Nanomaterials. Nanotoxicology, 
1:243–250.
Hansen SF et al. (2008). Categorization framework to 
aid exposure assessment of nanomaterials in consumer 
products. Ecotoxicology, 17(5):438–447.
Harrison RM (1999). Sources and behaviour of atmospheric 
particulate matter. In: Maynard RL, Howard CV, eds. 
Particulate matter: properties and effects upon health. 
Oxford, BIOS Scientific Publishers Ltd, 63–84.
Helland A et al. (2007). Reviewing the environmental and 
human health knowledge base of carbon nanotubes. 
Environmental Health Perspectives, 115(8):1125–1131.
Hillyer JF, Albrecht RM (2001). Gastrointestinal persorption 
and tissue distribution of differently sized colloidal gold 
nanoparticles. Journal of Pharmaceutical Sciences, 
90(12):1927–1936.
Hodges GM et al. (1995). Uptake and translocation 
of microparticles in small intestine. Morphology and 
quantification of particle distribution. Digestive Diseases 
and Sciences, 40:967–975.
Hoet PH, Bruske-Hohlfeld I, Salata OV (2004). 
Nanoparticles – known and unknown health risks. Journal 
of Nanobiotechnology, 2(1):12.
Hohr D et al. (2002). The surface area rather than the 
surface coating determines the acute inflammatory 
response after instillation of fine and ultrafine TiO2 in the 
rat. International Journal of Hygiene and Environmental 
Health, 205(3):239–244.
Hoshino A et al. (2004). Quantum dots targeted to 
the assigned organelle in living cells. Microbiology and 
Immunology, 48(12):985–994.
Howard CV, de Jong W (2004). Concept note on a hazard 
trigger algorithm as a potential prioritization tool for use by 
regulators. In: Nanotechnologies: a preliminary risk analysis 
on the basis of a workshop organized in Brussels on 1–2 
March 2004 by the Health and Consumer Protection 
Nanotechnology and human health: Scientific evidence and risk governance94
Directorate General of the European Commission. 
Brussels, European Commission, 35-36 (http://ec.europa.
eu/health/ph_risk/documents/ev_20040301_en.pdf, 
accessed 16 April 2013).
Howard CV, Reed MG (2010). Unbiased Stereology. 2nd 
edition. Liverpool, QTP Publications.
HSE (2006). The assessment of different metrics of the 
concentration of nano (ultrafine) particles in existing 
and new industries. Health and Safety Executive report 
RR513 (http://www.hse.gov.uk/research/rrpdf/rr513.pdf, 
accessed 16 April 2013).
Hsu LY, Chein HM (2007). Evaluation of nanoparticle 
emission for TiO2 nanopowder coating materials. Journal 
of Nanoparticle Research, 89:157–163.
Hullmann A (2007). Measuring and assessing the 
development of nanotechnology. Scientometrics, 
70(3):739–758.
Hunter DD, Dey RD (1998). Identification and neuropeptide 
content of trigeminal neurons innervating the rat nasal 
epithelium. Neuroscience, 83:591–599.
Hunter DD, Undem BJ (1999). Identification and substance 
P content of vagal afferent neurons innervating the 
epithelium of the guinea pig trachea. American Journal of 
Respiratory and Critical Care Medicine, 159:1943–1948.
Hussain SM et al. (2005). In vitro toxicity of nanoparticles 
in BRL 3A rat liver cells. Toxicology in Vitro, 19(7):975–983.
IRGC (2007). Nanotechnology risk governance: 
recommendations for a global, coordinated approach to 
the governance of potential risks. Geneva, International 
Risk Governance Council.
Isaacson CW, Kleber M, Field JA (2009). Quantitative 
analysis of fullerene nanomaterials in environmental 
systems: a critical review. Environmental Science & 
Technology, 43(17):6463–6474.
Ishii D et al. (2003). Chaperonin-mediated stabilization and 
ATP-triggered release of semiconductor nanoparticles. 
Nature, 423:628–632.
ISO (2008). Nanotechnologies — Terminology and 
definitions for nano-objects — Nanoparticle, nanofibre 
and nanoplate. ISO/TS 27687:2008. Geneva, International 
Organization for Standardization.
Jani P et al. (1990). Nanoparticle uptake by the rat 
gastrointestinal mucosa: quantitation and particle size 
dependency. Journal of Pharmacy and Pharmacology, 
42(12):821–826.
Jefferson DA, Tilley EEM (1999). The structural and physical 
chemistry of nanoparticles. In: Maynard RL, Howard CV, 
eds. Particulate matter: properties and effects upon health. 
Oxford, BIOS Scientific Publishers Ltd, 63–84.
Ji ZQ et al. (2006). Biodistribution and tumor uptake of 
C60(OH)x in mice. Journal of Nanoparticle Research, 
8:53–63.
Jia G et al. (2005). Cytotoxicity of carbon nanomaterials: 
single-wall nanotube, multiwall nanotube, and fullerene. 
Environmental Science & Technology, 39(5):1378–1383.
Johnston HJ et al. (2010). The biological mechanisms and 
physicochemical characteristics responsible for driving 
fullerene toxicity. Toxicological Sciences, 114 (2):162–182.
Jontes JD, Phillips GR (2008). Selective stabilization and 
synaptic specificity: a new cell biological model. Trends in 
Neuroscience, 29:185–191.
Kabanov AV, Gendelman HE (2007). Nanomedicine in the 
diagnosis and therapy of neurodegenerative disorders. 
Progress in Polymer Science, 32:1054–1082.
Kaegi R et al. (2008). Synthetic TiO2 nanoparticle emission 
from exterior facades into the aquatic environment. 
Environmental Pollution, 156(2):233–239.
Kaiser JP et al. (2008). Single walled carbon nanotubes 
(SWCNT) affect cell physiology and cell architecture. 
Journal of Materials Science: Materials in Medicine, 
19(4):1523–1527.
Kamat JP et al. (2000). Reactive oxygen species mediated 
membrane damage induced by fullerene derivatives and 
its possible biological implications. Toxicology, 155:55–61.
Kennedy P, Chaudhuri A (2002). Herpes simplex 
encephalitis. Journal of Neurology, Neurosurgery and 
Psychiatry, 73:237–238.
Kim et al. (1999). Mechanism of silica- and titanium 
dioxide-induced cytotoxicity in alveolar macrophages. 
Journal of Toxicology and Environmental Health, Part A, 
58(7):437–450.
Kohli AK, Alpar HO (2004). Potential use of nanoparticles 
for transcutaneous vaccine delivery: effect of particle 
size and charge. International Journal of Pharmaceutics, 
275(1–2):13–7.
Kreuter J (2001). Nanoparticulate systems for brain delivery 
of drugs. Advanced Drug Delivery Reviews, 47:65–81.
Kreuter J et al. (2002) Apolipoprotein-mediated transport 
of nanoparticle-bound drugs across the blood-brain 
barrier. Journal of Drug Targeting, 10(4):317–325.
Kreyling WG et al. (2002). Translocation of ultrafine insoluble 
iridium particles from lung epithelium to extrapulmonary 
organs is size dependent but very low. Journal of Toxicology 
and Environmental Health, Part A, 65(20):1513–1530.
Kuhlbusch TAJ, Fissan H (2006). Particle characteristics 
in the reactor and pelletizing areas of carbon black 
production. Journal of Occupational and Environmental 
Hygiene, 3:558–567.
Background Document 95
Kuhlbusch TAJ, Neumann S, Fissan H (2004). Number 
size distribution, mass concentration, and particle 
composition of PM1, PM2.5, and PM10 in bag filling areas 
of carbon black production. Journal of Occupational and 
Environmental Hygiene, 1:660–671.
Lademann J et al. (1999). Penetration of titanium dioxide 
microparticles in a sunscreen formulation into the horny 
layer and the follicular orifice. Skin Pharmacology and 
Physiology, 12(5):247–256.
Lam CW et al. (2004). Pulmonary toxicity of single-wall 
carbon nanotubes in mice 7 and 90 days after intratracheal 
instillation. Toxicological Sciences, 77:126–134.
Li N et al. (2003). Ultrafine particulate pollutants induce 
oxidative stress and mitochondrial damage, Environmental 
Health Perspectives, 111(4):455–460.
Limbach LK et al. (2007). Exposure of engineered 
nanoparticles to human lung epithelial cells: influence of 
chemical composition and catalytic activity on oxidative 
stress. Environmental Science & Technology, 41(11):4158–
4163.
Linkov I, Steevens J, eds. (2009). Nanotechnology. Risks 
and benefits. Dordrecht, Springer, 3–29.
Linkov I et al. (2007) Multicriteria decision analysis and 
environmental risk assessment for nanomaterials. Journal 
of Nanoparticle Research, 9(4):543–554.
Linse S et al. (2007). Nucleation of protein fibrillation by 
nanoparticles. Proceedings of the National Academy of 
Sciences, 104(21):8691–8696.
Lomer MC, Thompson RP, Powell JJ (2002). Fine and 
ultrafine particles of the diet: influence on the mucosal 
immune response and association with Crohn’s disease. 
Proceedings of the Nutrition Society, 61:123–130. 
Long TC. (2006). Titanium Dioxide (P25) Produces Reactive 
Oxygen Species in Immortalized Brain Microglia (BV2): 
Implications for Nanoparticle Neurotoxicity. Environmental 
Science & Technology 40(14): 4346-4352.
Longmire M, Choyke PL, Kobayashi H (2008). Clearance 
properties of nano-sized particles and molecules as imaging 
agents: considerations and caveats. Nanomedicine, 
3:703–717.
de Lorenzo AJ (1970). The olfactory neuron and the blood-
brain barrier. In: Wolstenholme G, Knight J, eds. Taste and 
smell in vertebrates. London, Churchill, 151–176.
Lovric J (2005). Differences in subcellular distribution and 
toxicity of green and red emitting CdTe quantum dots. 
Journal of Molecular Medicine, 83(5):377–385.
Lowe PJ et al. (1985). Transcytosis and paracellular 
movements of horseradish peroxidase across liver 
parenchymal tissue from blood to bile. Effects of alpha-
naphthylisothiocyanate and colchicine. Biochemical 
Journal, 229:529–537.
Luoma SN (2008). Silver nanotechnologies and 
the environment: old problems or new challenges? 
Washington, DC, Project on Emerging Nanotechnologies, 
Woodrow Wilson International Center for Scholars.
Maynard AD (2006a). Nanotechnology: a research strategy 
for addressing risk. Washington, DC, Project on Emerging 
Nanotechnologies, Woodrow Wilson International Center 
for Scholars.
Maynard AD (2006b). “Magic nano” product recall 
update. Nanotechwire [web site], 13 April (http://www.
nanotechwire.com/news.asp?nid=3178, accessed 17 
April 2013)
Maynard AD (2009). New study seeks to link seven cases 
of occupational lung disease with nanoparticles and 
nanotechnology. 2020 Science [web site], 18 August 
(http://2020science.org/2009/08/18/new-study-seeks-
to-link-seven-cases-of-ocupational-lung-disease-with-
nanoparticles-and-nanotechnology/, accessed 17 April 
2013).
Maynard AD, Aitken RJ (2007). Assessing exposure 
to airborne nanomaterials: current abilities and future 
requirements. Nanotoxicology, 1:26–41.
Maynard RL, Howard CV (1999). Particulate matter: 
properties and effects upon health. Oxford, BIOS Scientific 
Publishers.
Maynard AD et al. (2004). Exposure to carbon nanotube 
material: aerosol release during the handling of unrefined 
single-walled carbon nanotube material. Journal of 
Toxicology and Environmental Health, Part A, 67:87–107.
Maynard AD et al. (2009). Nanoparticle exposure 
and occupational lung disease – six expert 
perspectives on a new clinical study. 2020 
Science [web site], 18 August (http://2020science.
org/?s= Nanoparticle+exposure+and+occupational 
+ l u n g + d i s e a s e + % E 2 % 8 0 % 9 3 + s i x + e x p e r t 
+perspectives+on +a+ new+clinical+study, accessed 17 
April 2013).
Methner MM (2008). Effectiveness of local exhaust 
ventilation (LEV) in controlling engineered nanomaterial 
emissions during reactor cleanout operations. Journal of 
Occupational and Environmental Hygiene, 5(6):D63–D69.
Methner MM et al. (2007). Identification and 
characterization of potential sources of worker exposure 
to carbon nanofibers during polymer composite laboratory 
operations. Journal of Occupational and Environmental 
Hygiene, 4(12):D125–D130.
Meyer M, Schreck R, Baeuerle PA (1993). H2O2 and 
antioxidants have opposite effects on activation of NF-
kappa B and AP-1 in intact cells: AP-1 as secondary 
Nanotechnology and human health: Scientific evidence and risk governance96
antioxidant-responsive factor. EMBO Journal, 12:2005–
2015.
Mills NL et al. (2006). Do inhaled carbon nanoparticles 
translocate directly into the circulation in humans? 
American Journal of Respiratory and Critical Care 
Medicine, 173(4):426–431.
Mueller N, Nowack B (2008). Exposure modeling of 
engineered nanoparticles in the environment. Environmental 
Science & Technology, 42:4447–4453.
Myllynen PK et al. (2008). Kinetics of gold nanoparticles in 
the human placenta. Reproductive Toxicology, 26(2):130–
137.
National Academy of Sciences (2008). Review of the 
federal strategy for nanotechnology-related environmental, 
health, and safety research. Washington, DC, National 
Academies Press, 1–191.
Nefzger M et al. (1984). Distribution and elimination 
of polymethyl ethacrylate nanoparticles after peroral 
administration to rats. Journal of Pharmaceutical Sciences, 
73:1309–1311.
Nel AE et al. (2009). Understanding biophysicochemical 
interactions at the nano–bio interface. Nature Materials, 
8:543–557.
Nemmar A et al. (2001). Passage of intratracheally instilled 
ultrafine particles from the lung into the systemic circulation 
in hamster. American Journal of Respiratory and Critical 
Care Medicine, 164:1665–1668.
Nemmar A et al. (2002). Passage of inhaled particles into the 
blood circulation in humans. Circulation, 105(4): 411–414.
Next Big Future (2007). Carbon nanotubes production in 
2007 and projected (http://nextbigfuture.com/2007/07/
carbon-nanotubes-production-in-2007-and.html , 
accessed 17 April 2013).
Nigavekar SS et al. (2004). 3H dendrimer nanoparticle 
organ/tumor distribution. Pharmaceutical Research, 
21:476–483.
NIOSH (2006). Approaches to safe nanotechnology: 
managing the health and safety concerns associated with 
engineered nanomaterials. Cincinnati, National Institute for 
Occupational Safety and Health. 
NNI (2008). Strategy for nanotechnology-related 
environmental, health and safety research. Washington, 
DC, United States National Nanotechnology Initiative.
NNI (2009). FY 2009 budget and highlights. Washington, 
DC, United States National Nanotechnology Initiative.
Nohynek GJ et al. (2007). Grey goo on the skin? 
Nanotechnology, cosmetic and sunscreen safety. Critical 
Reviews in Toxicology, 37(3):251–277.
NRC (1979). Airborne Particles. Baltimore, National 
Research Council, National Academy of Sciences, 
University Park Press, 108–110.
Oberdörster G et al. (1992). Role of the alveolar macrophage 
in lung injury: studies with ultrafine particles. Environmetnal 
Health Perspectives, 97:193-199.
Oberdörster E (2004). Manufactured nanomaterials 
(fullerenes, C60) induce oxidative stress in the brain 
of juvenile largemouth bass. Environmental Health 
Perspectives, 112:1058–1062.
Oberdörster G (2000). Toxicology of ultrafine particles: 
in vivo studies. Philosophical Transactions of the Royal 
Society of London A: Mathematical, Physical & Engineering 
Sciences. 358(1775):2719–2740.
Oberdörster G (2009). Safety assessment for 
nanotechnology and nanomedicine: concepts of 
nanotoxicology. Journal of Internal Medicine, 267:89–105.
Oberdörster G (2010). Safety assessment for 
nanotechnology and nanomedicine: concepts of 
nanotoxicology. Journal of Internal Medicine, 267(1):89–
105. 
Oberdörster G, Oberdörster E, Oberdörster J (2005). 
Nanotoxicology: an emerging discipline evolving from 
studies of ultrafine particles, Environmental Health 
Perspectives, 113:823–839.
Oberdörster G et al. (2002) Extrapulmonary translocation 
of ultrafine carbon particles following wholebody inhalation 
exposure of rats. Journal of Toxicology and Environmental 
Health, Part A, 65(20):1531–1543.
Oberdörster G et al. (2004). Translocation of inhaled 
ultrafine particles to the brain. Inhalation Toxicology, 
16(6/7):437–445.
OECD (2009). Preliminary analysis of exposure 
measurement and exposure mitigation in occupational 
settings: manufactured nanomaterials. Paris, Organisation 
for Economic Cooperation and Development.
Osier M, Oberdörster G (1997). Intratracheal inhalation 
vs intratracheal instillation: differences in particle effects. 
Fundamental and Applied Toxicology, 40(2):220–227.
Owen R, Handy R (2007). Formulating the problems 
for environmental risk assessment of nanomaterials. 
Environmental Science & Technology, 41(16):5582–5588.
Panté N, Kann M (2002). Nuclear pore complex is able to 
transport macromolecules with diameters of about 39 nm. 
Molecular Biology of the Cell, 13(2):425–434.
Park B. et al. (2008). Hazard and Risk Assessment of 
a Nanoparticulate Cerium Oxide-Based Diesel Fuel 
Additive—A Case Study. Inhalation Toxicology, 20:547-
566.
Background Document 97
Patrick G, Stirling C (1992). Transport of particles of colloidal 
gold within and from rat lung after local deposition by 
alveolar microinjection. Environmental Health Perspectives, 
97:47–51.
Pescovitz D (2006). Magic Nano recall. Boing boing [web 
site], April 10, (http://boingboing.net/2006/04/10/magic-
nano-recall.html, accessed 17 April 2013).
Peters A et al. (2001). Increased particulate air pollution 
and the triggering of myocardial infarction. Circulation, 
103:2810–2815.
Peters TM et al. (2009). Airborne monitoring to distinguish 
engineered nanomaterials from incidental particles for 
environmental health and safety. Journal of Occupational 
and Environmental Hygiene, 6:73–81.
Poland CA et al. (2008). Carbon nanotubes introduced 
into the abdominal cavity of mice show asbestos-like 
pathogenicity in a pilot study. Nature Nanotechnology, 
3(7):423–428.
Pope CA 3rd, Dockery DW (2006). Health effects of fine 
particulate air pollution: lines that connect. Journal of the 
Air and Waste Management Association, 56(6):709–742.
Pratten MK, Lloyd JB (1986). Pinocytosis and phagocytosis: 
the effect of size of a particulate substrate on its mode of 
capture by rat peritoneal macrophages cultured in vitro. 
Biochimica et Biophysica Acta, 881:307–313.
Rahman Q et al. (2002). Evidence that ultrafine titanium 
dioxide induces micronuclei and apoptosis in Syrian 
hamster embryo fibroblasts. Environmental Health 
Perspectives, 110(8):797–800.
Rim D, Wallace L, Persily A (2010). Infiltration of outdoor 
ultrafine particles into a test house. Environmental Science 
& Technology, 44(15):5908–5913.
Rocks S et al. (2008). Comparison of risk assessment 
approaches for manufactured nanomaterials. United 
Kingdom Department for Environment, Food and Rural 
Affairs.
Roco MC (2003). Broader societal issues of nanotechnology. 
Journal of Nanoparticle Research, 5:181–189. 
Roco M, Renn O (2006). Nanotechnology and the need 
for risk governance. Journal of Nanoparticle Research, 
8(2):153–191.
Rouse JG et al. (2007). Effects of mechanical flexion on 
the penetration of fullerene amino acid-derivatized peptide 
nanoparticles through skin. Nano Letters, 7(1):155–160.
Royal Society (2004). Nanoscience and nanotechnologies: 
opportunities and uncertainties. London, Royal Society 
and Royal Academy of Engineering.
Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere 
NA (2006). Penetration of intact skin by quantum dots 
with diverse physicochemical properties. Toxicological 
Sciences, 91(1):159–165.
Salnikov V et al. (2007). Probing the outer mitochondrial 
membrane in cardiac mitochondria with nanoparticles. 
Biophysical Journal, 92(3):1058–1071.
Sayes SM et al. (2004). The differential cytotoxicity of 
water-soluble fullerenes. Nano Letters, 4:1881–1887.
Sayes CM et al. (2006). Correlating nanoscale titania 
structure with toxicity: a cytotoxicity and inflammatory 
response study with human dermal fibroblasts and human 
lung epithelial cells. Toxicological Sciences, 92(1):174–185.
Sayes CM et al. (2007). Comparative pulmonary toxicity 
assessments of C60 water suspensions in rats: few 
differences in fullerene toxicity in vivo in contrast to in vitro 
profiles. Nano Letters, 7:2399–2406.
SCENIHR (2007). The appropriateness of the risk 
assessment methodology in accordance with the Technical 
Guidance Documents for new and existing substances for 
assessing the risks of nanomaterials, 21–22 June 2007. 
Brussels, Scientific Committee on Emerging and Newly 
Identified Health Risks, European Commission (http://
ec.europa.eu/health/ph_risk/committees/04_scenihr/
docs/scenihr_o_010.pdf, accessed 17 April 2013).
SCENIHR (2009). Risk assessment of products of 
nanotechnologies. Brussels, Scientific Committee on 
Emerging and Newly Identified Health Risks, European 
Commission (http://ec.europa.eu/health/ph_risk/
committees/04_scenihr/docs/scenihr_o_023.pdf , 
accessed 17 April 2013).
Schmidt K (2007). NanoFrontiers: visions for the future 
of nanotechnology. Washington, DC, Woodrow Wilson 
Center for International Scholars.
Schulz J et al. (2002). Distribution of sunscreens on skin. 
Advanced Drug Delivery Reviews, 54(1):S157–S163.
Schwartz J, Dockery DW (1992). Increased mortality 
in Philadelphia associated with daily air pollution 
concentrations. American Review of Respiratory Disease, 
145:600–604.
Seaton A et al. (1995). Particulate air pollution and acute 
health effects. Lancet 345:176–178.
Seaton A et al. (2009). Nanoparticles, human health hazard 
and regulation. Journal of The Royal Society Interface 
(doi:10.1098/rsif.2009.0252.focus).
Shatkin JA (2008). Informing environmental decision-
making by combining life cycle assessment and risk 
analysis. Journal of Industrial Ecology, 12(3):278–281.
Shinohara N, Gamo M, Nakanishi J (2009). Risk 
assessment of manufactured nanomaterials. Kawasaki, 
National Institute of Advanced Industrial Science and 
Nanotechnology and human health: Scientific evidence and risk governance98
Technology, Research Institute of Science for Safety and 
Sustainability.
Singh S, Nalwa HS (2007). Nanotechnology and health 
safety—toxicity and risk assessments of nanostructured 
materials on human health. Journal of Nanoscience and 
Nanotechnology, 7:3048–3070. 
Song Y, Xue L, Du X (2009). Exposure to nanoparticles 
is related to pleural effusion, pulmonary fibrosis and 
granuloma. European Respiratory Journal, 34(3):559–567.
Stern ST, McNeil SE (2008). Nanotechnology safety 
concerns revisited. Toxicological Sciences, 101(1):4–21.
Stone V et al. (1998). The role of oxidative stress in the 
prolonged inhibitory effect of ultrafine carbon black on 
epithelial cell function. Toxicology in Vitro, 12(6):649–659.
Stone V et al. (2010). Engineered nanoparticles: review 
of health and environmental safety. Edinburgh Napier 
University, Institute of Occupational Medicine, Technical 
University of Denmark, Institute for Health and Consumer 
Protection of the European Commission’s Joint Research 
Centre and Institute of Nanotechnology.
Swiss Re (2004). Nanotechnology: small matter, many 
unknowns. Zurich, Swiss Re. 
Takagi A et al. (2008). Induction of mesothelioma in p53+/- 
mouse by intraperitoneal application of multiwall carbon 
nanotube. Journal of Toxicological Sciences, 33(1):105–116.
Tan MH et al. (1996). A pilot study on the percutaneous 
absorption of microfine titanium dioxide from sunscreens. 
Australasian Journal of Dermatology, 37(4):185–187.
Thayer AM (2007). Carbon nanotubes by the metric ton. 
Anticipating new commercial applications, producers 
increase capacity. Chemical & Engineering News, 
85(46):29–35.
Tickell O (2008). How war debris could cause cancer. New 
Scientist, 7 September.
Tickner J (2007). Why risk assessment is not enough 
to protect public health: rationale for a precautionary 
approach to science and policy. In: Robinson M, Toscano 
W, eds. Risk assessment for environmental health. The 
Association of Schools of Public Health, Jossey-Bass 
Publisher, 431.
Tinkle SS et al. (2003). Skin as a route of exposure and 
sensitization in chronic beryllium disease. Environmental 
Health Perspectives, 111(9):1202–1208.
Tomatis L et al. (2007). The role of asbestos fiber dimensions 
in the prevention of mesothelioma. International Journal of 
Occupational and Environmental Health, 13(1):64–69.
Tsai S et al. (2008a). Airborne nanoparticle exposures 
associated with the manual handling of nanoalumina 
and nanosilver in fume hoods. Journal of Nanoparticle 
Research, 11(1):147.
Tsai S et al. (2008b). Airborne nanoparticle release 
associated with the compounding of nanocomposites 
using nanoalumina as fillers. Journal of Aerosol and Air 
Quality Research, 8:160–177.
Tsuchiya T et al. (1996). Novel harmful effects of [60]
fullerene on mouse embryos in vitro and in vivo. FEBS 
Letters. 393(1):139–145.
Uchino T et al. (2002). Quantitative determination of OH 
radical generation and its cytotoxicity induced by TiO2–
UVA treatment. Toxicology in Vitro, 16:629–635.
Unfried K et al. (2007). Cellular responses to nanoparticles: 
target structures and mechanisms. Nanotoxicology, 1:52–
71.
Volkheimer G (1974). Passage of particles through the 
wall of the gastrointestinal tract. Environmental Health 
Perspectives, 9:215–225.
von Bubnoff A (2010). What’s in a nano name? Electroiq 
[web site], 1 July (http://www.electroiq.com/articles/stm/
print/volume-6/issue-4/features/global-watch/whatrsquos-
in-a-nano-name.html, accessed 17 April 2013).
Vorbau M, Hillemann L, Stintz M (2009). Method for the 
characterization of the abrasion induced nanoparticle 
release into air from surface coatings. Journal of Aerosol 
Science, 40:209–217.
Warheit DB et al. (2006). Pulmonary instillation studies 
with nanoscale TiO2 rods and dots in rats: toxicity is 
not dependent upon particle size and surface area. 
Toxicological Sciences, 91:227–236. 
Warheit DB et al. (2007). Pulmonary toxicity study in rats 
with three forms of ultrafine-TiO2 particles: differential 
responses related to surface properties. Toxicology, 
230(1):90–104.
Wichmann HE et al. (2000). Daily Mortality and Fine and 
Ultrafine Particles in Erfurt, Germany. Part I: Role of Particle 
Number and Particle Mass. Cambridhe MA, Health Effects 
Institute (HEI Research Report No. 98).
Wichmann HE, Peters A (2000). Epidemiological 
evidence of the effects of ultrafine particle exposure. 
Philosophical Transactions of the Royal Society of London 
A: Mathematical, Physical & Engineering Sciences. 
358(1775):2751–2769.
WHO Regional Office for Europe (2006) Air Quality 
Guidelines. Global Update 2005. Copenhagen, WHO 
Regional Office for Europe (http://www.euro.who.int/__
data/assets/pdf_file/0005/78638/E90038.pdf, accessed 
17 April 2013)
WHO Regional Office for Europe (2008). Fifth Ministerial 
Conference on Environment and Health. Report of the 
Second High-level Preparatory Meeting, Madrid, Spain, 
22–24 October 2008. Copenhagen, WHO Regional 
Office for Europe (http://www.euro.who.int/__data/assets/
Background Document 99
pdf_file/0020/104555/26th_EEHC_Madrid_ereport.pdf, 
accessed 17 April 2013).
WHO/FAO (2010). Expert meeting on the application of 
nanotechnologies in the food and agriculture sectors: 
potential food safety implications. Geneva, World Health 
Organization/Rome, Food and Agriculture Organization of 
the United Nations.
Wijnhoven SWP et al. (2009). Nano-silver – a review 
of available data and knowledge gaps in human and 
environmental risk assessment. Nanotoxicology, 3:2,109–
138.
Xia T et al. (2006). Comparison of the abilities of ambient 
and manufactured nanoparticles to induce cellular toxicity 
according to an oxidative stress paradigm. Nano Letters, 
6(8):1794–1807.
Yeganeh B et al. (2008). Characterization of airborne 
particles during production of carbonaceous nanomaterials. 
Environmental Science & Technology, 42:4600–4606. 
Zhang LW, Monteiro-Riviere NA (2008). Assessment 
of quantum dot penetration into intact, tape-stripped, 
abraded and flexed rat skin. Skin Pharmacology and 
Physiology 21(3):166-180.
Zhu Y et al. (2006). The interaction and toxicity of 
multiwalled carbon nanotubes with Stylonychia mytilus. 
Journal of Nanoscience and Nanotechnology, 6(5):1357–
1364.


World Health Organization 
Regional Office for Europe
UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark
Tel.: +45 45 33 70 00 Fax: +45 45 33 70 01
Email: contact@euro.who.int 
Website: www.euro.who.int
This report is available at: 
www.euro.who.int/EH-Nanotechnology-health-evidence-2012 
Nanotechnology, the science and application of objects smaller 
that 100 nanometres, is evolving rapidly in many fields. Besides the 
countless beneficial applications, including in health and medicine, 
concerns exist on adverse health consequences of unintended 
human exposure to nanomaterials. 
In the 2010 Parma Declaration on Environment and Health, 
ministers of health and of environment of the 53 Member States of 
the WHO Regional Office for Europe listed the health implications 
of nanotechnology and nanoparticles among the key environment 
and health challenges.
The WHO Regional Office for Europe undertook a critical 
assessment of the current state of knowledge and the key evidence 
on the possible health implications of nanomaterials, with a view 
to identify options for risk assessment and policy formulation, and 
convened an expert meeting to address the issue.
Current evidence is not conclusive.  As complexity and uncertainty 
are large, risk assessment is challenging, and formulation of 
evidence-based policies and regulations elusive.
Innovative models and frameworks for risk assessment and risk 
governance are being developed and applied to organize the 
available evidence on biological and health effects of nanomaterials 
in ways to inform policy.
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